|
5th Conference on Retroviruses and Opportunistic InfectionsChicago, IL - February 1-5, 1998 |
Cite as: Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:Abstract No. xx
| Session 1— Opening Session |
||
| S1 | Memorial Lecture: Measures of reality. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S1) Haase AT; University of Minnesota, Minneapolis, MN |
|
| S2 | Keynote Lecture: The challenge of making an AIDS vaccine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S2) Baltimore D; Caltech, Pasadena, CA |
|
| Session 2— State-of-the-Art Lecture HIV-1 Entry into Cells: Targets for Drug and Vaccine Development |
||
| L1 | HIV-1 Entry into Cells: Targets for Drug and Vaccine Development Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L1) Sodroski J, Kwong PD, Wyatt R, Desjardins E, Sweet R, Robinson J, and Hendrickson W |
|
| Session 3— State-of-the-Art Lecture Monitoring the Epidemic of HIV/AIDS in the U.S.: Current Status and Future Prospects |
||
| L2 | Epidemiologic Trends Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L2) De Cock KM |
|
| Session 4— State-of-the-Art Lecture Immunopathogenesis of Primate Immunodeficiency Virus Interactions |
||
| L3 | Immunopathogenesis of Primate Immunodeficiency Virus Interactions Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L3) |
|
| Session 5— Slide Antiretroviral Chemotherapy I |
||
| 1 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF LAMIVUDINE (3TC) IN COMBINATION WITH ZIDOVUDINE (ZDV), STAVUDINE (D4T), OR DIDANOSINE (DDI) IN TREATMENT NAÏVE PATIENTS Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 1) DR Kuritzkes, IC Marschner, VA Johnson, RL Bassett, JJ Eron, MA Fischl, GJ Boone, J Skovronski, K Wood, DL Bell, CB Pettinelli, JP Sommadossi 299 antiretroviral-naïve subjects with HIV-1 infection and CD4 counts of 200-600 cells/mm3 were randomized to either a d4T or ddI limb and then randomized in a blinded fashion to one of three arms within each limb (d4T limb: d4T alone, d4T/3TC, or ZDV/3TC; ddI limb: ddI alone, ddI/3TC, or ZDV/3TC). | |
| 2 | COMBINATION ZIDOVUDINE (ZDV) AND STAVUDINE (D4T) THERAPY VERSUS OTHER NUCLEOSIDES: REPORT OF TWO RANDOMIZED TRIALS (ACTG 290 AND 298) Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 2) DV Havlir, G Friedland, R Pollard, C Tierney, L Smeaton, L Fox, DD Richman and the ACTG 290/298 Teams These data suggest a) ZDV/d4T does not have more potent antiviral effect than d4T alone, probably due to pharmacologic antagonism. ZDV/d4T is associated with CD4 cell decline in ZDV experienced patients. ZDV/d4T therefore should not be used in combination; b) ddI produces greater viral suppression than d4T in ZDV experienced patients; c) ZDV/ddI was not associated with virologic activity discernable from ddI in ZDV experienced patients. |
|
| 3 | IMPAIRMENT OF STAVUDINE (d4T) PHOSPHORYLATION IN PATIENTS RECEIVING A COMBINATION OF ZIDOVUDINE (ZDV) AND d4T (ACTG 290) Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 3) JP Sommadossi, XJ Zhou, J Moore, DV Havlir, G Friedland, C Tierney, L Smeaton, F Fox, D Richman, R Pollard R In one patient who received the d4T/ZDV comb for 42 weeks and subsequently a d4T monotherapy for 8 weeks, no d4T-TP was detected at 2, 4 and 6 weeks following ZDV discontinuation. These data suggest that in patients receiving a comb of ZDV/d4T, the intracellular phosphorylation of d4T to d4T-TP is hampered and this negative effect may be prolonged for several weeks after discontinuation of ZDV treatment. |
|
| 4 | ANTIRETROVIRAL EFFECTS OF THERAPY COMBINING ABACAVIR (1592) WITH HIV PROTEASE INHIBITORS (PIS) Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 4) Mellors J, Lederman M, Haas D, Horton J, Haubrich R, Stanford J, Cooney E, McMahon D, Spreen W, Smiley M, Kelleher D Abacavir (300 mg, ql2h) in dual combination with 5 different PIs was well tolerated and demonstrated potent antiretroviral activity. |
|
| 5 | Abstract Withdrawn | |
| 6 | PRELIMINARY ASSESSMENT OF 141W94 IN COMBINATION WITH OTHER PROTEASE INHIBITORS Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 6) Eron J, Haubrich R, Richman D, Lang W, Tisdale M, Myers R, Pagano G, Rogers M During the initial 4 weeks of this study, the combinations were generally well tolerated and had significant antiviral activity. Continued investigation of these combinations is ongoing. |
|
| 7 | IN VITRO AND IN VIVO ACTIVITY OF ANTI-RETROVIRAL COMPOUNDS ATTACKING NC ZINC FINGERS Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 7) Henderson LE, Chertova E, Ott D, Hewes SM, Cases-Finet JR, Kane B, Johnson DG, Sowder II RC, Rossio J, Lifson J, Arthur LO These results show that at least one compound has been identified which has an enhanced reactivity with the target NC protein, inactivates whole virus (SIV, HIV-1 and MuLV), react selectively with the whole viral NC protein, is non-toxic, can be taken orally and reduces viral replication in the MuLV/mouse model and in the SIV/monkey model. These results strongly support the suggestion that the reactivity of the NC protein CCHC ZFs can be exploited to develop a new class of anti-retroviral compounds that may find therapeutic applications. |
|
| 8 | AVANTI 3. A RANDOMISED, DOUBLE BLIND, COMPARATIVE TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERANCE OF AZT/3TC VS AZT/3TC/NELFINAVIR IN ANTI-RETROVIRAL NAÏVE PATIENTS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 8) Clumeck N Both treatment groups demonstrated improvement in viral load over the 28 week period and AUCMB analysis demonstrated a statistically significant reduction in viral load over same timeframe for AZT/3TC/nelfinavir as compared to AZT/3TC. Further data on CD4 and safety will also be presented. |
|
| Session 6— Slide Epidemiology |
||
| 9a | IMPROVED SURVIVAL TIME AFTER DIAGNOSIS WITH AIDS AMONG ADULTS IN NEW YORK CITY (NYC), 1980-1994 Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 9a) Muthambi BR, Chiasson MA, Lehner T, Singh TP Survival time improved consistently with each successive time period of diagnosis and across all groups assessed. |
|
| 9b | ACCELERATING DECLINE IN NEW YORK CITY AIDS MORTALITY Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 9b) Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, Mojica B The dramatic decline in AIDS deaths first observed in NYC in 1996 continued through the 1st half of 1997 in all demographic groups. This occurred at a time when new antiretroviral therapy became widely available. |
|
| 10 | THE EFFECTS OF ANTIRETROVIRAL THERAPY AND OPPORTUNISTIC ILLNESS PRIMARY CHEMOPROPHYLAXIS ON SURVIVAL AFTER AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 10) McNaghten AD, Hanson DL, Jones JL, Ward JW, Dworkin MS The risk of death is 2.5 times lower for persons receiving triple ART than persons receiving monotherapy. These results provide early indication of the beneficial effects of protease inhibitors on survival in an observational study. Additionally, we found that PCP and MAC prophylaxis and pneumococcal vaccination have positive effects on survival. |
|
| 11 | Beyond clinical trials--population-based HIV viral load monitoring and antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 11) Denning P, Fleming P These data demonstrate the benefits of PI therapy in minimizing VL in the general population of HIV-infected persons. However, 53% of persons reported with HIV/AIDS in 1997 on these areas had not received VL testing; and of those who had, 42% had not received ARV therapy despite advanced HIV disease. |
|
| 12 | Longitudinal plasma HIV RNA patterns among HIV-1 infected individuals with late disease progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 12) Gange SJ, Mellors JW, Schrager L, Margolick JB, Giorgi JV, Detels R, Phair J, Munoz A &&&Johns Hopkins School of Public Health, Baltimore, MD |
|
| 13 | HIV-1 is actively produced in the female genital tract. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 13) Lennox JL, Ellerbrock TV, Schinazi RF, Clancy K, Pratt-Palmore M, Bush T, Hough L, Schnell C, Hart C &&&Emory University, Atlanta, GA |
|
| 14 | Risk factors for unprotected sex among men reported with AIDS in Los Angeles County: implications for HIV prevention. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 14) Simon P, Thometz E, Bunch G, Sorvillo F, Detels R &&&Centers for Disease Control and Prevention, Atlanta, GA |
|
| 15 | A peer education intervention reduces HIV infection among factory workers in Zimbabwe. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 15) Machekano R, Mcfarland W, Mzezewa V, Ray S, Mbizvo M, Bassett M, Latif A, Mason P, Gwanzura L, Moses L, Ley C, Brown B, Parsonnet J, Katzenstein D &&&Stanford University Medical Center, Stanford, CA |
|
| 16 | The efficacy of counseling and testing in reducing HIV risk in developing countries: a three-country randomized controlled trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 16) Coates TJ; University of California, San Francisco, CA |
|
| Session 7— Slide Immunopathogenesis of HIV-1 Infection |
||
| 17 | Analysis of TCR repertoire against a conserved HIV-RT CTL epitope in a cohort of HIV+ patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 17) Kolowos W, Bachmann O, Schmitt M, Herrmann M, Goldwich A, Baurle M, Low P, Harrer E, Kalden JR, Harrer T &&&Department of Medicine III, University of Erlangen-Nurnberg, Germany |
|
| 18 | Abnormal T cell receptor repertoire in children with vertically-acquired HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 18) McFarland EJ, Harding PA, Striebich CC, Kuritzkes DR, Kotzin BL; University of Colorado Health Science Center, Denver, CO |
|
| 19 | Antiretroviral drug-mediated suppression of HIV-1 results in loss of CD8+ T cell receptor (TCR) skewing and reduced frequency of epitope-specific CD8+ Cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 19) Gray CM, Schapiro JM, Altman J, Lawrence J, Crompton M, Merigan TC; Stanford University, Stanford, CA |
|
| 20 | Immunological reconstitution after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 20) Miedema F, Pakker NG, Notermans DW, De Boer R, Kostense S, Roos MT, De Wolf F, Hill A, Leonard JM, Danner SA, Raaphorst FM, Schellekens PT &&&Academic Medical Centre, University of Amsterdam, The Netherlands |
|
| 21 | Immunologic changes in blood and lymph nodes induced by highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 21) Hicks CB, Markert L, Ottinger J, Ferrari G, Harmon L, Demarest J, Bartlett JA, Hale L, Weinhold K &&&Duke University Medical Center, Durham, NC |
|
| 22 | Increased turnover of CD4 and CD8 T cells in untreated HIV infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 22) Sachsenberg N, Perelson A, Perrin L &&&Laboratory of Virology, University Hospital, Geneva, Switzerland |
|
| 23 | M-tropic HIV-1 strains are extremely sensitive to inhibition by RANTES. Sensitivity of T-tropic strains to RANTES is donor cell dependent. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 23) Trkola A, Vesanen M, Monard S, Siani MA, Hoxie JA, Wu L, Moore JP; Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY |
|
| 24 | Anergy and dysfunction of CD4+ and Vgamma 2Vdelta 2+ lymphocytes associated with Mycobacterium bovis BCG-induced disease in SIV-infected monkeys. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 24) Zhou Z, Lee-Parritz D, Chalifoux L, Simon M, Morita CT, Letvin NL, Chenz ZW &&&Beth Israel Deaconess Medical Center, Boston, MA |
|
| Session 8— Slide Virology I |
||
| 25 | A novel human protein that interacts with HIV-1 Vpu, connects CD4 to the ER degradation pathway. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 25) Margottin F, Bour SP, Durand H, Strebel K, Benarous R &&&INSERM, ICGM, Paris, France |
|
| 26 | HIV-1 Vpr enters the nucleus via a novel import pathway. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 26) Jenkins Y, McIntee M, Kuo A, Weis K, Greene WC |
|
| 27 | The putative alpha helix 2 of HIV-1 Vpr contains a determinant which is responsible for the translocation of the proviral DNA in growth-arrested cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 27) Cohen EA, Subbramanian RA, Nie Z, Yao XJ, Rougeau N, Bergeron D |
|
| 28 | Co-operative interaction of V(1)-V(2) region with V(3) region of HIV-1 gp120 is important for productive viral infection: its role in binding of gp120 to viral co-receptor. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 28) Chen M, Gupta PA |
|
| 29 | Vpr is the key regulator of HIV-1 nuclear import. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 29) Bukrinsky M, Popov S, Zybarth G |
|
| 30 | NC protein role in selective HIV-1 genomic RNA packaging. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 30) Poon DT, Li G, Aldovini A |
|
| 31 | Trans complementation of integrase function. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 31) Soares MA, Weng Z, Wakefield J, Mcphearson S, Shaw GM, Leavitt AD, Boeke JD, Hahn BH |
|
| 32 | Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 32) Arion D, Borkow G, Kaushik N, Parniak MA |
|
| Session 9— Symposium Chemokine Receptors and HIV/SIV |
||
| S3 | The effect of polymorphisms in the regulatory regions of the CCR5 promoter on HIV-1 vertical transmission and on disease progression in infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S3) Moore JP, Kostrikis LG, Ho DD |
|
| S4 | Infection of macrophages by primary, syncytium-inducing HIV-1 strains: the role of CCR5, CXCR4 and other coreceptors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S4) Clapham PR, Simmons G |
|
| S5 | Structure of Function of CCR2 and CCR5: Molecular Mechanisms of Directed Cell Migration Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S5) Charo I |
|
| S6 | Unwelcome guests with master keys: how HIV-1 used chemokine receptors to infect cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S6) Dorns RW |
|
| Session 10— Symposium AIDS Malignancies |
||
| S7 | Recent Advances in AIDS Malignancies Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S7) Ellen Feigal Abstract not submitted |
|
| S8 | HPV and anogenital cancer: Interaction with HIV Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S8) Lowy DR, Schiller JT |
|
| S9 | Epstein-Barr virus and lymphoma in patients with HIV Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S9) Ambinder RF |
|
| S10 | Malignancies in HIV-infected children Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S10) Mueller BU |
|
| Session 11— Symposium Advances in HIV Prevention |
||
| S11 | Prevention of perinatal HIV transmission. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S11) Mofenson L |
|
| S12 | The use of post-exposure therapy (PET) to prevent non-occupational transmission of HIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S12) Smith DK |
|
| S13 | Rapid test strategies for HIV testing. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S13) Branson BM and Janssen R |
|
| S14 | Prevention successes in Thailand's HIV/AIDS prevention. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S14) Wiput Phoolcharoen |
|
| Session 12— Poster Chemokines and Their Receptors |
||
| 33 | Selective exclusion of HIV coreceptors from HIV virions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 33) Bastiani L, Laal S, Hoxie JA, Zolla-Pazner S, Bandres JC |
|
| 34 | Characterization of HIV-1 susceptibility and co-receptor expression of herpesvirus saimiri (HVS) immortalized CD4+ cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 34) Mosoian A, Klotman ME |
|
| 35 | The inability of HIV-1 to infect highly purified CD25-CD4+ T lymphocytes is not due to lack of co-receptor expression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 35) Van Dyke G, Ramilo O, Vitetta ES |
|
| 36 | HIV-1 co-receptor expression is insufficient for infection of hematopoietic stem cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 36) Shen H, Cheng T, Yang O, Golan D, Preffer FI, Luster AD, Scadden DT |
|
| 37 | GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry in human monocytes and macrophages. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 37) Di Marzio P, Mariani R, Tse J, Thomas EK, Landau NR |
|
| 38 | Macrophage replication kinetics of SI and NSI clinical isolates using diverse co-receptors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 38) Lathey JL, Brambilla D, Notka M, Rasheed S, Siwak E, Goodenow M, Bremer JW, Ladd B, Collman R, Reichelderfer P &&&NIAID, Bethesda, MD |
|
| 39 | Modulation of CCR5 expression on macrophages infected with HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 39) Peng G, Hale-Donze H, Wild T, Orenstein JM, Wahl SM |
|
| 40 | Increased surface expression of CCR5 on monocyte-derived macrophages mediates enhanced susceptibility to HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 40) Tuttle DL, Harrison JK, Sleasman JW, Goodenow MM |
|
| 41 | Role of T-tropic HIV-1 V(3) loop in viral entry into cells analyzed with 3 different anti-CXCR-4 monoclonal antibodies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 41) Hori T, Sakaida H, Hattori T, Sato A, Nakajima T, Shida H, Yoshie O, Uchiyama T |
|
| 42 | Role of CXCR-4, CCR5 and CCR3 in the differential tropism of HIV-1 isolates for distinct thymocyte subsets. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 42) Martins LP, Gurney K, Connors C, Torbett B, Uittenbogaart C |
|
| 43 | HIV-1 replication is substantially supported in rabbit cells expressing human CCR5 and human CD4. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 43) Speck RF, Penn ML, Wimmer J, Esser U, Kindt TJ, Atchison RE, Goldsmith MA |
|
| 44 | Entry and cytopathicity of FIV in human cells is mediated by the CXCR4 chemokine receptor. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 44) Poeschla E, Looney DJ |
|
| 45 | Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: type 1 cytokine upreguation of CCR5 mRNA expression can be abolished by IL-10. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 45) Patterson BK, Czerniewski MA, Andersson J, Felice SU, Landay A |
|
| 46 | Genomic organization and functional characterization of CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 46) Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Michael NL |
|
| 47 | Flow cytometric analysis of the binding of HIV envelope to CXCR4, relevance of the interaction with soluble CD4 and HIV envelope glycosylation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 47) Bandres JC, Wang QF, O'Leary J, Hoxie JA, Zolla-Pazner S, Gorny MK |
|
| 48 | CCR5 co-receptors derived from nonhuman primates and their usage by SIV, HIV-1 and HIV-2 primary strains. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 48) Kunstman K, Wolinsky S, Agy M, Shibata R, Yoder A, Jones M, Marx P, Chen Z |
|
| 49 | Alpha and beta chemokines exert opposing effects on HIV-GP120-induced B lymphocyte functions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 49) Patke C, Green C, Shearer W |
|
| 50 | Characterization of a panel of anti-CXCR4 monoclonal antibodies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 50) Turner JD, Willet BJ, Peiper SJ, Endres MJ, Hoxie JA |
|
| 51 | HIV pathogenesis in human lymphoid tissues ex vivo. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 51) Glushakova S, Grivel JC, Fitzgerald W, Yin S, Hatfill S, Sylwester A, Zimmerberg J, Murphy P, Margolis LB |
|
| Session 13— Poster Effects of Chemokine Receptors on Natural History |
||
| 52 | Viral and immunological features and CCR-5 polymorphism in HIV-1 infected long-term non progressors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 52) Galli M, Balotta C, Clementi M, Clerici M |
|
| 53 | HIV-1 qasispecie in a HIV-1 infected patient homozygous for Δ32 deletion of the CCR5 chemokine receptor gene. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 53) Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Papagno L, Sampaolesi R, Riva C, Mazzola F, Berlusconi A, Corvasce S, Clementi M, Galli M, Moroni M |
|
| 54 | The joint effects of chemokine receptor (CCR) variants, plasma HIV RNA (RNA) and CD4+ cells on HIV progression in hemophiliacs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 54) Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots K, Chernoff D, O'Brien SJ |
|
| 55 | Lack of evidence for a role of the &Delta32; deletion mutation in disease progression in HIV infected injection drug users. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 55) Schinkel CJ, Langendam MW, Coutinho RA, Brouwer M, Schuitemaker H |
|
| 56 | Significantly lower plasma viral load in long term slow progressors heterozygous for &Delta32;-CCR5. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 56) Walli R, Reinhart B, Muhlhofer A, Lederer E, Loch O, Gurtler L, Schlondorff D, Goebel FD |
|
| 57 | Co-receptor usage, viral phenotype, and V(3) sequences of HIV-1 isolates obtained from long-term infected hemophilic patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 57) Picchio G, Sabbe R, Boggiano C, Mosier DE |
|
| 58 | Patterns of HIV-1 evolution in vivo and phenotypic specificity correlate with disease progression and the loss of T cell homeostasis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 58) Shankarappa R, Margolick JB, Farzadegan H, Gange S, Gupta P, Rinaldo CR, Upchurch D, Rodrigo AG, Mullins JI |
|
| 59 | Exclusive and persistent use of the entry co-receptor CXCR4 by HIV-1 from a subject homozygous for CCR5 &Delta32;. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 59) Michael NL, Nelson JA, Kewalramani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, Littman DR, Swanstrom R, O'Brien TR |
|
| 60 | A second mutation associated with the CCR5 Δ32 deletion in Δ32-heterozygous individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 60) Aikhionbare F, Newman C, Roth W, Bond C, Stringer G Jr |
|
| 61 | Maintenance of chemokine receptor expression on peripheral and central lymphocytes in human immunodeficiency virus-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 61) Penn ML, Speck RF, Abbey N, Wieder E, Loftus R, Deeks S, Hernder B, Goldsmith MA |
|
| 62 | Expression of chemokine receptors CXCR4 and CCR5 in HIV-1 infected and uninfected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 62) Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell LB, Kumar PN, Mican J, Fauci AS |
|
| Session 14— Poster Viral and Host Determinants of the Natural History of Retroviral Infection |
||
| 63 | Virological study of HIV-1-infected long term asymptomatic subjects (ALTs). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 63) Candotti D, Costagliola D, Rouzioux C, Autran B, Agut H |
|
| 64 | Does cell-associated infectious HIV-1 viral load predict HIV-1 disease progression independently of plasma HIV-1 RNA levels? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 64) Lyles C, Farzadegan HI, Astemborski J, Quinn T, Hoover D, Masters B, Margolick J, Vlahov D |
|
| 65 | The natural history of viral load over 16 years of HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 65) Sabin CA, Devereux H, Phillips AN, Hill AM, Lee CA, Loveday C |
|
| 66 | Emergence of syncytium-inducing HIV-1 variants coincides with burst in viral RNA level and is an independent predictor for progression to AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 66) Spijkerman IJ, de Wolf F, Langendam MW, Schuitemaker H, Coutinho RA |
|
| 67 | Evolution of HIV-1 env sequences in plasma and peripheral blood lymphocytes from subjects with nonprogressive and progressive infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 67) Bagnarelli P, Mazzola F, Sampaolesi R, Menzo S, Clementi M |
|
| 68 | Comparison of nef alleles from PBMC-associated proviral DNA and plasma virion RNA in a cohort of progressors and LTNP hemophiliacs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 68) Vicenzi E, Turchetto L, Brambilla A, Santagostino E, Clementi M, Poli G, Bagnarelli P |
|
| 69 | Cytopathicity of biological clones isolated from HIV-1 infected patients with intact and depleted CD4 T cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 69) Forte SE, Somasundaran M, Sullivan JL |
|
| 70 | HIV-1 cell tropism, viral RNA levels, and rate of CD4 T cell loss in human PBL-SCID mice. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 70) Mosier DE, Gulizia RJ, Sabbe R, Picchio GR &&&Scripps Research Institute, La Jolla, CA |
|
| 71 | Neutralising antibodies and specific anti-Env and anti-pol IgG1 levels are correlated to HIV-1 replication in long term non progressors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 71) Ngo-Giang-Huong N, Candotti D, Goubar A, Costagliola D, Agut H, Autran B, Rouzioux C |
|
| 72 | Comparison of HIV-1 infected long-term nonprogressors and average progressors in HIV-specific CTL activity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 72) Betts MR, Krowka J, Eron J, Sheppard H, Frelinger J |
|
| 73 | Narrowly directed HIV-1-specific CTL responses in rapidly progressive disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 73) Hay C, Ruhl D, Dipasquale MP, D'Aquila R, Walker B |
|
| 74 | Multiple HLA class I, class II and TAP markers collectively predict AIDS-free time in 5 groups of homosexual men. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 74) Keet IP, Tang J, Carrington M, Mann D, Goedert J, Enger C, Kaslow RA |
|
| 75 | Comparison of viral load and HLA statistical and artificial intelligence predictive models for the rate of HIV disease progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 75) Ioannidis JP, Goedert JJ, McQueen PG, Enger C, Kaslow RA |
|
| 76 | HIV disease progression and associated genetic markers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 76) Buchbinder S, Vittinghoff E, Kaslow R, Keet I, O'Brien S, Carrington M |
|
| 77 | Amsterdam Cohort Study: presence of the variant mannose-binding lectin (MBL) alleles associated with slower progression to AIDS? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 77) Maas J, De Roda Husman AM, Brouwer M, Krol A, Coutihno R, Keet I, Schuitemaker H |
|
| 78 | Individual T-cell homeostasis failure and progression to clinical AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 78) Gange SJ, Munoz A, Chmiel JS, Donnenberg AD, Detels R, Margolick JB |
|
| 79 | Effects of SIV(smm) and STLV(sm)-I dual infection on viral burden and disease progression in pig-tailed macaques. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 79) McGinn TM, Stallworth J, Smith S, Wilson A, Fultz PN |
|
| Session 15— Poster Vaccine Development |
||
| 80 | Humoral immune responses to recombinant HIV-1 envelope antigens in newborns receiving gp120 vaccines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 80) McFarland EJ, Borkowsky W, Wara D, Macnamara J, Kang M, Fenton T, Cunningham C, Mofenson L, Duliege A, Sinangil F, Francis D |
|
| 81 | Safety of recombinant HIV-1 envelope vaccines in neonates born to HIV-1 infected women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 81) Cunningham CK, Wara DW, Fenton T, Kang M, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland E, Borkowsky W |
|
| 82 | Generation of HIV-epitope-specific CTL by HIV-peptide pulsed, allogeneic dendritic cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 82) Raychaudhuri SK, Dupuis M, Benike C, Engleman E, Merigan TC |
|
| 83 | Therapeutic vaccination with p24-VLP and AZT augments HIV specific CTL activity in HIV infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 83) Clarkson J, Ffrench R, Law M, Marshall P, Kelleher T, Smith D, Patou G, Stewart G, Cooper D, Benson EM |
|
| 84 | Peptide immunogens representing conserved epitopes of gp120 can induce immune responses recognizing gp120 that are not formed by immunization with whole rgp120. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 84) Kelker HC, Nardelli B, Itri V, Paolino A, Valentine FT |
|
| 85 | Comparative analysis of immune responses to HIV-1 envelope glycoproteins in mice immunized respectively with a DNA vaccine, a recombinant Semliki Forest virus RNA and a recombinant Semliki Forest virus particle. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 85) Brand D, Lemiale F, Buzelay L, Brunet S, Barin F |
|
| 86 | Vaccine evaluation studies of replication-defective SIVsmB7. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 86) Kraiselburd E, Salaman A, Rivera M, Kessler M, Knezevich M, Rodriguez A, Montefiori D, Martinez I |
|
| 87 | Enhancement of anti-HIV T cell responses by delivery of HIV-1 proteins to dendritic cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 87) Zheng L, Huang X, Fan Z, Borowski L, Wilson C, Rinaldo C |
|
| 88 | QS21 is superior to alum as an adjuvant with low dose, recombinant MN gp120 for immunization of HIV-1 uninfected volunteers: cellular and humoral responses. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 88) Kallas KG, Evans TG, Gorse G, McElrath MJ, Mulligan M, Matthews T, McNamara J, Wolff M, Francis D |
|
| 89 | Effect of boosting and jet-injection on safety and immune responses in recipients of a DNA-based HIV-1 vaccine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 89) MacGregor R, Boyer J, Ugen K, Higgins T, Baine Y, Ginsberg R, Weiner D |
|
| Session 16— Poster Immune Correlates of Resistance to Retroviral Infection |
||
| 90 | CD8+ T cells mediate resistance to HIV challenge in SCID mice engrafted with PBL of long term non-progressors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 90) Lopez JC, McNeil AC, Gea-Banacloche JC, Connors M |
|
| 91 | Vaccine induced CTL activity correlates with resistant phenotype in an in vitro challenge system. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 91) Castillo RC, Arango-Jaramllo S, Humphrey W, Weinhold K, Schwartz DH |
|
| 92 | Detection of HIV-specific CTL activity in HIV exposed uninfected subjects. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 92) Yannakis C, Bernard NF, Lee J, Tsoukas CM |
|
| 93 | Correlates of immune protection in sexually exposed HIV seronegative individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 93) Mazzoli S, Lo Palco L, Meacci F, Trabattoni D, Salvi A, Biasin M, Lo Caputo S, Ble C, Semplici F, Siccardi AG, Clerici M |
|
| 94 | Homozygosity for CCR5 deletion (&Delta32;/&Delta32;) explains protection from HIV-1 infection in few very high risk HIV-1 homosexual men. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 94) Detels R, Enger C, Dean M, Carrington M, Zimmerman P, Murphy P, Koup R, O'Brien S, Kaslow R |
|
| 95 | Investigation of CD8 suppression as a mechanism of HIV resistance in highly exposed, persistently seronegative (HEPS) individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 95) Pisell TL, Hodge TW, Qari S, McNicholl JM, Bond KB, Limpakarnjanarat K, Mastro TD, Folks TM, Butera ST |
|
| Session 17— Poster Humoral and Cellular Immunity to HIV-1 |
||
| 96 | Binding of monoclonal antibodies (mAb) to intact HIV-1 virions: a new strategy for mapping conserved HIV-1 epitopes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 96) Nyambi PN1, Gorny MK1, Williams C1, Zolla-Pazner S1,2 |
|
| 97 | Antigenic relationships among group M HIV-1 viruses revealed by identification of shared V(3) epitopes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 97) Gorny MK, Nadas A, Vancott TC, Nyambi PN, Williams C, Zolla-Pazner S |
|
| 98 | Neutralization of several HIV-1 primary isolates by sera from HIV-negative recipients of candidate HIV vaccines Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 98) Zolla-Pazner S, Xu S, Burda S, Dayaraj C, Kewalramani V, Littman D, Clements-Mann ML, Excler JL, Duliege AM |
|
| 99 | Characterization of highly conserved epitopes in the V(1)/V(2) domain of HIV-1 gp120 that mediate potent neutralization of primary HIV-1 isolates. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 99) Pinter A, Burkhart M, Honnen W, Kayman S, Reiken S, Tan G, Trochev O, Wu Z |
|
| 100 | Partial Glycosylation at Asn-X-Ser/Thr Sequons Contributes to Structural Diversity in the V3 Region of HIV-1 gp120 Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 100) Mellquist J1,2, Wunner WH3, Jackson JB1, and Shakin-Eshleman SH1 |
|
| 101 | Passive administration of an anti-HIV-1 monoclonal neutralizing Ab does not modify the course of established HIV-1 infection in the hu-PBL SCID mouse model. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 101) Poignard P, Gulizia R, Picchio G, Wang M, Parren P, Mosier D, Burton D |
|
| 102 | Interactions between domains in gp120 and gp41 determine neutralization sensitivity phenotype of HIV-1 envelope glycoproteins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 102) Park EJ, Theodore TS, Quinnan GV Jr |
|
| 103 | Inactivation of HIV-1 infectivity with preservation of conformational and functional integrity of virion surface proteins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 103) Rossio JL, Esser MT, Schneider DK, Bess JW Jr, Grimes MK, Arthur LO, Henderson LE, Lifson JD |
|
| 104 | Resistance of primary isolates of HIV-1 to complement mediated lysis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 104) Takefman D, Sullivan B, Spear G |
|
| 105 | Circulating CD8 T lymphocytes in HIV-infected individuals have impaired function and downmodulate CD3zeta, the signaling chain of the T cell receptor complex. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 105) Trimble LA, Lieberman J |
|
| 106 | Effective lysis of HIV-infected primary CD4 T cells by a CTL clone directed against a novel A2-restricted HIV-1 reverse transcriptase epitope. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 106) Shankar P, Sprang H, Lieberman J |
|
| 107 | CD86 confers and directs and MHC class I restricted CTL induction. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 107) Kim JJ, Agadjanyan MG, Trivedi N, Wilson DM, Morrison LD, Maldonado MA, Williams WV, Weiner DB |
|
| 108 | HIV regulatory gene expression alters the surface density of T-cell receptor-(TCR)/CD3 complexes on a CD4+ T cell line. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 108) Willard-Gallo K, Furtado M, Burny A, Wolinsky S |
|
| Session 18— Poster Miscellaneous Immunology |
||
| 109 | Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays in HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 109) Weinberg A, Betensky R, Zhang L, Ray G |
|
| 110 | Survival in advanced HIV disease is more stringently related to lymphocyte activation as reflected by expression of elevated CD38 antigen on T cells than to plasma HIV viral burden. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 110) Giorgi JV, Wolinsky SM, Hultin L, Phair JJ, Jacobson L, Detels R |
|
| 111 | Activation of the p38 MAP kinase pathway by lipopolysaccharide (LPS) interferes with HIV-1 infection of monocyte-derived macrophages. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 111) Reiling N, Zybarth G, Bukrinsky M |
|
| 112 | Expression and function of SLAM-positive lymphocytes in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 112) Clerici M, Meroni L, Fusi ML, Varchetta S, Biasin M, De Vries J, Aversa G, Galli M |
|
| Session 19— Poster Diagnostics: Viral Diversity |
||
| 113 | Detection of HIV-2 in specimens submitted for HIV-1 testing in New York City from 1993-1995. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 113) Beatrice ST, Oleszko WR, Torian V, Chiasson MA, Punsalang A, Weisfuse IB, Schable CA |
|
| 114 | A highly sensitive method for HIV-2 DNA amplification. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 114) Damond F, Loussert-Ajaka I, Apetrei C, Descamps D, Souquiere S, Lepretre A, Matheron S, Brun-Vezinet F, Simon F |
|
| 115 | V3 serotyping of HIV-1 infection: correlation with genotyping, limitations and identification of subtype-specific amino-acid sequences. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 115) Plantier JC, Simon F, Peeters M, Kanki PJ, Barin F |
|
| 116 | A rapid assay for the simultaneous detection and differentiation of antibodies to HIV-1 group M, HIV-1 group O and HIV-2. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 116) Vallari A, Varitek V, Necklaws E, Hickman R, Hackett J Jr, Devare S |
|
| 117 | Quantitation of group O and group M subtypes A-H by the Gen-Probe HIV-1 viral load assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 117) Sanders M, Gurtler L, Simon F, Bott M, Dise E, Giachetti C, Nunomura K, Bodrug S |
|
| 118 | Sensitive and accurate quantitation of diverse HIV-1 subtypes utilizing the Digene HIV RNA test. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 118) Schiltz H, Tang Y, Glock J, Davis K, Lorincz A, Lazar J, De la Rosa A |
|
| 119 | Sensitivity, linear range and performance on HIV-1 subtypes of the AMPLICOR HIV-1 MONITOR Test, version 1.5 and the ultra-sensitive specimen preparation method. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 119) Herman S, Sun R, Wang J, Debonville D, Payne H, Dreyer K, Lavallee K, Chutoransky L, Arole M, Arch K, Jayakar H, Kuo JC, Ku J, Spadoro J |
|
| 120 | Anti-HIV-1/2 assay with increased detection to group O by addition of group O recombinant antigens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 120) Sullivan M, Finley A, Kite A, Lainio S, Chang CD, Jiang L, Munson S, Mestek A, Shah D, Shumard-Sauer C |
|
| 121 | A simultaneous HPLC assay for quantification of indinavir (IDV), saquinavir (SQV), ritonavir (RTV), and nelfinavir (NLV) in human plasma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 121) Kawle SP, Remmel RP, Weller D, Fletcher CV |
|
| Session 20— Poster Epidemiology: Molecular Subtypes of HIV |
||
| 122 | Heterogenic distribution patterns of HIV-1 epidemic in Brazil. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 122) Ramos A, Tanuri A, Rayfield MA, Janini LM, Pieniazek D |
|
| 123 | Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 123) Pinto ME, Tanuri A, Schechter M |
|
| 124 | Human immunodeficiency virus type 1 diversity in Romania. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 124) Apetrei C, Necula A, Holm-Hansen C, Duca M, Pecec M, Brun-Vezinet F, Simon F |
|
| 125 | Non-B subtypes of HIV-1 Group M in specimens from New York City between 1993-1995. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 125) Beatrice ST, Oleszko WR, Punsalang A Jr, Chiasson MA, Torian LV, Weisfuse IB, Schable CA |
|
| 126 | Evidence for quadruple recombination between subtypes A, C, G And I in an HIV-1 isolate from Cyprus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 126) Gao F, Robertson DL, Carruthers CD, Li Y, Salminen M, Kostrikis L, Ho DD, Hahn BH |
|
| 127 | Genomic sequence of HIV-1 group O isolate HAM112. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 127) Golden A, Lund J, Gurtler L, Devare S |
|
| Session 21— Poster Epidemiology: Substance Abuse |
||
| 128 | The increasing impact of injecting drug use (IDU) on the AIDS epidemic, New York City (NYC), the first 100,000 AIDS cases. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 128) McFarland JW, Singh T, Vasquez F, Forlenza S |
|
| 129 | Overlapping AIDS epidemic among injecting drug use (IDU) and heterosexual exposure (HT) in New York City (NYC) AIDS cases. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 129) Chu A, Torbert A, Brown L, Ellison J, Matthew I, McFarland J, Forlenza S |
|
| 130 | Sustained high HIV seroprevalence in crack users attending sexually transmitted disease clinics in New York City, 1990-1996. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 130) Menzies IB, Makki HA, Schween FW, Weisfuse IB, Benson DA, Torian LV |
|
| 131 | Age-specific differences in HIV incidence and risk behaviors among illicit drug users admitted to drug treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 131) Murrill CS, Miller MS, Gwinn M |
|
| 132 | HIV+ IDUs eligible for antiretrovirals: what are the barriers to receiving therapy despite universal access? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 132) Strathdee SA, Palepu A, Cornelisse PG, O'Shaughnessy MV, Schechter MT, Montaner JS, Hogg RS |
|
| 133 | Explosive HIV epidemics in injection drug users - what are the causes and controls? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 133) Raboud JM, Thorne AK, Strathdee SA, O'Shaughnessy MV, Schechter MT |
|
| 134 | Needle exchange programs: availability and participation among injection drug using women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 134) Rich JD, Astemborski J, Smith DK, Schoenbaum E, Davenny K, Schuman P, Vlahov D |
|
| Session 22— Poster Epidemiology: Infection Control |
||
| 135 | Passive HIV antibody reactivity following a health care worker (HCW) accident: implications for HCW post-exposure management. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 135) deOliveira CF, Harmache A, Frenkel LM, Gupta P, Mullins JI, Busch MP |
|
| 136 | Postexposure antiretroviral treatment for non-occupational exposure to HIV at Bichat-Claude Bernard Hospital, in Paris. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 136) Bouvet E, Prevot MH, Matheron S, Laporte A |
|
| 137 | Clinical characteristics and HIV serostatus of patients (P) in respiratory isolation in a large urban county hospital. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 137) Denbesten K, Pulvirenti J, Wester W, Ajudia K, Braswell K, de Guzman D, Welbel S |
|
| 138 | HIV seroprevalence in patients being evaluated for tuberculosis (TB). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 138) Welbel S, deGuzman D, Denbesten K, Wester W, Ajudia K, Braswell K, Pulvirenti J |
|
| 139 | Self-assessment of PPD skin test reactions by drug users with or at risk for HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 139) Gourevitch MN, Teeter R, Klein RS &&&Montefiore Medical Center, Bronx, NY |
|
| Session 23 — Poster Epidemiology: Miscellaneous |
||
| 140 | Per-contact risk for transmission of HIV associated with four types of homosexual contact. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 140) Vittinghoff E, Buchbinder SP, Judson F, Douglas J, McKirnan D, MacQueen K |
|
| 141 | Study of acute and early infections yields surprising risk profile. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 141) Senterfitt JW, Harawa NT, Whitfeld C, Kerndt PR, Daar E |
|
| 142 | Changes in HIV seroprevalence in entrants to the New York City correctional system, 1992-1996. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 142) Torian LV, Makki HA, Weisfuse IB |
|
| 143 | Integration and optimization of HIV rapid testing algorithms in client-centered HIV counseling. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 143) Fridlund C, Downing RG, Alwano-Edyegu MG, Otten RA, Marum E, Dondero T, Campbell C, Rayffeld M |
|
| Session 24 — Poster Antiretroviral Therapy: Practice Patterns, Adherence, and Outcomes |
||
| 144 | Recent patterns of antiretroviral therapy (AR) and clinical response in ambulatory HIV patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 144) Moorman A, Delaney K, Palella F, Ashman D |
|
| 145 | Outcomes of triple therapy that included a protease inhibitor (PI) among 2139 patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 145) Fessel WJ, Hurley LB |
|
| 146 | Antiretroviral usage patterns before and after instituting national treatment guidelines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 146) Gruta CL, Liljestrant P, Balano KB, Legg JJ, Dong BJ, Goldschmidt RH |
|
| 147 | 1996 IAS-USA recommendations in clinical practice in Argentina: one year after. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 147) Cahn P, Zala C, Gun A, Maralit J, Perez H, Callegari M, Kauffman S |
|
| 148 | Maintaining protease inhibitor therapy in a clinic setting. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 148) Bozek PS, Perdue BE, Forrest-Smith M |
|
| 149 | Relationship between adherence to HAART and disease state. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 149) Tebas P, Royal M, Fichtenbaum C, Blutman J, Arens M, Horgan M, Powderly W |
|
| 150 | Abstract Withdrawn | |
| 151 | Adherence and effectiveness of protease inhibitors in clinical practice. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 151) Hecht FM, Colfax G, Swanson M, Chesney MA |
|
| 152 | HIV-infected homeless and marginally housed (H/M) patients adhere to and receive early virologic benefit from protease inhibitors (PI). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 152) Bangsberg DR, Zolopa AR, Charlebois E, Tulsky J, Hecht FM, Robertson M, Chesney M, Holodniy M, Merigan TC, Moss AR |
|
| Session 25 — Poster Immunologic Effects of Highly Active Antiretroviral Therapy |
||
| 153 | Improvement in T-cell receptor BV perturbations following combination therapy with indinavir and nucleoside RT inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 153) Jaramillo A, Zaunders J, Kelleher T, Cooper DA |
|
| 154 | Disordering of CD4 and CD8 T-cell repertoires during progression to AIDS and restoration of the CD4 repertoire under antiviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 154) Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C, Karmochkine M, Raguin G, Autran B, Debre P |
|
| 155 | Longitudinal study of cytokine gene expression and TCR Vb repertoire in patients after initiation of ritonavir plus saquinavir therapy (ANRS 069). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 155) Lantz O, Martinon F, Peguillet I, Taoufik Y, Lefebvre P, Bellissant E, Goujard C, Michelet C, Guillet JJ, Delfraissy JF |
|
| 156 | Changes in immunological status of HIV-infected patients receiving triple combination antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 156) Weiss L, Girard PM, Roux A, Ancuta P, Tessey C, Kazatchkine MD, Haeffner-Cavaillon N |
|
| 157 | Reconstitution of "naïve" (CD45RA +CD62L +) CD4+ T-cells after potent anti-HIV-1 therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 157) Hengel RL, Jones BM, Kennedy SM, Hubbard MS, McDougal JS |
|
| 158 | Reconstitution of memory (CD45RO) and naïve (CD45RA) CD4+ T cells following ritonavir therapy in HIV-infected children with advanced disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 158) Sleasman J, Goodenow M, Nelson R, Wilfert D, Hutson A, Heath-Chiozzi M, Pizzo P, Mueller B |
|
| 159 | Downregulation of cytokine production in lymphoid tissue following successful HIV suppressive therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 159) Andersson J, Fehniger T, Patterson BK, Pottage J, Jones P, Landay A |
|
| 160 | Altered cytokine production in patients following institution of highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 160) Siegel JN, Spritzler J, Wade M, Lederman MM, Connick E, Kessler H, Landay AL |
|
| 161 | One year follow-up of CD4 and CD8 cytokine secreting lymphocytes in HIV infected patients treated with stavudine + didanosine + ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 161) Levacher M, Bouscarat F, Chau F, Landman R, Gaudebout C, Prevot MH, Damond F, Mathez D, Leibowitch J, Sinet M, Saimot A |
|
| 162 | Immune activation of T-helper cells in lymphoid tissue is associated with viral replication which can effectively be controlled by highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 162) Van Lunzen J, Hufert F, Bosch B, Tenner-Racz K, Racz P, Stellbrink HJ |
|
| 163 | Delayed and sustained immunologic recovery after 15 months of active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 163) Goujard C, Wallon C, Taoufik Y, Lantz O, Delfraissy JF |
|
| 164 | CD8 T cell-mediated suppression of HIV-1 is enhanced in patients receiving stavudine/indinavir therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 164) Wilkinson J, Zaunders J, McQueen P, Delaney S, Cooper DA |
|
| 165 | The effect of potent anti-HIV therapy on circulating and secreted levels of beta chemokines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 165) Kumar D, Parato K, Kumar A, Sun E, Cameron DW, Angel JB &&&Ottawa General Hospital, Ottawa, Canada |
|
| 166 | Activation and function markers of CD4+ and CD8+ T cells after potent anti-HIV-1 therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 166) Hengel RL, Jones BM, Kennedy SM, Hubbard MS, McDougal JS |
|
| 167 | Correction of immunological disorders with highly active antiretroviral therapies (HAART) of acute HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 167) Carcelain G, Blanc C, Debre P, Mathez D, Saimot AG, Leibowitch J, Autran B |
|
| 168 | Emergence of genotypic resistance in HIV-1 protease in children with reduced virus burden and significant immune reconstitution in response to highly active retrovirus therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 168) Burkhardt B, Perez EE, Mueller B, Pizzo P, Dunn BH, Sleasman JW, Goodenow MM |
|
| 169 | Highly active antiretroviral therapy (HAART) results in delayed enhancement of CD4+ T cell reactivity to mitogen and recall antigens, but not HIV-1 antigens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 169) Liebmann I, Huang X, Fan Z, Mellors J, Al-Shboul Q, McMahon D, Riddler S, Day R, Chen W, Bazmi A, Rinaldo C |
|
| 170 | Reduction in B cell hyperactivity during combination therapy for HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 170) Morris L, Binley JM, Clas B, Astill T, Kost R, Hurley A, Talal A, Cao Y, Markowitz M, Ho DD, Moore JP |
|
| 171 | Reversal of immune activation during potent anti-retroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 171) Majchrowicz MA, Hultin LE, Hultin P, Hausner MA, Kaplan A, Johnson T, Detels R, Giorgi JV |
|
| 172 | Long term immune recovery in CD4 and CD8+ T cells with highly active anti-retroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 172) Li TS, Tubiana R, Calvez V, Durali M, Mollet L, Carcelain G, Ait Mohand H, Mathez D, Debre P, Katlama C, Autran B |
|
| 173 | Treatment with highly active antiretroviral therapy (HAART) suggests that T cell depletion in HIV-infected individuals correlates with apoptosis mediated by Fas/FasL interactions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 173) Dockrell D, Badley A, Ziesmer S, Landay A, Lederman M, Connick E, Kessler H, Kuritzkes D, Lynch D, Roche P, Yagita H, Paya C |
|
| 174 | AICD in CD4 T cells from HIV seropositive patients is proportional to viral load and decreases on combination antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 174) Dockrell D, Badley A, Duffy M, Temesgen Z, Simpson M, Schut R, Yagita H, Lynch D, Leibson P, Paya C |
|
| 175 | Longitudinal analysis of virus specific IgG subclass titres in HIV-1 infected individuals before and during highly active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 175) Hardy G, Imami N, Gazzard B, Gotch F |
|
| 176 | Restoration of neutralizing activity of sera from HIV-infected patients receiving effective antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 176) Nokta M, Turk P, Pollard R |
|
| 177 | Abstract Withdrawn | |
| 178 | Activation and quantitation of latently infected T cells present in HIV-infected patient blood. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 178) Derdeyn CA, Kilby JM, Horton D, Hockett RD, Bucy RP |
|
| Session 26 — Poster Impact of HAART on the Incidence and Spectrum of Opportunistic Complications |
||
| 179 | Changing incidence and spectrum of AIDS-defining illnessess (ADIs) in the modern antiretroviral era. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 179) Forrest DM, Seminari E, Montaner JS, Yip B, Raboud J, Lawson L, Schechter MT, O'Shaughnessy MV, Hogg RS |
|
| 180 | Differences in the incidence rates of opportunistic processes before and after the availability of protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 180) Michaels S, Clark R, Kissinger P |
|
| 181 | Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 181) Murphy R, El-Sadr W, Cheung T, Luskin-Hawk R, Yurik T, Neaton J, Hafner R; Northwestern University, Chicago, IL |
|
| 182 | Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 182) Costagliola D |
|
| 183 | Decline in specific opportunistic infections (OI) at San Francisco General Hospital (SFGH). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 183) Holtzer CD, Jacobson MA, Hadley WK, Huang L, Stanley HD, Montanti R, Wong M, Stansell JD |
|
| 184 | Decline in CMV and other opportunistic disease with combination antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 184) Moore RD, Keruly JC, Chaisson RE |
|
| 185 | Pneumocystis carinii pneumonia in the protease inhibitor era. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 185) Huang L, Turner J, Swanson M, Holtzer C, Stansell J, Hecht F |
|
| 186 | Protease inhibitors are associated with less neuropsychological impairment in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 186) Ferrando S, Rabkin J, Van Gorp W, McElhiney M |
|
| Session 27 — Poster Epidemiology: Effects of Therapy on Transmission, Disease Progression, and Survival |
||
| 187 | The effect of protease inhibitor therapy and "undetectable" viral load on perceived risk of HIV transmission and need for safer practices. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 187) Kravcik S, Victor G, Houston S, Sutherland D, Garber GE, Foss NH, Angel JB, Badley A, Cameron DW |
|
| 188 | Impact of anti-retroviral therapy on HIV-1 seminal viral load. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 188) Barroso PF, Harrison LH, Souza YC, Bonfim AS, Schechter M, Gupta P |
|
| 189 | Correlates of HIV-1 detection by viral load and culture in semen. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 189) Evans JS, Dolan MJ, Walter EA, Anderson SA, Merritt T, Wegner S; Wilford Hall Medical Center, Lackland, Texas |
|
| 190 | Quantitative HIV-DNA detection in semen of HIV-infected individuals: correlation with HIV-RNA and culture. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 190) Vernazza PL, Dollenmaier G, Gowland PL, Roth F, Eron JJ, Fiscus SA |
|
| 191 | Use of immunological and virological markers and a continuous time Markov model to estimate the effect of multitherapies in a cohort of severe HIV infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 191) Le Pen C, Rozenbaum W, Downs A, Wirbel E, Adda N, Lilliu H, Maurel F, Beresniak A; Dauphine University, Paris, France |
|
| 192 | Progression of disease in the Pacific Oaks Population Study (POPS) since the introduction of protease inhibitors and use of highly active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 192) Shaefer M, Shaker-Irwin L, Maude C, Williams V, Morales D, Thommes J, Graham N |
|
| 193 | Increased survival time to AIDS and death associated with use of combined therapy in the multicenter AIDS cohort study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 193) Detels R, Munoz A, McFarlane G, Kingsley L, Margolick J, Giorgi J, Schrager L, Phair J |
|
| 194 | Improved survival time and CD4 slope associated with recent advances in HIV antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 194) Rachlis AR, Palmer RW, Doswell M |
|
| 195 | Regional survival differences across Europe in HIV positive patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 195) Vella S, Chiesi A, Mocroft A, Dally LG, Phillips AN, Miller V, Staszewski S, Lundgren JD |
|
| 196 | Temporal trends in survival for adults diagnosed with AIDS in Massachusetts, 1979-1994. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 196) Gallagher KM, Demaria A, Seage GS, Hereen T |
|
| 197 | Decreased morbidity and mortality among HIV+ individuals following initiation of antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 197) Hogg RS, Yip B, Heath KV, Craib KJ, Schechter MT, O'Shaughnessy MV, Montaner JS |
|
| 198 | Dramatically declining morbidity and mortality in an ambulatory HIV-infected population. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 198) Palella F, Moorman A, Delaney K, Loveless M, Fuhrer J, Aschman D, Holmberg S |
|
| Session 28 — Poster Epidemiology: Effects of HIV-1 Therapy on Cost of Care and Hospitalization |
||
| 199 | Rate of AIDS defining events (ADEs) and resulting cost of care: indinavir (IDV) in combination with zidovudine (ZDV) [or stavudine (d4T)] + lamivudine (3TC) versus ZDV [or d4T] + 3TC. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 199) Cook J, Coplan P, Markson L, Yin D, Meibohm A, Dasbach E, Nguyen BY |
|
| 200 | HAART reduced overall costs of HIV care at DVAMC-Denver. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 200) McCollum M, Klaus B, La Rue R, Bessesen M |
|
| 201 | Impact of aggressive management of HIV infection on clinical outcome and cost of care within a health maintenance organization. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 201) Melnick D, Greiner D, Little P, Melnick K |
|
| 202 | HIV physicians who provide continuity of care decrease the cost of HIV inpatients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 202) Brown I, Demissie K, Rhoads GG |
|
| 203 | Stabilization of in-patient daily census despite continued reduction in HIV-related admissions at a New York City hospital. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 203) Torres RA, Baney M, Barr MR |
|
| 204 | Decreased hospital utilization and costs are associated with protease inhibitor therapy but not with nucleoside therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 204) Keiser P, Kvanli M, Turner D, Smith JW, Nassar NN, Gregg CR |
|
| 205 | Impact of HAART on rates and types of hospitalization at a New York City hospital. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 205) Paul S, Ziecheck W, Gilbert HM, Jacobs J, Sepkowitz KA |
|
| 206 | Six year improvement in HIV hospital outcomes at Cook County hospital, Chicago: impact of AIDS care units and HAART. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 206) Sherer R, Pulvirenti J, Cohen M, Barker D, Fried M, Jasek J, Dykeman M, Rogers J, Weinstein R |
|
| Session 29 — Poster Epidemiology: Correlates of Disease Progression and Survival |
||
| 207 | Quantitative HIV-1 RNA (RNA) and other factors associated with survival in the women's interagency HIV study (WIHS). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 207) Anastos K, Kovacs A, Kalish L, Hessol N, Delapenha R, Burns D, Weiser B, Cohen M, Meyer W, Bremer J, Melnick S |
|
| 208 | HIV-1 viral burden predicts survival among severely immunosuppressed HIV-1-infected men. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 208) Jacobson LP, Wolinsky S, Detels R, Giorgi J, Margolick J, Riddler S, Phair J |
|
| 209 | A prospective cohort study of HIV disease progression among drug users by gender. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 209) Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS |
|
| 210 | Survival differences between younger and older HIV positive patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 210) Weissman S, Fuehrer S, Justice A |
|
| 211 | Clinical follow-up and markers of progression in a cohort of haemophilic men infected with HIV for up to 17 years. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 211) Sabin CA, Phillips AN, Devereux H, Bofill M, Janossy G, Cloveday C, Lee CA |
|
| 212 | HIV-1 p24 antibody in relation to plasma RNA and CD4+ lymphocytes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 212) Povolotsky J, Baron P, Carrow M, Stiles J, Polsky B |
|
| 213 | Comparing measured HIV-1 viral load across risk groups and between assays. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 213) Lyles C, Farzadegan H, Hoover D, Masters B, Astemborski J, Quinn T, Margolick J, Vlahov D |
|
| 214 | CKR-5-gene allele mutants in Mexican population. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:119 (abstract no. 214) Gonzalez-Diaz E, Delgado F, Ruiz-Palacios GM, Soto-Ramirez LE |
|
| 215 | Lack of access to CD4 counts and RNA measurements associated with inability to distinguish patients at risk of progression or experiencing virologic treatment failure in Brazil. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:119 (abstract no. 215) Pilcher C, Perkins M, Dietze R, Duque U, Zago A, Fiscus SA, Schock J, Eron JJ |
|
| 216 | Factors related to HIV+ versus AIDS presentation at the first contact with health services. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:119 (abstract no. 216) Bangdiwala SI, Hunter RF, Gomez MA |
|
| 217 | Supplemental multivitamins or vitamin B complex significantly delay progression to AIDS and death in South African patients infected with HIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:119 (abstract no. 217) Kanter AS, Spencer D, Steinberg M |
|
| Session 30 — Poster Clinical Trials: Statistical Issues and Predictors of Response |
||
| 218 | A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:119 (abstract no. 218) Cozzi Lepri A, Davey Smith G, Mocroft A, Sabin CA, Morns RW, Phillips AN |
|
| 219 | HIV-1 RNA and CD4 cell count as prognostic markers and surrogate endpoints: final results of the meta-analysis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:120 (abstract no. 219) Hughes MD; Harvard School of Public Health, Boston, MA |
|
| 220 | Meta-analysis of the concordance between anti-retroviral effects on HIV-1 RNA and CD4 count and progression to AIDS or death. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:120 (abstract no. 220) DeMasi R, Hill A, Dawson D; Glaxo Wellcome, United Kingdom |
|
| 221 | CD4 cell expansion ex vivo predicts clinical responses to antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:120 (abstract no. 221) Merrill DP, Martinez-Picado J, Tremblay C, Sax PE, Boswell SL, Wong J, D'Aquila R, Walker B, Hirsch MS |
|
| 221a | CD4 cell count (CD4) and serum viral RNA (vRNA) as predictors of clinical efficacy in a study of indinavir (IDV) alone and with zidovudine (ZDV) in treatment-naïve HIV-1 patients with 50-250 CD4 cells/mm(3). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:120 (abstract no. 221a) Nessly M, Suleiman J, Lewi D, Uip D, Pedro R, Kalichman A, Moraes-Filho JP, Motti E, Pecoraro ML, Makurath M, Leavitt R; Merck Research Labs., West Point, PA |
|
| Session 31 — Poster Pharmacokinetic Studies of Antiretroviral and Immunomodulatory Drugs in HIV-1 Infected Children and Pregnant Women |
||
| 222 | Pharmacokinetics, tolerance and immunomodulatory activity of recombinant IL-2 in HIV-infected children and adolescents: results of a pilot study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:120 (abstract no. 222) Wood LV, Wigginton JM, Zuckerman J, Washington B, Higham C, Townley E, Jankelevich S, Serchuck L, Zeichner S, Lane HC, Ficker A, Bailey L |
|
| 223 | Pharmacologic characteristics of saquinavir soft gelatin capsules (SQV-SGC) given with nucleoside antiretroviral agents (NRTIs) with and without nelfinavir (NLV) in HIV infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:121 (abstract no. 223) Fletcher CV, Kline MW, Brundage RC, Buss NE, Steimer JL, Calles NR, Moreau EL, Eason M, Delora P, Duff F |
|
| 224 | Population pharmacokinetics (PK) and pharmacodynamics (PD) of dideoxyinosine (ddI) in children with HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:121 (abstract no. 224) Capparelli E, Connor J, Englund J, Baker C, Raskino C, Palumbo P, Spector S |
|
| 225 | Does pregnancy affect the pharmacokinetics of didanosine (ddI) in HIV-1 infected women? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:121 (abstract no. 225) Patil SD, Livingston E, McKinney RE, Abreu E, O'Sullivan MJ, Bardequez A, Unadkat JD |
|
| 226 | Placental transfer of didanosine (ddI) and initial evaluation of didanosine toxicity in HIV-1 infected pregnant women and their offspring. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:121 (abstract no. 226) Livingston E, Patil S, Unadkat J, McKinney R, Abreu E, Bardequez A, O'Sullivan M |
|
| 227 | Safety and tolerability of PRO 2000 gel: a potential vaginal virucide. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:121 (abstract no. 227) Wright A, Rosenstein I, Poulter L, McKinlay M, Weber J, Profy A, Kitchen V |
|
| Session 32 — Poster Antiretroviral Therapy in Neonates, Infants, and Children |
||
| 228 | Response of antiretroviral therapy naïve children less than 3 years old to monotherapy ddI or combination ZDV/3TC: a post-hoc analysis of data from PACTG protocol 300 Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:122 (abstract no. 228) McKinney RE |
|
| 229 | Combination therapy including saquinavir soft gelatin capsules (SQVSGC) in HIV-infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:122 (abstract no. 229) Kline MW, Fletcher CV, Brundage RC, Calles NR, Moreau EL, Buss NE, Steimer JL, Eason M, Mastrodonato-Delora P, Duff F |
|
| 230 | Efficacy and adherence to highly active antiretroviral therapy (HAART) in HIV-1 infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:122 (abstract no. 230) Watson DC, Farley JJ, Lovelace S, Vink P |
|
| 231 | Long-term activity of indinavir/ZDV/3TC in HIV-1 infected children: results of a phase I/II study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:122 (abstract no. 231) Jankelevich S, Mueller B, Smith S, Boss C, Zwerski S, Steinberg S, Wood L, Zeichner S, Serchuck L, Sleasman J, Nelson R, Nguyen BY, Shadle C, Pizzo P, Yarchoan R |
|
| 232 | One-year follow-up of HIV-infected children receiving combination therapy with indinavir, stavudine (d4T), and didanosine (ddI). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:122 (abstract no. 232) Kline MW, Fletcher CV, Harris AT, Brundage RC, Evans KD, Simon C, Calles NR |
|
| 233 | Virologic and CD4 response to treatment with nelfinavir in therapy experienced but protease inhibitor naïve HIV-infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:123 (abstract no. 233) Martel L, Valentine M, Ferguson L, Muelenaer P, Katz SL, McKinney RE |
|
| 234 | Changes in viral load and immunologic markers in children treated with triple therapy including ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:123 (abstract no. 234) Pelton SI, Yogev R, Johnson D |
|
| 235 | Combination antiretroviral therapy for the treatment of HIV infection in pregnant women: safety profiles in women and newborns. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:123 (abstract no. 235) Eriksen N, Helfgott A, Doyle M |
|
| 236 | Adrenal suppression in HIV-infected children treated with megestrol acetate (M). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:123 (abstract no. 236) Stockheim J, Daaboul J, Scully S, Yogev R, Chadwick E |
|
| Session 33 — Poster Pathogenesis and Prevention of Vertical HIV-1 Transmission |
||
| 237 | Distribution and role of CCR5 genotype in vertical transmission and disease progression in Argentina. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:123 (abstract no. 237) Mangano A, Prada F, Roldan A, Piccho G, Bologna R, Sen L |
|
| 238 | Maternal cell-free viremia as a predictor of perinatal HIV-1 transmission: a meta-analysis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:124 (abstract no. 238) Contopoulos-Ioannidis DG, Ioannidis JP |
|
| 239 | Molecular evidence for the mother-to-child transmission of multiple variants of human immunodeficiency virus type 1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:124 (abstract no. 239) Pasquier C, Cayrou C, Izopet J, Tourne-Peteilh C, Blancher A, Puel J |
|
| 240 | Analysis of env V3 loop sequences from longitudinal samples of infected mother-infant pairs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:124 (abstract no. 240) Kornegay JR |
|
| 241 | Cervical viral burden and humoral immunity in relation to maternal-infant transmission in northern Thailand. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:124 (abstract no. 241) Robb ML, Sriplienchan S, Vancott T, Wera-Arpachai M, Gulgolgarn V, Ketsara-Rat W, Tovanabutra S, Niyomthai S, Desouza M, Birx D, Nelson K, Khamboon-Ruang C |
|
| 242 | Early postnatal mother-to-child transmission of HIV-1 in Bangui, Central African Republic. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:124 (abstract no. 242) Becquart P, Garin B, Sepou A, Hocini H, Matta M, Brogan T, Barre-Sinoussi F, Kazatchkine M, Belec L |
|
| 243 | Preterm delivery and risks of intrauterine and intrapartum HIV transmission. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:124 (abstract no. 243) Kuhn L, Thea DM, Steketee RW |
|
| 244 | Evidence for intermediate rates of perinatal HIV transmission with partial 076 regimens: results of an observational study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:125 (abstract no. 244) Birkhead GS, Warren BL, Charbonneau TT, Wade NA, Baum JB, Wang L, Zielinski MA, French PT, Tesoriero JM, Savicki R |
|
| 245 | Effect of prenatal and perinatal zidovudine on disease progression in vertically HIV-1 infected infants. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:125 (abstract no. 245) Desouza R, Mitchell C, Gomez-Marin O, Guasti S, Oliveira R, Scott G |
|
| 246 | A 4 State evaluation of ZDV use to reduce perinatal HIV transmission. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:125 (abstract no. 246) Wortley PM, Lindegren ML, Fleming PL |
|
| 247 | Prevalence of zidovidine use to reduce maternal-infant HIV transmission, 1994-95. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:125 (abstract no. 247) Gwinn M, Mei J, Linley L, Hannon WH |
|
| 248 | Impact of antiretroviral therapy (ART) on the outcome of infants born to HIV seropositive mothers in British Columbia, Canada. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:125 (abstract no. 248) Forbes J, Burdge D, Money D |
|
| Session 34 — Poster Immunopathogenesis and Immune Responses in HIV-1 Infected Children and Pregnant Women |
||
| 249 | Intracellular interlukin-2 (IL-2) production in HIV infected pregnant women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:126 (abstract no. 249) Sutton M, Bardeguez A, Garcia Z, Stein D, Denny T |
|
| 250 | Immunological and virological characterization of long-term non progressor in children with vertical HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:126 (abstract no. 250) Munoz-Fernandez MA, Resino S, Navarro J, Obregon E, Garcia D, Alonso R, Jimenez JL, Sampelayo T, Gurbindo D, Fernandez-Cruz E |
|
| 251 | Safety and immunogenity of HIV recombinant envelope vaccines in HIV-infected infants and children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:126 (abstract no. 251) Lambert J, McNamara J, Katz S, Fenton T, Kang M, Vancott T, Livingston R, Hawkins E, Moye J Jr, Borkowsky W, Johnson D, Yogev R, Duliege A, Francis D, Gershon A, Wara D, Martin N, Levin M, McSherry G, Smith G |
|
| 252 | A dynamic model of the effect of somatic growth on CD4+ lymphocyte-virus interactions in HIV infected infants. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:126 (abstract no. 252) Krogstad P, Uittenbogaart C, Dickover R, Bryson YJ, Plaeger S, Garfinkel A |
|
| 253 | Correlation of tissue HIV-1 RNA viral loads and clinical history of two pediatric autopsies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:126 (abstract no. 253) Vavro C, McCleron D, Zimmermann A, Valentine M, McKinney R, St. Clair M |
|
| 254 | Response to hepatitis B virus (HBV) vaccination in children at risk for human immunodeficiency virus (HIV) infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:127 (abstract no. 254) Machado DM, Succi RC, Galiano ME |
|
| 255 | Pneumococcal and influenza immunization and HIV viral load in children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:127 (abstract no. 255) Cutillar-Garcia M, Deveikis A, Gagajena A, Elkins K, Plaeger S, Kaplan A, Bryson YJ, Zangwill K, Keller MA |
|
| Session 35— State-of-the-Art Lecture HIV Infection: The Body Fights Back |
||
| L4 | HIV-1 Entry into Cells: Targets for Drug and Vaccine Development Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L4) Walker BD |
|
| Session 36 — State-of-the-Art Lecture HHV8/KSHV |
||
| L5 | HIV-1 Entry into Cells: Targets for Drug and Vaccine Development Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L5) Ganem D |
|
| Session 37 — Slide Pathogenesis, Prophylaxis, and Treatment of Opportunistic Infections |
||
| 256 | HIV RNA and CD4 lymphocyte count relate differently to the occurrence of PCP, CMV, and MAC disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:127 (abstract no. 256) Lyles RH, Chu C, Margolick J, Detels R, Giorgi J, Al-Hboul Q, Phair J |
|
| 257 | Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir + ZDV + 3TC to ZDV + 3TC. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:127 (abstract no. 257) Currier JS, Williams PL, Grimes JM, Squires KS, Fischl MA, Hammer SM |
|
| 258 | Prediction of cervical human papillomavirus (HPV) infection and disease by magnitude of HIV-1 plasma RNA level. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:128 (abstract no. 258) Luque A, Demeter L, Raubertas R, Reichman R |
|
| 259 | Persistent elevation of HIV viral load during therapy for tuberculosis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:128 (abstract no. 259) Morris L, Martin DJ, Sacks L, Pendle S, Page-Shipp L, Bredell H, Quinn TC, Chaisson RE |
|
| 260 | HSV suppression is associated with a significant decrease in plasma levels of HIV RNA. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:128 (abstract no. 260) Schacker TW, Lu HL, Zeh J, Shaughnessy M, Corey L |
|
| 261 | Elucidation of the roles of the conserved domains of human cytomegalovirus DNA polymerase (UL54) in drug resistance. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:128 (abstract no. 261) Cihlar T, Fuller MD, Kemble GW, Cherrington JM |
|
| 262 | Incidence of resistant cytomegalovirus (CMV) in patients being treated for CMV retinitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:128 (abstract no. 262) Jabs DA |
|
| 263 | A controlled study of foscarnet-ganciclovir combination for central nervous system (CNS) infection with cytomegalovirus (CMV) in HIV patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:128 (abstract no. 263) Katlama C, Anduze-Faris B, Fillet AM, Boukli N, Gasnault J, Costagliola D |
|
| Session 38 — Poster Pathogenesis of Vertical HIV-1 Transmission and Antiretroviral Therapy in HIV-1 Infected Children |
||
| 264 | An activating factor found in the female reproductive tract induces HIV-1 gene expression through the NF-kappaB binding sites in the viral LTR. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:129 (abstract no. 264) Al-Harthi L, Spear GT, Landay A, Roebuck KA |
|
| 265 | Selective vertical transmission of HIV-1 zidovudine resistance mutations. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:129 (abstract no. 265) Colgrove R, Pitt J, Chung PH, Welles S, Japour A |
|
| 266 | Tests for HIV-1 and zidovudine in lymph node cells (LNC) from newborns of infected mothers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:129 (abstract no. 266) Hard RC Jr, Bagwell CE, Dinsmoor MJ, Draper DA, Ellis CR, Ferreiro-Gonzalez A, Garrett CT, Goehle D, Hart ME, Haynes JH, Lavoie S, Meloy LD, Morris RW, Shapiro JH, Singh MK, Smith T, Sonnino RE, Tipton GA |
|
| 267 | Thymus imaging in the evaluation of T-cell destruction and reconstitution in vertical HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:129 (abstract no. 267) Vigano A, Vella S, Principi N, Bricalli D, Di Sanzo G, Saresella M, Cleric M |
|
| 268 | Lymphoproliferative responses (LP) to receive HIV-1 envelope antigens in neonates & infants receiving gp120 vaccines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:129 (abstract no. 268) Borkowsky W, Wara D, McNamara J, Kang M, Fenton T, McFarland E, Cunningham C, Mofenson L, Duliege A, Francis D |
|
| 269 | A phase I study of 1592U89 in HIV-infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:130 (abstract no. 269) Kline MW, Blanchard S, Shenep JL, McKinney RE Jr, Van Dyke RB, Culnane M, Dane-Hower S, Lanier ER, Hetherington S |
|
| 270 | Evidence of potent antiviral activity in a phase I/II study of nelfinavir mesylate (Viracept) in HIV infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:130 (abstract no. 270) Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Kerr B, Hendricks A, Gersten M, Boczany B, Spector S, Bryson Y |
|
| 271 | Virologic activity of didanosine (ddI), zidovudine (ZDV) and nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:130 (abstract no. 271) Burchett SK, Carey V, Yong F, Sullivan J, Sulzbacher S, Civitello L, Culnane M, Mofenson L, Siminski S, Robinson P, Luzuriaga K |
|
| Session 39 — Poster Pathogenesis: Lymphocyte Turnover, Co-Receptor Expression, and Primate Studies |
||
| 272 | Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:130 (abstract no. 272) Mohri H, Bonhoeffer S, Monard S, Perelson AA, Ho DD |
|
| 273 | Direct measurement of CD4+ and CD8+ T cell proliferation rates in vivo in AIDS patients using a stable isotope-mass spectrometric technique. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:130 (abstract no. 273) Cesar D, Papageorgopoulos C, McCune JM, Hanley MB, Preston C, Wieder E, Fullerton C, Deeks S, Cope F, Hellerstein MK |
|
| 274 | Viral turnover is rapid and associated with increased cell proliferation in non-pathogenic SIV infection of sooty mangabeys. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:131 (abstract no. 274) Grant RM, O'Neil S, Kaur A, McClure H, Bandra-Palli N, Staprans S, Bishofberger N, Johnson RP, Feinberg MB |
|
| 275 | Chemokine receptors and the molecular basis for HIV-1 entry into hematopoietic stem cells and their progeny. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:131 (abstract no. 275) Pomerantz RJ, Zhao SF, Li W, Dicker D, Hoxie J, Peiper SC, Duan LX |
|
| 276 | In vivo distribution of the HIV/SIV co-receptors: CXCR4, CCR3 and CCR5. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:131 (abstract no. 276) Zhang L, He T, Talal A, Wang G, Ho DD |
|
| 277 | Initial productive infection and cell tropisms in acute infection of rhesus monkeys with intravaginal inoculation of an uncloned SIVmac 251. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:131 (abstract no. 277) Zhang ZQ, Schuler T, Wietgrefe S, Reimann KA, Letvin NL, Haase AT |
|
| 278 | Selective mucosal transmission of variants of a strain of HIV-1 that is pathogenic for chimpanzees. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:131 (abstract no. 278) Fultz PN, Wei Q, Davis I |
|
| 279 | Replication of the Rev-independent nef(-) SIV in juvenile macaques. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:131 (abstract no. 279) Felber BK, von Gegerfelt AS, Liska V, Ruprecht RM |
|
| Session 40 — Slide Virology II |
||
| 280 | An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:132 (abstract no. 280) Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD |
|
| 281 | HIV-1 phenotype, co-receptor usage and disease progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:132 (abstract no. 281) Zhang L, He T, Kunstman K, Wu S, Guo Y, Neumann AU, Ho DD, Wolinsky SM |
|
| 282 | Identification of a highly divergent human immunodeficiency virus type 1 related to a chimpanzee lentivirus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:132 (abstract no. 282) Simon F, Loussert-Ajaka I, Mauclere P, Roques P, Muller M, Saragosti S, Georges-Courbot C, Barre-Sinoussi F, Brun-Vezinet F |
|
| 283 | Usage of coreceptors by primary and cell line-adapted human immunodeficiency virus type 2. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:132 (abstract no. 283) Sol N, Ferchal F, Braun J, Alizon M |
|
| 284 | HTLV-I tax induction of NF-kappaB is mediated through sequential activation of the NIK and IKKalpha cellular kinases. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:132 (abstract no. 284) Geleziunas R, Lin X, Ferrell S, Cunningham ET, Connelly MA, Marcu KB, Greene WC |
|
| 285 | Direct T cell killing by HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:133 (abstract no. 285) Gandhi RT, Chen BK, Baltimore D |
|
| 286 | The effect of tetanus immunization on HIV-1 quasispecies dynamics. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:133 (abstract no. 286) Ostrowski MA, Krakuer D, Li Y, Justement SJ, Fauci AS |
|
| 287 | A small molecule CXCR4 inhibitor that blocks T-cell line-tropic HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:133 (abstract no. 287) Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Hoxie A, Kishimoto t, Nagasawa T, Yamamoto N |
|
| Session 41— Symposium Tissue Reservoirs of HIV |
||
| S15 | HIV-1 in cervical and seminal fluid cells: potential reservoirs for HIV-1 in vivo. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S15) Pomerantz RJ, Bagasra O, Bobroski L, Zhang H, Shaheen F |
|
| S15a | Latent Reservoirs for HIV in Patients with HAART Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S15a) Siliciano R |
|
| S16 | Residual Pool of HIV after Prolonged Combination Therapy Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S16) Ho D |
|
| S17 | Tissue reservoirs of HIV in lymph node before and after HAART. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:233 (abstract no. S17) Bucy RP, Kilby JM, Derdeyn CA, Horton D, Sillers M, Squires K, Saag M, Shaw GM, Hockett RD |
|
| S18 | CD4-independent virus entry: a key mechanism for infection of the CNS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:233 (abstract no. S18) Clements JE, Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee Benhur, Rucker J, Zink MC, Doms RW |
|
| S19 | Persistence of replication competent HIV in patients with undetectable plasma virus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:233 (abstract no. S19) Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Furtado M, Wolinsky SM, Spina CA, Richman DD |
|
| Session 42— Symposium Neurologic Aspects of HIV Disease |
||
| S20 | The molecular pathogenesis of progressive multifocal leukoencephalopathy in AIDS: JC virus induced demyelinating disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:233 (abstract no. S20) Major EO, Jensen P, Monaco MC |
|
| S21 | An integrate cross disciplinary research program in neuroAIDS: studies of viral neuropathogenesis and developmental therapeutics. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:234 (abstract no. S21) Gendelman HE |
|
| S22 | HIV-1 viral load in the CSF and brain. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:234 (abstract no. S22) Marra CM; Marra CM |
|
| S23 | HIV associated peripheral neuropathy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:234 (abstract no. S23) Bradley WG, Verma A; Verma A |
|
| Session 43— Symposium HIV Regulatory Proteins and Virus-Host Cell Interactions |
||
| S24 | The cellular export pathway that transports HIV-1 Rev from the nucleus to the cytoplasm. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:234 (abstract no. S24) Weis K, Stade K, Guthrie C, Ford-Rayl C |
|
| S25 | Regulation of HIV replication. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:234 (abstract no. S25) Peterlin BM; University of California, San Francisco, CA |
|
| S26 | Distinct nucleocytoplasmic export pathways utilized by retroviral mRNAs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:235 (abstract no. S26) Felber BK, Zolotukhin A, Tabernero C, Saavedra C, Izaurralde E; ABL-Basic Research Program, NCI-FCRDC, Frederick, MD |
|
| S27 | PTEFb kinase: an essential HIV Tat cellular cofactor. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:235 (abstract no. S27) Mancebo H, Lee G, Tomassini J, Hazuda D, Flores O |
|
| Session 44— Poster HIV Replication: Molecular Regulation, Accessory Proteins, and Assembly |
||
| 288 | Either NF-kappaB or Sp-1 but not Ap-1 binding site HIV-1 LTR is necessary for viral replication in activated T cells cocultured with dendritic cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:133 (abstract no. 288) Tsunetsugu-Yokota Y, Yasuda S, Kato T, Souda Y, Suzuki Y, Koyanagi Y, Yamamoto N, Matsuda Z, Akagawa K, Takemori T |
|
| 289 | Synergistic activation of HIV by PKA and PKC requires cooperation of the kappaB enhancer and elements in the 5'-UTR. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:133 (abstract no. 289) Roebuck KA, Rabbi MF, Al-Harthi L |
|
| 290 | Arginine residues in the HIV-1 Vpr C-terminal domain are important for nuclear localization and cell cycle arrest. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:134 (abstract no. 290) Zhou YI, Lu Y, Ratner L |
|
| 291 | Evolution of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:134 (abstract no. 291) Hassaine G, Agostini I, Candotti D, Bessou G, Caballero M, Agut H, Autran B, Barthalay Y, Vigne R |
|
| 292 | Structural studies of peptide fragments derived from the HIV-1 Vpr protein. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:134 (abstract no. 292) Luo Z, Butcher DJ, Murali R, Srinivasan A, Huang Z |
|
| 293 | The diverse profile of attachment of HIV-1 nef to the CD4(+) T cell surface. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:134 (abstract no. 293) Fujii Y, Michael NL |
|
| 294 | Mutational analysis of HIV-1 accessory genes: requirement of site in nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:134 (abstract no. 294) Koyanagi Y, Kawano Y, Tanaka Y, Yamamoto N |
|
| 295 | Cell-free assembly of HIV-like particles. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:134 (abstract no. 295) Xiao Q, Vander Heyden N, Ratner L |
|
| 296 | Identification and functional analysis of the PGQM motif in HIV-1 Gag: changing specific residues terminates viral replication. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:135 (abstract no. 296) Srivastava M, Cartas M, Rizvi TA, Serio D, Kalyanaraman VS, Pollard HB, Srinivasan A |
|
| Session 45 — Poster HIV Replication: Reverse Transcription and Integration |
||
| 297 | Evidence for MTAase as a novel mediator of H-7-induced HIV-1 transcriptional inhibition. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:135 (abstract no. 297) Ho ON, Butera ST, Critchfeld JW |
|
| 298 | HIV-1 integrase protein promotes reverse transcription. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:135 (abstract no. 298) Wu X, Liu H, Xiao H, Conway JA, Kappes JC |
|
| 299 | Terminal deoxynucleotidyl transferase (TDT) activity of retroviral reverse transcriptase (RT) and its association with DNA strand transfer. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:135 (abstract no. 299) Hu YW, Balaskas E, Gill P, Zeibdawi A, Smeenk C, Aye MT |
|
| 300 | HIV-1 with PBS complementary to tRNA(His) or tRNA(Ile) predominantly use the cognate tRNA for the first round of replication. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:135 (abstract no. 300) Yu Q, Zhang Z, Morrow CD |
|
| 301 | Critical role for U5 of HIV-1 in the discrimination between tRNA(Lys1,2) and tRNA(Lys,3) for initiation of reverse transcription. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:136 (abstract no. 301) Kang SM, Zhang Z, Morrow CD |
|
| 302 | The nature of HIV-1 strand transfers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:136 (abstract no. 302) Jetzt AE, Yu H, Ron Y, Preston BD, Dougherty JP |
|
| Session 46 — Poster Diagnostics: Viral Load Assays |
||
| 303 | Low HIV-1 RNA copy number assessed by bDNA and RT-PCR assays: implications for managing patients above or below the viral RNA quantitation limit. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:136 (abstract no. 303) Yerkovich M, Ng KW, Sampoleo R, Dragavon J, Coombs RW |
|
| 304 | Quantification of HIV-1 proviral DNA: the next step to patient monitoring. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:136 (abstract no. 304) Christopherson C, Sheppard H, Krowka J, Conway B, Scheibel S, Saget B, Sninsky J, Kwok S |
|
| 305 | Performance of three versions of the Amplicor HIV-1 monitor. Test on clinical samples of HIV-1 subtypes A, B, C, D, E and G. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:137 (abstract no. 305) Triques K, Coste J, Perret JL, Mpoudi E, Reynes J, Segondy M, Delaporte E, Herman S, Dreyer K, Wang J, Gomes J, Spadoro J, Peeters M |
|
| 306 | Synthetic ribonuclease resistant RNA standards (armored RNA) for RT-PCR-based HIV-1 RNA assays. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:137 (abstract no. 306) Walkerpeach C, Dubois DB, Pasloske BL, Winkler M |
|
| 307 | Highly sensitive HIV-1 proviral DNA quantitation by using an internal polymerase chain reaction gag gene standard and colorimetric detection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:137 (abstract no. 307) Dickover R, Saddiq K, Bryson YJ |
|
| 308 | Changes in HIV-1 RNA viral load following the tuberculin skin test (PPD). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:137 (abstract no. 308) Garcia F, Vidal C, Gatell JM, Miro JM, Cruceta A, Pumarola T |
|
| 309 | Evaluation of Nuclisens HIV-1 QT for the quantitation of HIV-1 RNA in plasma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:137 (abstract no. 309) Ly TD, Montes B, Malkin JE, Segondy M |
|
| 310 | A comparative study of HIV-1 RNA levels measured by the NucliSens and quantiplex bDNA assays in serial plasma samples from patients on antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:137 (abstract no. 310) Ginocchio CC, Tetali S, Washburn D, Kaplan MH |
|
| 311 | Comparison of Quantiplex HIV-1 and Monitor HIV-1 for evaluating antiretroviral effect of a d4T/ddI combination therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:138 (abstract no. 311) Segondy M, Pellegrin I, Izopet J, Montes B, Lafon ME, Pasquier C, Peeters M, Fleury H, Puel J, Reynes J |
|
| 312 | Quantitation of HIV-1 RNA by the NucliSens HIV-1 QT assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:138 (abstract no. 312) Oudshoom P, Simons F, Cronin M, Vella S, de Wolf F, Cuypers T |
|
| 313 | Determination of a level of 500 copies/ml of plasma HIV-1 RNA by 29 labs using the Roche Monitor HIV-1 "200 copies" assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:138 (abstract no. 313) Aboulker JP, Damond F, Carriere I, Descamps D, Halley A, Brun-Vezinet F |
|
| 314 | Reverse transcriptase activity (RTA) by Amp-RT analysis as an early diagnostic test and prognostic indicator of disease progression and perinatal transmission of HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:138 (abstract no. 314) Thea DM, Reisler R, Pliner V, Steketee R, Kalish M, Heneine W |
|
| 315 | Dried blood spots (DBS) for monitoring HIV-1 RNA load in neonates and infants. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:138 (abstract no. 315) Cassol S, Pilon R, Cormier M, Hillyer GV, Tuomala R, LaRussa P, Landesman S, Bremer J, Rosenblatt HM, Lew J, Moye J, Smeriglio V, Fitzgerald G, Su X, Pan D, Gerstel J, Comeau AM |
|
| 316 | Comparability of rapidly processed and overnight shipped blood specimens for plasma HIV-1 RNA quantitation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:138 (abstract no. 316) Moye J, Mofenson L, Meyer W, Nugent R, Whitehouse J, Reichelderfer P, Qin Z, Bethel J |
|
| 317 | Performance of HIV RNA quantitation assays on HIV-negative specimens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:139 (abstract no. 317) Bremer JW, Brambilla D, Staes B, Reichelderfer P |
|
| 318 | Quality-controlled pooling strategies for nucleic-acid based HIV screening: using PCR as a primary screen on dried blood spot specimens in population studies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:139 (abstract no. 318) Comeau AM, Su X, Mushinsky G, Pan D, Gerstel J, Grady GF |
|
| 319 | Development of a quantitative HIV-1 assay using 5' nuclease technology. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:139 (abstract no. 319) Lu SD, Fong DM, Wang Z, Kwok S |
|
| 320 | Comparison of HIV-1 DNA PCR and qualitative and quantitative HIV-1 RNA PCR in young children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:139 (abstract no. 320) Cunningham CK, Charbonneau T, Sullivan T, Poiesz B |
|
| 321 | Viral load determination by NASBA does not differ by fluid type. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:139 (abstract no. 321) Thea DM, Pliner V, Brown T, Kalish M |
|
| 322 | Evaluation of the VACUTAINER PPT with the Roche Amplicor RT-PCR HIV monitor kit. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:139 (abstract no. 322) Green S, Rainen L, Bodnar K, Bergendahl R, Alcami J |
|
| 323 | Prediction of cost and outcomes for HIV patients monitored with viral load versus CD4 counts. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:140 (abstract no. 323) Richter A, Simpson K, Mauskopf JA |
|
| 324 | Cost effective strategies for the use of currently available plasma viral load (PVL) testing assays. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:140 (abstract no. 324) Seminari E, Raboud J, Rae S, Conway B, Montessori V, O'Shaugnessy M, Montaner JS |
|
| 325 | Evaluation of interference conditions in specimens analyzed with nucleic acid amplification technology. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:140 (abstract no. 325) Witt D, Penning L, Kaufman MK, Kemper M, Ginocchio C, McClernon D |
|
| Session 47 — Poster Viral Quantitation During Antiretroviral Therapy |
||
| 326 | Ultra sensitive detection of plasma HIV-1 RNA for predicting the durability of 3-drug antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:140 (abstract no. 326) Izopet J, Salama G, Pasquier C, Sandres K, Kuhlein E, Blancher A, Marchou B, Massip P, Puel J |
|
| 327 | Subtle differences in low-level HIV viral load on treatment is important for outcome. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:140 (abstract no. 327) Maeland A, Holberg M, Bruun JN, Lovegarden G |
|
| 328 | PBMC-HIV-RNA quantification during therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:141 (abstract no. 328) Rouzioux C, Izopet J, Pellegrin I, Dumon B, Tamalet C, Descamps D, Burgard M, Ivanoff S, Ruffault A, Vabret A, Bargues G, Calvez V, Seigneurin JM |
|
| 329 | Correlation of plasma and cerebrospinal fluid (CSF) HIV RNA quantitation in protease inhibitor (PI) anti-HIV treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:141 (abstract no. 329) Roth V, Kravcik S, Garber G, Angel JB, Badley A, Victor G, Gallicano K, Hawley-Foss N, Seguin I, Cameron DW, Cassol S |
|
| 330 | An open randomized study to test the influence of maintaining a pre-established viral load reduction in the progression of chronic HIV-1 infected patients in very early stages (Spanish early antiretroviral therapy in HIV: Spanish EARTH study). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:141 (abstract no. 330) Garcia F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gatell JM, Miro JM |
|
| Session 48 — Poster Techniques for Assessing Susceptibility to Antiretroviral Drugs |
||
| 331 | Quantification and Sequencing with NucliSens HIV-1 QT Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:141 (abstract no. 331) McClernon DR1, Danehower D1, Stocum M2, Cronin2 and St. Clair MH1 |
|
| 332 | HIV-1 reverse transcriptase inhibitor resistance patterns in blood of patients during primary HIV-1 infection by a novel line probe assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:141 (abstract no. 332) Cunningham P, Hurren L, Cooper DA |
|
| 333 | LiPa HIV-1 RT predicts phenotypic zidovudine resistance in HIV-1 patient isolates. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:142 (abstract no. 333) Schneider F, Plesseria JM, Stuyver L, Lambert C, Fontaine E, Kirpach P, Ninove D, Arendt V, Hemmer R, Schmit JC |
|
| 334 | Rapid phenotypic detection of HIV-1 resistance to lamivudine (3TC) by direct analysis of plasma reverse transcriptase (RT) activity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:142 (abstract no. 334) Garcia Lerma JG, Weinstock H, Soriano V, Juodawlkis AS, Folks TM, Schinazi RF, Heneine W |
|
| 335 | Rapid phenotypic determination of nevirapine-resistant HIV-1 by direct analysis of reverse transcriptase (RT) activity in plasma samples. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:142 (abstract no. 335) Vazquez-Rosales JG, Yamamoto S, Switzer WM, Havlir DV, Richman DD, Folks TM, Heneine W |
|
| 336 | A new technology for measuring genotypic resistance to nucleoside analogs. Application to the study of naïve patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:142 (abstract no. 336) Livrozet JM, Jeanblanc F, Brunel F, Makhloufi D, Saint-Marc T, Touraine JL, Aymard M, Tardy JC |
|
| 337 | Microbial expression libraries for identification of HIV-PR drug resistant variants. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:142 (abstract no. 337) Melnick L, Yang SS, Rossi R, Heefner D |
|
| 338 | Genotyping HIV drug resistance mutations by automated fluorescent sequencing: methods for the clinical laboratory. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:142 (abstract no. 338) White CB, Song K, Myers A, Nguyen V, Dexter A, Archer R, Demeter L, Johnston-Dow L |
|
| 339 | Response to antiretroviral therapy and development of pol gene mutations associated with drug resistance in HIV-1 group O isolates. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:143 (abstract no. 339) Mas A, Machuca A, Mur A, Soriano V |
|
| Session 49 — Poster Antiretroviral Therapy: Pharmacology and Drug Interactions |
||
| 340 | Pharmacokinetic (PK) interaction between 141W94 and rifabutin (RFB) and rifampin (RFP) after multiple-dose administration. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:143 (abstract no. 340) Polk RE, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Brophy D, Kristoff D, Lou Y, Bye A |
|
| 341 | Effects of ketoconazole (KCZ) and 141W94 on P450 (CYP)3A4 activity measured by the erythromycin breath test (ERMBT). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:143 (abstract no. 341) Polk RE, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Lou Y, Crouch MA, Gouldin W |
|
| 342 | Ritonavir does not increase methadone exposure in healthy volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:143 (abstract no. 342) Hsu A, Granneman GR, Carothers L, Dennis S, Chiu YL, Valdes J, Sun E |
|
| 343 | Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delavirdine (DLV). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:143 (abstract no. 343) Morse GD, Shelton MJ, Hewitt RG, Adams JM, Baldwin JR, Della-Coletta AA, Freimuth WW, Cox SR |
|
| 344 | Delavirdine (D) and rifabutin (R): pharmacokinetic (PK) evaluation in HIV-1 patients with concentration-targeting of delavirdine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:144 (abstract no. 344) Cox SR, Herman BD, Batts DH, Carel BJ, Carberry PA |
|
| 345 | Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:144 (abstract no. 345) Cox SR, Schneck DW, Herman BD, Carel BJ, Gullotti BR, Kerr BM, Freimuth WW |
|
| 346 | Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:144 (abstract no. 346) Piscitelli S, Vogel S, Sadler B, Fiske W, Metcalf J, Masur H, Falloon J |
|
| 347 | Pharmacokinetic (PK) interaction studies in healthy volunteers with efavirenz (EFV) and the macrolide antibiotics, azithromycin (AZM) and clarithromycin (CLR). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:144 (abstract no. 347) Benedek IH, Joshi A, Fiske WD, White SJ, Jobes JL, Joseph JL, Kornhauser DM |
|
| 348 | Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:144 (abstract no. 348) Joshi AS, Fiske WD, Benedek IH, White SJ, Joseph JL, Kornhauser DM |
|
| 349 | Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:144 (abstract no. 349) Fiske WD, Benedek IH, White SJ, Pepperess KA, Joseph JL, Kornhauser DM |
|
| 350 | Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): preliminary safety, activity and pharmacokinetic (PK) interactions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:145 (abstract no. 350) Skowron G, Leoung G, Dusek A, Anderson R, Grosso R, Lamson M, Beebe S |
|
| 351 | The pharmacokinetics of nelfinavir alone and in combination with nevirapine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:145 (abstract no. 351) Merry C, Barry MG, Mulcahy FM, Ryan M, Back DJ |
|
| 352 | Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:145 (abstract no. 352) Merry C, Barry MG, Mulcahy FM, Back DJ |
|
| 353 | Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV-HGC) in HIV+ patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:145 (abstract no. 353) Gallicano K, Sahai J, Kravcik S, Seguin I, Bristow N, Cameron DW |
|
| 354 | Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:145 (abstract no. 354) Buss N |
|
| 355 | Abstract Withdrawn | |
| 356 | Indinavir pharmacokinetics and menstrual cycle physiology. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:145 (abstract no. 356) Adams J, Frost C, Shelton M, Gugino L, Hewitt R, Steinwandel C, Difrancesco R, Ingalls L, Cousins S, Hu J, Morse G |
|
| 357 | Predictions of anti-AIDS drug-interactions using human liver microsomes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:146 (abstract no. 357) Wang Y, Hickman D, Takahashi C, Ambrocio D, Unadkat JD |
|
| 358 | Induction of zidovudine (Z) glucuronidation and amination pathways by rifampin (R) in HIV infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:146 (abstract no. 358) Gallicano K, Sahai J, Cameron DW |
|
| 359 | Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:146 (abstract no. 359) Hsu A, Cameron DW, Valdes J, Garber G, Seguin I, Carothers L, Dennis S, Granneman R, Sun E |
|
| 360 | Quantification of lamivudine by competitive immunoassay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:146 (abstract no. 360) Guedj R, Grassi J, Creminon C, Akeb F |
|
| 361 | Measurements of intracellular lamivudine and zidovudine metabolites in peripheral blood mononuclear cells (PBMCs) from HIV-treated patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:146 (abstract no. 361) Robbins BL, Tran TT, Pinkerton FH Jr, Akeb F, Guedj R, Grassi J, Fridland A |
|
| 362 | Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naïve and zidovudine (ZDV) experienced HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:146 (abstract no. 362) Sommadossi JP, Valantin MA, Zhou XJ, Xie MY, Moore J, Calvez V, Desa M, Katlama C |
|
| Session 50 — Poster Combination Antiretroviral Chemotherapy: Nucleoside Analogs and Protease Inhibitors |
||
| 363 | Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:147 (abstract no. 363) Kost R, Cao Y, Vesanen M, Talal A, Hurley A, Schluger R, Monard S, Rogers M, Johnson J, Smiley L, Ho D, Markowitz M |
|
| 364 | Early T-lymphocyte responses to antiretroviral therapy with abacavir (1592) and HIV protease inhibitors (PIs). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:147 (abstract no. 364) Lederman M, Mellors J, Haas D, Horton J, Haubrich R, Stanford J, Cooney E, Donnenberg A, Neisler M, Kelleher D |
|
| 365 | Combination 1592/141W94 therapy in HIV-1-infected antiretroviral naïve subjects with CD4+ counts greater than 400 cells/microliter and viral load greater than 5000 copies/ml. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:147 (abstract no. 365) Bart PA, Rizzardi GP, Gallant S, Welbon C, Graziosi C, Chave JP, Meylan P, Martin G, Steel H, Spreen W, McDade H, Pantaleo G |
|
| 366 | Use of ritonavir in combination with nucleoside reverse transcriptase inhibitor agents in children and adolescents with perinatally acquired HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:147 (abstract no. 366) Febo I, Chantry C, Lugo L |
|
| 367 | Double (3TC + d4T) vs triple (3TC + d4T + Saquinavir) therapy in HIV-1 experienced patients (ZDV + ddC/ddI) with a low baseline HIV-1 viral load. (median 4,089 copies/ml). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:147 (abstract no. 367) Tural C, Clotet B, Peraire J, Sirera G, Liibre J, Masabeu A, Niubo J, Richart C, Cucurull J, Romeu J, Ruiz L |
|
| 368 | Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naïve patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:148 (abstract no. 368) Slater L |
|
| 369 | Fortovase (saquinavir soft gel capsule; SQV-SGC) in combination with AZT and 3TC in antiretroviral-naïve HIV-1 infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:148 (abstract no. 369) Sension M, Farthing C, Palmer Pattison T, Pilson R, Siemon-Hryczyk P |
|
| 370 | An open randomized trial comparing the effect of a triple combination therapy including d4T, 3TC, and a protease inhibitor (saquinavir, ritonavir, or indinavir) in adult HIV-1 infected patients previously treated with nucleoside reverse transcriptase inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:148 (abstract no. 370) Martinez E, Gatell J, Buira E, Aznar E, Vidal C, Guelar A, Mallolas J, Pumarola T, Soriano E |
|
| 371 | Virologic and immunologic response to triple therapy with nelfinavir in combination with AZT/3TC in 12 antiretroviral naïve HIV-infected subjects at 20 months. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:148 (abstract no. 371) Markowitz M, Cao Y, Hurley A, Schluger R, Monard S, Kost R, Kerr B, Anderson R, Eastman S, Ho DD |
|
| 372 | Analysis of long-term virologic data from the VIRACEPT (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:148 (abstract no. 372) Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y |
|
| 373 | Comparison of BID and TID dosing of Viracept (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:148 (abstract no. 373) Johnson M, Petersen A, Winslade J, Clendeninn N |
|
| 374 | Thirty two week follow-up of indinavir sulfate (IDV) administered q8 hours (h) versus q12 h in combination with zidovudine (ZDV) and lamivudine (3TC). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:149 (abstract no. 374) Nguyen BY, Haas DW, Ramirez-Ronda C, Thompson MA, Gallant J, Currer J, Paar D, White C, Collier A, Mehrotra D, Chung M, Harvey C, Chodakewitz J |
|
| 375 | Indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) in Brazilian population, and the role of CCR5-32bp heterozygosity in antiretroviral response. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:149 (abstract no. 375) Accetturi C, Pardini R, Turcato G, Lewi D, Diaz RS |
|
| 376 | ALTIS plus: long-term d4T-3TC with and without ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:149 (abstract no. 376) Katlama C, Valantin MA, Calvez V, Matheron S, Coutelier A, Descamps D, Longuet C, De Sa M, Bonmarchand M, Lancar R, Brun-Vezinet F, Costagliola D |
|
| 377 | A randomized controlled trial to compare AZT/3TC vs d4T/3TC with a response-dependent addition of indinavir in ART naïve patients with HIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:149 (abstract no. 377) Foudraine NA, De Jong JJ, Van Benthem B, Weverling GJ, Maas J, Keet IP, Roos MT, De Wolf F, Vandermeulen K, Lange JM |
|
| 378 | Antiviral activity and acceptance of two different triple combinations: d4T + indinavir + 3TC vs d4T + indinavir + ddI. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:149 (abstract no. 378) Villalba N, Gomez-Cano M, Casas E, Mas A, Soriano V, Gonzalez-Lahoz J |
|
| 379 | Combination therapy with AZT+3TC+indinavir vs. D4T+3TC+indinavir in pretreated patients with less than 200 CD4/mm(3). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:149 (abstract no. 379) Rubio R, Pulido F, Martin J, Barrios A, Costa JR, Alcami J |
|
| 380 | An open-label, randomized, comparative study of d4T+ 3TC + IDV versus ZDV + 3TC + IDV in treatment naïve HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:150 (abstract no. 380) Start I, Squires K, Gulick R, Santana J, Powderly W, Esinhart J, Schoellkopf N, Stevens M |
|
| 381 | An open-label, randomized, comparative study of d4T + ddI + IDV versus ZDV + 3TC + IDV in treatment naïve HIV infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:150 (abstract no. 381) Start II, Eron J, Peterson D, Murphy R, Jemsek J, Pottage J, Parenti D, Esinhart J, Schoellkopf N, Stevens M |
|
| 382 | Concentration-controlled antiretroviral therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV): rationale, methods, and preliminary results. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:150 (abstract no. 382) Page LM, Henry K, Schacker T, Acosta EP, Brundage RC, Kakuda T, Rhame F, Erice A, Balfour HH Jr, Fletcher CV |
|
| 383 | Indinavir (IDV) in combination with ZDV and 3TC in ZDV-experienced patients with CD4 cell count less than or equal to 50 cells/mm(3) - 60 week followup. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:150 (abstract no. 383) Hirsch EM, Meibohm A, Rawlins S, Leavitt R |
|
| 384 | Clearance of HIV-1 following treatment with three, four and five anti-HIV drugs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:150 (abstract no. 384) De Wolf F, Lukashov VV, Danner SA, Goudsmit J, Lange JM |
|
| 385 | An attempt at maximally suppressive anti-HIV therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:150 (abstract no. 385) Prins J, Jurriaans S, Roos M, De Wolf F, Miedema F, Lange J |
|
| 386 | Randomized comparative outcome trial of indinavir (I) and ritonavir (R) in protease inhibitors (PI) naïve HIV patients (p) with CD4 below 100 cells/microliter. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:151 (abstract no. 386) Clumeck N, Colebunders B, Vandercam B, Kabeya K, Cassano P, Sommereijns B, De Wit A |
|
| 387 | Can nelfinavir substitute for other protease inhibitor(s) in persons with plasma HIV-1 RNA below 500 copies/ml before the substitution? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:151 (abstract no. 387) Cohen CJ, Hellinger JA, Stein AJ, Gathe J, Keiser P |
|
| 387a | Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept (nelfinavir mesylate) combined with NRTI's in HIV-infected treatment-naïve patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:151 (abstract no. 387a) Sension M, Elion R, Farthing C, Currier J, Lindquist C, Richardson B, Becker M |
|
| 387b | First comparative study of saquinavir soft gel capsules vs indinavir as part of triple therapy regimen (CHEESE). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:151 (abstract no. 387b) Borleffs JC |
|
| 387c | Combivir, a fixed formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given bid plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:151 (abstract no. 387c) Eron J, Yetzer E, Poertz D, Ruane P, Becker S, Graham N, Snidow J, Fisher R, Sawyerr G, Shaefer M |
|
| Session 51 — Poster Dual Protease Inhibitor Therapy |
||
| 388 | Antiretroviral safety & durability of ritonavir(RIT)-saquinavir (SQV) in protease inhibitor-naïve patients in year two follow-up. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:152 (abstract no. 388) Cameron DW, Japour A, Mellors, Farthing C, Cohen C, Markowitz M, Poretz D, Follansbee S, Ho D, McMahon D, Berg J, Nieves J, Xu Y, Rode R, Salgo M, Leonard J, Sun E |
|
| 389 | Treatment with ritonavir/saquinavir versus ritonavir/saquinavir/stavudine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:152 (abstract no. 389) Gisolf E, Colebunders R, Van Wanzeele F, Van Der Ende M, Koopmans P, Portegies P, Hoetelmans R, Japour A, Ward P, De Wolf F, Danner S |
|
| 390 | Durability of quadruple antiretroviral therapy including ritonavir and saquinavir in patients with advanced HIV-1 disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:152 (abstract no. 390) Duncombe C, Kaufmann G, Beveridge A, Chuah J, Carr A, Cunningham P, Cooper DA |
|
| 393 | Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:152 (abstract no. 393) Havlir DV, Riddler S, Squires K, Winslow D, Kerr B, Nguyen BY, Yeh K, Hawe L, Zhong L, Deutsch P, Saah A |
|
| 394 | Virologic, immunologic and histologic responses to a 4-drug combination therapy in antiretroviral naïve, HIV infected persons. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:152 (abstract no. 394) Polis MA, Schrager L, Yoder C, Mican J, Kelly G, Metcalf J, Kovacs J, Walker R, Masur H, Fallon J, Schwartzentruber D, Davey R, Hasse A, Fox C, Feinberg M |
|
| 394a | Safety and efficacy of nelfinavir-ritonavir combination therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:153 (abstract no. 394a) Gallant JE, Heath-Chiozzi M, Raines C, Anderson R, Katz T, Fields C, Flexner C |
|
| 394b | Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:153 (abstract no. 394b) Opravil M; University Hospital, Zurich, Switzerland |
|
| 394c | Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:153 (abstract no. 394c) Kravcik S, Farnsworth A, Patick A, Duncan I, Hawley-Foss N, Anderson R, Bristow N, Salgo M, Cameron DW |
|
| Session 52 — Poster Resistance to Antiretroviral Protease Inhibitors |
||
| 395 | Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:153 (abstract no. 395) Hertogs K, Mellors JW, Schel P, Van Cauwenberghe A, Larder B, Kemp S, Miller V, Stasewski S, Conant M, Pauwels R; Virco, Belgium |
|
| 396 | RTV and IDV therapy at 28 weeks after 32 weeks' SQV therapy - influence of HIV-1 protease mutations. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:153 (abstract no. 396) Bodsworth N, Slade M, Ewan J, McNally L |
|
| 397 | Evolution and stability of HIV-1 protease inhibitor resistance mutations during saquinavir monotherapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:154 (abstract no. 397) Eastman PS, Moffatt A, O'Sullivan E, Duncan IB, Race E |
|
| 398 | Increased exposure to the HIV protease inhibitor saquinavir (SQV) does not alter the nature of key resistance mutations. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:154 (abstract no. 398) Craig C, O'Sullivan E, Cammack N |
|
| 399 | Responsiveness to saquinavir is not affected by baseline HIV protease genotype in protease-inhibitor naïve patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:154 (abstract no. 399) O'Sullivan E, Cammack N, Craig C |
|
| 400 | Prior saquinavir therapy leads to a modest decrease in subsequent responses to drug regimens containing indinavir or ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:154 (abstract no. 400) Mayers DL, Neaton JD, Perez G, Baxter JD, MacArthur RD, Markowitz NP, Dehlinger ME, Howard SF, Thompson MA |
|
| 401 | HIV RNA and resistance mutations to saquinavir and zidovudine in patients receiving dual versus triple combination therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:154 (abstract no. 401) Schapiro JM, Lawrence J, Speck R, Winters MA, Coombs R, Collier AC, Efron B, Merigan TC |
|
| 402 | Impaired viral protein processing by resistant HIV proteases are only partially compensated by secondary changes in Gag. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:154 (abstract no. 402) Mammano F, Race E, Molla A, Clavel F |
|
| 403 | Anti-HIV activities of protease inhibitors in T-lymphocytic cell lines overexpressing multi-drug transporter proteins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:155 (abstract no. 403) Srinivas RV, Fridland A |
|
| 404 | Natural reduced susceptibility of HIV type 1 subtype G to protease inhibitors (PI). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:155 (abstract no. 404) Descamps D, Collin G, Apetrei C, Damond F, Loussert-Ajaka I, Simon F, Brun-Vezinet F |
|
| 405 | Highly drug-resistant HIV-1 isolates are cross resistant to many of the current anti-HIV compounds in clinical development. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:155 (abstract no. 405) Palmer S, Shafer R, Merigan TC |
|
| 406 | Single-cycle parameters of the inhibition of HIV infectivity by protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:155 (abstract no. 406) Nascimbeni M, Paulous S, Clavel F |
|
| 406a | Mutations selected in HIV plasma RNA during 141W94 therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:155 (abstract no. 406a) De Pasquale MP, Murphy R, Gulick R, Smeaton L, Sommadossi JP, Degruttola V, Caliendo A, Kuritzkes D, Sutton L, Savara A, D'Aquila R &&&Massachusetts General Hospital, Boston, MA |
|
| Session 53 — Poster Antiretroviral Therapy: Unique Adverse Effects of Protease Inhibitors |
||
| 407 | Multiple symmetrical lipomatosis associated with protease inhibitor therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:156 (abstract no. 407) Hengel RL, Geary JA, Vuchetich MA, Swartz AS, Brachman PS, Watts NB, Lennox JL |
|
| 408 | "Protease-paunch" in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:156 (abstract no. 408) Rosenberg HE, Mulder J, Sepkowitz KA, Giordano MF |
|
| 409 | Buffalo hump in HIV-infected patients on antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:156 (abstract no. 409) Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M |
|
| 410 | A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PI's). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:156 (abstract no. 410) Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA; St. Vincent's Hospital, Sydney, Australia |
|
| 411 | Development of a cervical fat pad following treatment with HIV-1 protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:156 (abstract no. 411) Roth VR, Angel JB, Kravcik S |
|
| 412 | Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA summary. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:157 (abstract no. 412) Mann M, Piazza-Hepp T, Koller E, Gibert C |
|
| 413 | Increased intra-abdominal fat deposits in patients on indinavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:157 (abstract no. 413) Miller K, Jones E, Yanovski J, Shankar R, Feuerstein I, Falloon J |
|
| 414 | Evidence of unique metabolic effects of protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:157 (abstract no. 414) Mulligan K, Tai VW, Algren H, Chernoff DN, Lo JC, Schambelan M; University of California, San Francisco, CA |
|
| 415 | Diabetes and hyperglycemia in patients receiving protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:157 (abstract no. 415) Keruly JC, Chaisson RE, Moore RD |
|
| 416 | Diabetes and use of protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:157 (abstract no. 416) Dong BJ, Gruta C, Legg J, Balano K, Goldschmit RH |
|
| 417 | Acute hepatitis in AIDS patients during ritonavir treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:157 (abstract no. 417) Arribas JR, Gonzalez-Garcia J, Ibanez C, Ruiz B, Pena JM, Esteban C, Frias J, Vazquez JJ |
|
| 418 | Increased risk of indinavir nephropathy in women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:158 (abstract no. 418) Sarcletti M, Petter A, Lhotta K, Konig P, Zangerle R |
|
| Session 54 — Poster Antiretroviral Therapy: Salvage Regimens |
||
| 419 | Viral load and CD4+ T cell changes in patients failing potent protease inhibitor therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:158 (abstract no. 419) Deeks S, Beatty G, Cohen PT, Grant R, Volberding P |
|
| 420 | Predictors and incidence of failure in 500 advanced stage HIV patients treated with indinavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:158 (abstract no. 420) Rozenbaum W, Adda N, Wirbel E, Hadacek B, Schneider V, Costagliola D |
|
| 421 | Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:158 (abstract no. 421) Hazelwood JD, Koel JL, Nail CD, Marangos M, Smith R, Miles S, Thompson M, Johnson VA |
|
| 422 | Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:158 (abstract no. 422) Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Winslow D, Merigan TC |
|
| 423 | Combined quadruple therapy with ritonavir-saquinavir (RTV-SQV) + nucleosides in patients (p) who failed in triple therapy with RTV, SQV or indinavir (IDV). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:159 (abstract no. 423) Cassano P, Hermans P, Sommereijns B, De Wit S, Kabeya K, O'Doherty E, Clumeck N |
|
| 424 | Salvage anti HIV triple therapy with foscarnet (F) in combination with nelfinavir (NEL) and nevirapine (NEV) in heavily pretreated patients (p). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:159 (abstract no. 424) Gerard M, De Wit S, Sprecher S, De Cock F, Van Laethem Y, Hermans P, Payen MC, Kabeya K, Cassano P, Clumeck N |
|
| 425 | Effects of a "salvage" combination therapy with ritonavir + saquinavir in HIV-infected patients previously treated with protease-inhibitors (PI). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:159 (abstract no. 425) de Truchis P, Force G, Zucman D, Leclerc V, Rouveix E, Simonpoli AM, Berthe H |
|
| 426 | Salvage therapy using six drugs in heavily pretreated patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:159 (abstract no. 426) Workman C, Mussen R, Sullivan J |
|
| 427 | Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:159 (abstract no. 427) Gallant JE, Hall C, Barnett S, Raines C |
|
| 428 | Indinavir (IND)/nevirapine (NVP) combination therapy in advanced HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:159 (abstract no. 428) Beach RS, Wohlfeiler MB, Silva A |
|
| 429a | 1 year followup of HIV patients treated with nevirapine, indinavir, and lamivudine in combination. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:160 (abstract no. 429a) Harris M, Whaley M, De Wet JJ, Raboud J, Rae S, Conway B, Montaner JS |
|
| Session 55 — Poster KSHV |
||
| 430 | Cofactors for progression to Kaposi's sarcoma in human herpesvirus 8-infected homosexual men: a population-based cohort study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:160 (abstract no. 430) Martin JN, Ganem DE, Osmond DH, Sheppard H, Page-Shafer K, MacRae DR, Kedes DH |
|
| 431 | AIDS-associated Kaposi's sarcoma and HIV-protease inhibitors a prospective study of 13 cases. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:160 (abstract no. 431) Dupin N, Rubin V, Gorin I, Calvez V, Pessis E, Rabian C, Viard JP, Huraux JM, Escande JP |
|
| 432 | Detection of human herpesvirus 8 DNA in peripheral blood mononuclear cells of HIV + subjects, with and without Kaposi's sarcoma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:160 (abstract no. 432) Min J, Katzenstein D |
|
| 433 | Temporal relationship of changes in plasma HIV RNA levels and clinical progression or regression of Kaposi's sarcoma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:160 (abstract no. 433) Lyter DW, Beckman EJ, Nowak J |
|
| 434 | AIDS Kaposi's sarcoma, viral load, CD4 lymphocyte count in patients following combined antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:161 (abstract no. 434) Monticelli A, Lewi D, Jauregui Rueda H, Pampuro S, Hodara V, Libonatti O, Salomon H |
|
| 435 | Seroprevalence of human herpesvirus type 8 (HHV8) infection in Spain. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:161 (abstract no. 435) Gambus G, Bourbolia D, Whitby D, Ruiz L, Weiss R, Casabona J; CEESCAT, Badalona. Spain |
|
| 436 | Lack of antibodies to Kaposi's sarcoma associated herpesvirus (KSHV) in patients with multiple myeloma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:161 (abstract no. 436) Marcelin AG, Dupin N, Bouscary D, Bossi P, Huraux JM, Escande JP, Cacoub P, Ravaud P, Calvez V |
|
| 437 | Human herpesviruses-8 (HHV-8)-mediated CD4+ T lymphocytopenia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:161 (abstract no. 437) Wu H, Mitra D, Mesri E, Laurence J |
|
| 438 | Transient angiofollicular hyperplasia and Kaposi's sarcoma following primary infection with HHV-8. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:161 (abstract no. 438) Oksenhendler E, Barateau V, Grollet L, Cazals-Hatem D, Sigaux F, Clauvel JP, Agbalika F |
|
| 439 | Detection of antibodies to human herpes virus type 8 (HHV-8) latent and lytic antigens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:161 (abstract no. 439) Edelman D, Constantine N, Herman JM, Ketema F, Schultz T, Gill P, Blattner W |
|
| 440 | Detection of IgG antibodies to KSHV/HHV-8 in patients with various malignancies and infectious diseases using whole virus ELISA, IFA, and Western blots. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:162 (abstract no. 440) Chatlynne L, Handy M, Lapps W, Whitman R, Mitchell K, Kaplan M, Dosik M, Masood R, Gill P, Friedman-Kien A, Whitman J, Ablashi D |
|
| 441 | Plasma vascular endothelial growth factor (VEGF(165)) in AIDS-patients with or without Kaposi's sarcoma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:162 (abstract no. 441) Mercie P, Devianne I, Viallard JF, Denisi R, Pellegrin I, Fleury H, Leng B, Dupon M, Pellegrin JL |
|
| Session 56 — Poster Neuropathogenesis of Retroviral Infection |
||
| 442 | Immunocytochemical reactivity of inducible nitric oxide synthase in the brain of rhesus monkeys infected with simian immunodeficiency virus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:162 (abstract no. 442) Qingsheng LI, Cavert W, Murray EA, Rausch DM, Eiden LE, Haase AT |
|
| 443 | Defining the cellular regulation of nitric oxide in HIV-1 encephalitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:162 (abstract no. 443) Ghorpade A, Che M, Gendelman HE |
|
| 444 | Cytokine modulation of astrocyte glutamate transport: implications in AIDS dementia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:163 (abstract no. 444) Pappas TC, O'Brien WA, Pollard RB, Nokta M |
|
| 445 | Association of CSF beta chemokine (BCK) concentrations with neurocognitive status (NCS) in HIV-infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:163 (abstract no. 445) Letendre SL, McArthur JC, Lanier ER |
|
| 446 | Unraveling the mechanisms for neuronal dysfunction in HIV-1 dementia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:163 (abstract no. 446) Zheng J, Thylin M, Persidsky Y, Ghorpade A, Leisman GB, Gendelman HE |
|
| 447 | Elevated levels of monocyte chemotactic protein-1 (MCP-1) and viral RNA in cerebrospinal fluid, but not in plasma, are correlates of HIV encephalitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:163 (abstract no. 447) Poli G, Vago L, Mengozzi M, Torri V, Vicenzi E, Sozzani S, Mantovani A, Lazzarin A, Cinque P |
|
| 448 | Expression of CD4 and chemokine receptors in human brain cells: astrocyte entry by HIV-1 T and M tropic strains is blocked by SDF-1 and RANTES. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:163 (abstract no. 448) Taoufik Y, Boutet A, Lannuzel A, Salim H, Azzarone B, Dussaix E, Vincent JD, Tardieu M, Delfraissy JF |
|
| 449 | Absence of NSI HIV-1 in tissues of CCR5 &Delta32; heterozygotes as explanation for reduced incidence of AIDS dementia complex. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:163 (abstract no. 449) Van Rij RP, Van't Wout AB, Portegies P, Halaby T, Ran L, De Roda Hustman AM, Lange JM, Schuitemaker H |
|
| 450 | Coreceptor use in HIV infection of microglial cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:164 (abstract no. 450) Albright AV, Shieh J, Sharron M, Gartner S, Strizki J, Doms RW, Gonzalez-Scarano F |
|
| 451 | HIV-1 co-receptors in the CNS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:164 (abstract no. 451) Gabuzda D, Vallat A, He J, Ohagen A, Chen Y |
|
| 452 | Evidence for an astrocytotropic HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:164 (abstract no. 452) Canki M, Potash MJ, Volsky DJ |
|
| 453 | HIV-1 viral dynamics differ in cerebrospinal fluid and plasma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:164 (abstract no. 453) Ellis RJ, Spector SA, Hsia K, Deutsch R, Gamst A, Grant I, McCutchan JA; University of California, San Diego, CA |
|
| 454 | Kinetics of CSF HIV-1 response to antiviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:164 (abstract no. 454) Staprans S, Inkina N, Novakovic-Agopian T, Deeks S, Heyes M, Aweeka F, Grant R, Price RW |
|
| 455 | Development of an in vitro Blood: Brain Barrier model and efficient transfer and expression of transgenes in various CNS-based cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:164 (abstract no. 455) Mukhtar M, Pomerantz RJ, Bagasra O |
|
| 456 | Studies of HIV-1 neurovirulence in a SCID mouse model of viral encephalitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:165 (abstract no. 456) Nukuna AN, Persidsky Y, Limoges J, Ghorpade A, Gendelman HE |
|
| 457 | Macrophage phenotype and not virus genotype correlates with viral replication and dementia in AIDS brains. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:165 (abstract no. 457) Teo I, Veryard C, Luthert P, Shaunak S &&&Imperial College School of Medicine at Hammersmith, London, United Kingdom |
|
| Session 57 — Poster Dementia, Peripheral Neuropathy, and Other CNS Complications |
||
| 458 | Reduced risk of progression to HIV encephalopathy with ddI or ddC in combination to AZT compared to AZT alone. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:165 (abstract no. 458) Charreau I, Chemlal K, Yeni P, Dormont J, Seligmann M, Aboulker JP; INSERM, Villejuif, France |
|
| 459 | Neurological manifestations during HIV-1 infection correlate to viral load in CSF but not to virus phenotype. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:165 (abstract no. 459) Di Stefano M, Monno L, Fiore JR, Buccoliero G, Appice A, Perulli LM, Angarano G |
|
| 460 | Cerebrospinal fluid (CSF) HIV-RNA: extensive study of 39 AIDS patients with intellectual deficiency. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:166 (abstract no. 460) Force G, Krivine A, Servan J, Cabee A, Dighiero L, Manicacci M, Lebon P |
|
| 461 | Features of Bartonella-associated HIV dementias. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:166 (abstract no. 461) Schwartzman WA, Patnaik M, Singer E, Visscher B |
|
| 462 | A randomized, placebo-controlled trial of a standardized acupuncture regimen or amitriptyline for pain caused by HIV-associated peripheral neuropathy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:166 (abstract no. 462) Shlay J, Chaloner K, Max M, Flaws B, Riechelderfer P, Wentworth D, Brizz B, Cohn D |
|
| Session 58 — Poster Neurologic Opportunistic Infections: PML and Toxoplasmosis |
||
| 463 | Factors associated with survival in HIV-infected patients with progressive multifocal leukoencephalopathy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:166 (abstract no. 463) Dworkin MS, Wan PC, Hanson DL, Jones JL |
|
| 464 | Therapy of AIDS-associated progressive multifocal leuko-encephalopathy with protease inhibitors combination regimens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:166 (abstract no. 464) Miralles P, Padilla B, Berenguer J, Cosin J, Moreno S, Munoz L, Bouza E; H. Gregorio Maranon, Madrid, Spain |
|
| 465 | Progressive multifocal leukoencephalopathy in AIDS: survival improvement with protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:167 (abstract no. 465) Gasnault J, Goujard C, Blondin-Diop A, Taoufik Y, Delfraissy JF |
|
| 466 | Fatal progressive multifocal leukoencephalopathy (PML) despite highly active antiretroviral therapy (HAART), interferon-alpha 2b (IFN-a-2b), and peptide T. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:167 (abstract no. 466) Piliero PJ, Nguyen AD, Reif M |
|
| 467 | Evaluation of Cidofovir for progressive multifocal leukoencephalopathy (PML). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:167 (abstract no. 467) Matheron S, Girard PM, Duval X, Petitdidier Ch, Bortolotti V, Gasnault J |
|
| 468 | Thrice-weekly vs. daily sulfadiazine-pyrimethamine(SP) for maintenance therapy of toxoplasmic encephalitis (TE). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:167 (abstract no. 468) Podzamczer D, Miro JM, Ferrer E, Gatell JM |
|
| 469 | HIV-related brain mass: a diagnostic clinical pathway based upon use of toxoplasma serology, CT/MRI and thallium-201 SPECT of the brain. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:167 (abstract no. 469) Hsiao CB, Naples N, Hewitt RG |
|
| Session 59 — Poster HIV Wasting and Diarrheal Opportunistic Infections |
||
| 470 | Antiretroviral therapy induced weight changes as a measure of clinical outcome in patients with HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:168 (abstract no. 470) Loeliger AE, Van Leeuwen R, Reiss P, Goebeol F, Stellbrink H, Mertenskotter T, Frissen J, Jablonowski H, Sprenger H, Van Der Ende M, Lange J |
|
| 471 | Weight loss as a marker for disease progression in Thai HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:168 (abstract no. 471) Mahler C, Luchters S, Phanuphak P, Teeratakulpisarn S, Van Leeuwen R, Ungsedhaphan C, Ruxrungtham K, Kroon E, Lange J; HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration Program on AIDS, The Netherlands |
|
| 472 | HIV RNA levels correlate with prior weight loss. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:168 (abstract no. 472) Rivera S, Briggs W, Qian D, Sattler F |
|
| 473 | Nutritional status and intake of HIV-infected men in 1996-1997. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:168 (abstract no. 473) Muurahainen N, Collins G, Wheeler D, Bartsch G, Gibert C |
|
| 474 | Muscle amino acid metabolism in AIDS-cachexia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:168 (abstract no. 474) Yarasheski KE, Arens M, Horgan MM, Tebas P, Powderly WG |
|
| 475 | Urinany cytokines in HIV associated wasting. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:169 (abstract no. 475) Rivera S, Moldawer L, Boyd H, Sattler F |
|
| 476 | Thalidomide promotes weight gain and increase in fat-free mass in HIV-associated wasting. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:169 (abstract no. 476) Kaplan G; Rockefeller University, New York, NY |
|
| 477 | Effects of oxandrolone on body weight and composition in patients with HIV-associated weight loss. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:169 (abstract no. 477) Fisher AE, Abbaticola MM; Coastal Medical, Providence, RI |
|
| 478 | Avascular necrosis in AIDS patients receiving megestrol acetate. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:169 (abstract no. 478) Gibert C, Koller E, Mann M, Bacsanyi J, Malozowski S |
|
| 479 | Macrolides do not prevent cryptosporidiosis in AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:169 (abstract no. 479) Fichtenbaum C, Griffiths J, Zackin R, Feinberg J, Benson C |
|
| 480 | Impact of antiretroviral therapy (ART) on cryptosporidiosis outcome and factors of clinical resistance. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:169 (abstract no. 480) Landau A, Aaron L, Pialoux G, Eliaszewicz M, Zylberberg H, Poncelet H, Dupont B |
|
| 481 | Combination paromomycin (P) and azithromycin (A) for cryptosporidiosis (CS) in AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:170 (abstract no. 481) Smith NS, Cron S, Chappell C, Valdez L, White AC |
|
| 482 | Clinical characteristics of HIV-infected patients with microsporidiosis six months after primary diagnosis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:170 (abstract no. 482) Dascomb K, Clark R, Kissinger P, Didier E, Rogers L |
|
| 483 | Outbreak of intestinal microsporidiosis in HIV infected and non-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:170 (abstract no. 483) Cotte L, Rabodonirina M, Raynal C, Chapuis F, Piens MA, Trepo C; Hotel-Dieu Hospital, Lyon, France |
|
| Session 60 — Poster Fungal Opportunistic Infections: Pathogenesis and Treatment |
||
| 484 | Elevated intracranial pressure (ICP) in patients with HIV-associated cryptococcal meningitis (HIV-CM): the role of cerebrospinal fluid (CSF) outflow resistance. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:170 (abstract no. 484) Fessler RD, Guyot L, Johnson RR, Diaz FG |
|
| 485 | Prospective study of oral candida colonization in advanced AIDS patients treated with ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:170 (abstract no. 485) Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia J, Gonzalez A, Canedo T, Pena JM, Vazquez JJ, Powderly WG |
|
| 486 | Anticandidal activity of a 12 amino acid fragment of a salivary peptide: potential use as a treatment for oral candidiasis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:171 (abstract no. 486) Madison P, Tran L, Spacciapoli P, Friden PM |
|
| 487 | Typing of sequential Candida albicans isolates by random amplification of polymorphic DNA (RAPD). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:171 (abstract no. 487) Lemonte AM, Smedema ML, Connolly PA, Goldman M, McKinsey DS, Wheat LJ |
|
| 488 | Effect of highly active anti-retroviral therapy (HAART) on recurrent oropharyngeal candidiasis in HIV-infected patients: a complex relationship. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:171 (abstract no. 488) Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF |
|
| 489 | Withdrawal of azole-suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:171 (abstract no. 489) Gripshover BM, Salata RA, Valdez H, Lederman MM |
|
| 490 | Antifungal cross-resistance among Candida spp. recovered from fluconazole-refractory thrush in AIDS patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:171 (abstract no. 490) Vazquez JA, Boikov D, Sobel JD |
|
| 491 | Use of granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant to fluconazole in antifungal refractory oropharyngeal candidiasis in advanced AIDS patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:171 (abstract no. 491) Vazquez JA, Gupta S, Villanueva A |
|
| 492 | Risk factors for esophageal candidiasis in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:172 (abstract no. 492) Abgrall S, Charreau I, Bloch J, Joly V, Reynes J, Yeni P, Aboulker JP; INSERM, Villejuif, France |
|
| Session 61 — Poster Opportunistic Infections: Hepatitis Viruses and Herpesviruses |
||
| 493 | Effect of hepatitis C (HCV) coinfection on survival from date of AIDS diagnosis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:172 (abstract no. 493) Rimland D, Staples CS; VA Medical Center, Atlanta, GA |
|
| 494 | Hepatitis C in patients with the immunodeficiency virus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:172 (abstract no. 494) Mendes Correa MC, Duarte MI, Guastini C, Barone A |
|
| 495 | Transaminase abnormalities in patients coinfected with HIV & HCV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:172 (abstract no. 495) Asmuth DM, Borucki M, Miskovsky E, O'Brien AW, Pollard RB |
|
| 496 | Effect of lamivudine on hepatitis B/HIV co-infected patients from the CAESAR study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:172 (abstract no. 496) Cooper DA, Dore G, Barrett C |
|
| 497 | Hepatitis B vaccination response to 6 versus 3 immunizations in HIV-infected patients, and effects on HIV-1 viral load. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:173 (abstract no. 497) Krantz V, Rey D, Libbrecht E, Partisani M, Schmitt MP, Vetter D, Nicolle M, Kempf-Durepaire G, Lang JM |
|
| 498 | Hepatitis A in HIV-infected subjects. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:173 (abstract no. 498) Wallace MR, Hill HE, Tasker SA, Miller LK |
|
| 499 | Improved efficacy of herpes simplex (HSV) suppression with higher acyclovir (ACV) exposure in patients with advanced HIV disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:173 (abstract no. 499) Feinberg JE, Chulay JD, Wang B |
|
| 500 | Acyclovir in HIV infection: meta-analysis of randomized updated individual patient data. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:173 (abstract no. 500) Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, Saag MS, Spruance SL, Youle MS |
|
| 501 | High incidence of herpes zoster early after starting antiretroviral therapy with a protease inhibitor. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:173 (abstract no. 501) Martinez E, Gatell JM, Moran Y, Buira E, Aznar E, Guelar A, Mallolas J, Sorlano E |
|
| 502 | Abrupt reactivation of HHV-6 in HIV patients after initiation of highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:173 (abstract no. 502) Wang XP, Kaplan MH, Ginnochio C |
|
| Session 62 — Poster Opportunistic Infections: Miscellaneous |
||
| 503 | Incidence of a TTP-HUS-like syndrome in patients hospitalized with AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:174 (abstract no. 503) Chaisson RE, Keruly JC, Moore RD |
|
| 504 | Treatment of recalcitrant molluscum contagiosum with cidofovir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:174 (abstract no. 504) Pavia AT, Meadows KP, Tyring SK, Rallis TM |
|
| 505 | The effect of fluconazole, clarithromycin, and rifabutin on the production of the toxic hydroxylamine metabolite of dapsone in people with HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:174 (abstract no. 505) Winter HR, Trapnell CB, Jacobson M, Greenspan DL, Marquis K, Boucher H, Unadkat JD |
|
| 506 | Pharmacokinetics of azithromycin (AZ) when administered alone and with atovaquone (AT). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:174 (abstract no. 506) Ngo LY, Yogev R, Dankner WM, Hughes WT, Xu J, Unadkat J |
|
| 507 | Responsiveness of the EuroQol and MOS-HIV in advanced HIV disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:174 (abstract no. 507) Wu AW, Jacobson D, Clark R, Revicki D, Scott-Lennox J, Feinberg J; Johns Hopkins University, Baltimore, MD |
|
| 508 | Reduction of HTLV-I proviral load in patients with HTLV-I-associated myelopathy through Lamivudine monotherapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:175 (abstract no. 508) Taylor GP, Hall S, Nowak M, Michie C, Rossor M, Davies R, Bangham CR, Weber IN |
|
| Session 63 — State-of-the-Art-Lecture HIV Drug Discovery: Issues and Challenges |
||
| L6 | HIV Drug Discovery: Issues and Challenges Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. L6) Tarpley WG |
|
| Session 64 — State-of-the-Art-Lecture T-Cell Immune Reconstruction in HIV Negative Hosts |
||
| L7 | T-Cell Immune Reconstruction in HIV Negative Hosts Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. L7) Mackall C |
|
| Session 65 — Slide Antiretroviral Chemotherapy II |
||
| 509 | Predictors of virologic and clinical responses to indinavir (IDV)+ZDV+3TC or ZDV+3TC. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:175 (abstract no. 509) Demeter L, Hughes M, Fischl M, Grimes J, Bosch R, Squires K, Hammer S |
|
| 510 | Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:175 (abstract no. 510) Tebas P, Kane E, Klebert M, Simpson J, Powderly WG, Henry K |
|
| 511 | Relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir (SQVhc) to indinavir (IDV) or saquinavir soft gelatin capsule (SQVsgc). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:175 (abstract no. 511) Para MF, Coombs R, Collier A, Glidden D, Bassett R, Duff F, Boucher C, Leavitt RY, Condra J, Pettinelli C |
|
| 512 | 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:175 (abstract no. 512) Murphy R, Degruttola V, Gulick R, D'Aquila R, Eron J, Sommadossi JP, Smeaton L, Currier J, Tung R, Kuritzkes D |
|
| 513 | CCTG 570: utility of HIV RNA measurement to monitor antiretroviral (ARV) therapy in patients with less than 500 CD4 cells/mm(3). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:176 (abstract no. 513) Haubrich R, Currier J, Forthal D, Beall G, Kemper C, Dube M, Ignosci J, Johnson D, Hwang J, McCutchan JA |
|
| 514 | The effect of stem cell mobilization with filgrastim (rG-CSF) on viral replication in persons with HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:176 (abstract no. 514) Campbell T, Rosandich M, Bakhtiari M, Shugarts D, Mitchell D, King J, Kuritzkes D, Ambruso D, Mladenovic J, Miles S, Pomerantz R, Schooley R |
|
| 515 | Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:176 (abstract no. 515) Chun TW, Fauci AS |
|
| 516 | Neurological substudies of ACTG protocol 193A: quantitative neurological performance measures and treatment outcomes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:176 (abstract no. 516) Price RW, Yiannoutsos C, Zaborski L, Kmack A, Henry K, Tierney C, Clifford D |
|
| Session 66 — Slide In Vivo Pathogenesis and Primary Infection |
||
| 517 | Multi-phasic HIV decline following triple drug antiviral therapy is correlated with viral rebound dynamics during therapy interruption. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:176 (abstract no. 517) Neumann AU, Tubiana R, Calvez V, Robert C, Autran B, Katlama C; Bar-Ilan University, Ramat-Gan, Israel |
|
| 518 | HIV-1 viral kinetics in gut-associated-lymphoid-tissue (GALT) in chronically infected patients treated with combination therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:177 (abstract no. 518) Vesanen M, Kost R, Ramratnam B, Talal A, Cao Y, Hurley A, Schluger R, Rogers M, Johnson J, Smiley L, Ho DD, Markowitz M |
|
| 519 | Analysis of lymph node biopsies in HIV infected patients before and after HAART. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:177 (abstract no. 519) Bucy RP, Kilby JM, Derdeyn CA, Horton D, Sillers M, Squires K, Saag M, Shaw GM, Hockett RD |
|
| 520 | In vivo attenuation of SIVmac239 by mutation of conserved Tyr in the TM cytoplasmic tail. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:177 (abstract no. 520) Hoxie JA, Endres MJ, Vance PJ, Tao B, Marsh M, Fultz PN |
|
| 521 | Viral population dynamics during acute HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:177 (abstract no. 521) Little S, Havlir D, Richman D, Spina C, McLean A |
|
| 522 | Impact of highly active antiretroviral therapy (HAART) on the stabilization of the TCR beta chain repertoire during primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:177 (abstract no. 522) Soudeyns H, Rizzardi GP, Demarest JF, Lazzarin A, Fauci AS, Corey L, Pantaleo G; CHUV, Lausanne, Switzerland |
|
| 523 | Rate of production of HIV in lymphatic tissue measured during the acute and very early stages of infection is not related to duration of infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:177 (abstract no. 523) Schacker TW, Gebhard K, Krieger J, Corey L, Haase AT |
|
| 524 | Efficacy of zidovudine, lamivudine and ritonavir combination in patients with symptomatic primary HIV-1 infection: the ANRS 053/53b trial. Can eradication be obtained? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:178 (abstract no. 524) Hoen B, Harzic M, Dumon B, Lascoux C, Gomard E, Venet A, Beauvais L, Chauvin JP, Sereni D; ANRS, France |
|
| Session 67 — Slide KSHV: Biology and Epidemiology |
||
| 525 | Utility of HHV-8 DNA QC PCR: relationship of PBMC burden to stage of Kaposi's sarcoma and response to therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:178 (abstract no. 525) Looney DJ, Witke W, Corbeil J, Richman D, Little S |
|
| 526 | Seroprevalence of human herpesvirus type 8 (HHV-8) among Zambian women of childbearing age without Kaposi's sarcoma (KS), and mother/child pairs with KS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:178 (abstract no. 526) Kankasa C, Bhat G, Mitchell CD, Chintu C, Jun H, Wood C |
|
| 527 | KSHV/HHV-8 G protein-coupled receptor is a viral oncogene and angiogenesis activator. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:178 (abstract no. 527) Bais C, Santomasso B, Coso O, Arvanitakis L, Geras Raaka E, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA |
|
| 528 | Infection of primary endothelial cells by KSHV/HHV 8 and establishment of long term endothelial cell lines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:178 (abstract no. 528) Flore O, Hyjek E, O'Leary J, Mesri E, Rafii S, Cesarman E |
|
| Session 68 — Poster Diagnostic Assays and Viral Quantification |
||
| 529 | Levels of plasma HIV RNA measured by the Roche ultrasensitive assay in HIV infected individuals with RNA levels below the bDNA detection limit. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:179 (abstract no. 529) Henry K, Melroe H, Simpson J, Kane E, Stawarz K, Erice A, Chen W, Paxton WB |
|
| 530 | Use of microsample dried blood spot RNA assays for diagnosis of pediatric HIV in the first week of life. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:179 (abstract no. 530) Comeau AM, Su X, Gerstel J, Pan D, Hillyer GV, Tuomala R, LaRussa P, Landesman S, Bremer J, Rosenblatt HM, Lew J, Moye J, Smeriglio V, Fitzgerald G, Pilon R, Cassol S |
|
| 531 | Estimation of HIV incidence in US blood donors using a novel detuned anti-HIV EIA test strategy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:179 (abstract no. 531) Busch MP, Rawal BD, Stramer SL, Satten GA, Aberle-Grasse J, Schreiber GB, Janssen RS |
|
| 532 | World-wide evaluation of DNA sequencing approaches for the identification of drug resistance mutations in the HIV-1 reverse transcriptase. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:179 (abstract no. 532) Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, De Groot T, Boucher C; ENVA Labs |
|
| 533 | A canarypox recombinant containing HIV-1 env, gag, pol and nef genes (vCP 300) given with SF-2 rgp120 elicits broad, durable CD8+ CTL in seronegative volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:180 (abstract no. 533) Evans TG, Keefer MC, Wolff M, Weinhold K, Excler JL, Duliege AM, Fast P, McElrath MJ, Graham BS, Clements-Mann ML, Mulligan M, Gorse GJ |
|
| 534 | Immunogenicity of systemically and mucosally administered oligomeric gp160 in rhesus macaques and protection from SHIV challenge. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:180 (abstract no. 534) Vancott TC, Lewis M, Kaminski R, Ratto-Kim S, Mascola J, Kalyanaraman V, Pragman S, Frampton L, Yalley-Ogunro J, Greenhouse J, Lu Y, Jenkins S, Richardson C, Ulrich T, Wassef N, Alving C, Lowell G, Robb M, Birx D |
|
| 535 | Full length SIV nucleocapsid mutant DNA vaccine: immunization and challenge. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:180 (abstract no. 535) Gorelick R, Benveniste R, Lifson JD, Yovandich J, Rossio J, Bess JW Jr, Henderson LE, Arthur LO |
|
| 536 | Induction of CD8 antiviral activity in rhesus macaques by vaccination: potential role in protective immunity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:180 (abstract no. 536) Leno M, Carter L, Romano J, Markham P, Limbach K, Tartaglia J, Paoletti E, Benson J, Franchini G, Robert-Guroff M |
|
| 537 | Protection against HIV-1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR-5 co-receptor defects. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:180 (abstract no. 537) Markee J, Goh WC, Akridge R, Musey L, Corey L, Emerman M, McElrath MJ; University of Washington, Seattle, WA |
|
| 538 | Use of genetically engineered cells in the development of an HIV neutralization assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:181 (abstract no. 538) Dayaraj C, Kewalramani V, Burda S, Littman D, Zolla-Pazner S; New York University, New York, NY |
|
| 539 | Molecular and cellular analysis of HIV-induced apoptosis in lymphoblastoid T cell line expressing wild-type and mutated CD4 receptors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:181 (abstract no. 539) Moutouh L, Richman DD, Corbeil J |
|
| 540 | Molecular aspects of CD40 ligand (CD40L) stimulation of macrophages to produce HIV-suppressive beta-chemokines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:181 (abstract no. 540) Kornbluth RS, Kee K, Richman DD |
|
| Session 70 — Symposium Changing Trends in the Epidemiology Pathogenesis of HIV-Related Opportunistic Infections |
||
| S28 | Clinical responses of opportunistic diseases to antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:235 (abstract no. S28) Carr A; St. Vincent's Hospital, Sydney, Australia. Fax: 61-2-9361-7498. E-mail: acarr@stvincents.com.au |
|
| S29 | Changing trends in the epidemiology and clinical presentation of HIV-related opportunistic infections. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:235 (abstract no. S29) Currier JS; University of Southern California, CA |
|
| S30 | Dynamics and mechanisms of immune reconstitution after potent antiretroviral therapies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:236 (abstract no. S30) Lederman MM |
|
| S31 | Immunomodulation in Mycobacterium infections. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:236 (abstract no. S31) Russell DG |
|
| S32 | Virus specific immunity and invasive HCMV infection in patients with AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:236 (abstract no. S32) Britt WJ; University of Alabama, Birmingham, AL |
|
| Session 71 — Symposium Biological Mechanisms of Viral Transmission Interruption |
||
| S33 | HIV-1 compartmentalization in the genital tract: implications for sexual transmission. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:236 (abstract no. S33) Coombs RW |
|
| S34 | Sexual transmission of HIV-1: where epidemiology meets biology. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:236 (abstract no. S34) Cohen MS |
|
| S35 | T cell tropic SIV/SHIVs are readily transmitted by vaginal inoculation and dendritic cells of the female genital tract are reservoirs for SIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:237 (abstract no. S35) Miller CJ, Marthas M, Hu J, Greenier J, Dailey PJ, Pope M, Lu Y |
|
| S36 | Virologic and immunologic correlates of HIV-1 transmission. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:237 (abstract no. S36) Wolinsky SM |
|
| S37 | Strategies for Prevention of Mother-to-Infant Transmission of HIV Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:237 (abstract no. S37) Spector SA |
|
| Session 72 — Symposium Accessory Gene Function |
||
| S38 | Post entry determinants of primate lentivirus infectivity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:237 (abstract no. S38) Stevenson M, Brichacek B, Jacque JM, Mann A, Sleigh R, Sharkey M, Sharova N, Lifson J, Hahn B, Hirsch V |
|
| S39 | Analysis of HIV-1 Vif protein function. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:237 (abstract no. S39) Malim MH, Simon JH, Fouchier RA, Gaddis NC |
|
| S40 | The many tricks Nef plays on the cell. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:238 (abstract no. S40) Trono D, Chen YL, Piguet V, Lama J, Mangasarian A, Wang JK |
|
| S41 | A Role for Nef in Lymphocyte Activation Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:237 (abstract no. S41) Desrosiers RC |
|
| S42 | HIV-1 Vpr and the cell cycle. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:238 (abstract no. S42) Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Hahn BH, Emerman M; Emerman M |
|
| Session 73 — Poster Viral Fitness |
||
| 541 | Restoration of HIV replication by compensatory mutations following deletion mutagenesis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:181 (abstract no. 541) Liang C, Wainberg MA |
|
| 542 | Dramatic effect of Muller Rachet in HIV-1 viral populations. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:181 (abstract no. 542) Yuste E, Sanchez-Palomino S, Lopez-Galindez C |
|
| 543 | Effect of resistance to protease inhibitors on HIV reverse transcriptase maturation and function. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:182 (abstract no. 543) Mammano F, Carron L, Zennou V, Paulous S, Clavel F |
|
| 544 | Defining regions outside of PR which influence processing of the gag-pol polyprotein precursor from HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:182 (abstract no. 544) Bloom G, Perez E, Parikh S, Kay J, Goodenow M, Dunn BM |
|
| 545 | Reverse transcriptase (RT) gene analysis in HIV-1 seroconverting patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:182 (abstract no. 545) Yerly S, Schockmel G, Hirschel B, Descamps D, Brun-vezinet F, Perrin L |
|
| 546 | HIV-1 evolutionary limitation of maintaining double resistance to lamivudine (3TC) and zidovudine (ZDV) in vitro. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:182 (abstract no. 546) Rusconi S, Milazzo L, de Pasquale MP, La Seta-Catamancio S, Bulgheroni E, Galli M |
|
| 546a | Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:182 (abstract no. 546a) Gunthard H, Wong J, Leigh Brown A, D'Aquila R, Ignacio C, Johnson V, Kuritzkes D, Richman D |
|
| Session 74 — Poster Retroviral and Cellular Turnover Kinetics |
||
| 547 | T cell activation and turnover in HIV-1 infection: relationship of HIV replication with activation markers, including Ki-67 cell cycle antigen. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:183 (abstract no. 547) Orendi JM, Bloem AC, Borleffs JC, Nottet HS, Visser MR, Snippe H, Verhoef J, Boucher CA |
|
| 548 | CD4+ cell dynamics in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:183 (abstract no. 548) Ruzin IM, Coffin JM; Tufts University, Boston, MA |
|
| 549 | Rate of SIV particle clearance in rhesus macaques. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:183 (abstract no. 549) Zhangi L, Dailey PJ, He T, Gettie A, Bonhoeffer S, Perelson AS, Ho DD |
|
| 550 | PBMCHIV proviral load remains in a steady state during HIV progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:183 (abstract no. 550) Cone RW, Gowland P, Opravil M, Grob P, Ledergerber B |
|
| 550a | Differential T cell induction of productive HIV replication in samples from patients on prolonged suppressive therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:183 (abstract no. 550a) Hezareh M, Wong JK, Ignacio CC, Richman DD, Spina CA |
|
| Session 75 — Poster Miscellaneous Retrovirology |
||
| 551 | Genetic classification of HIV-1 and HCV strains determined from a combinatorial DNA melting assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:184 (abstract no. 551) Kostrikis LG, Shin S, Ho DD |
|
| 552 | Non-recombinant reference clones and sequences for human immunodeficiency virus type 1 subtypes A, C, D, F, and H. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:184 (abstract no. 552) Robertson DL, Gao F, Barre-Sinoussi F, Girad M, Srinvasan A, Abimiku AG, Shaw GM, Sharp PM, Hahn BH |
|
| 553 | Selective capture of HIV-1 to determine cellular origin hindered by infected patient serum in a manner not mimicked by use of purified lab strains. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:184 (abstract no. 553) Roberts BD, Sandstrom P, Evans-Strickfaden T, Busch MP, Folks TM, Butera ST |
|
| 554 | High affinity LFA-1 induces a greater level of HIV-1-induced syncytium formation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:184 (abstract no. 554) Fortin JF, Barbeau B, Genois N, Tremblay M |
|
| 555 | Dissociation between HIV-1 p24 antigen and HIV-1 RNA in chronically infected T cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:184 (abstract no. 555) Knuchel M, Kuster H, Schlaepfer E, Cone R |
|
| 556 | Genotypic analysis of subtype C HIV-1 suggests SI-like viruses are rare. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:185 (abstract no. 556) Ping LH, Nelson JA, Hoffman I, Schock J, Fiscus S, Vernazza P, Kazemb P, Zimba D, Maida M, Cohen MS, Swanstrom R; University of North Carolina, Chapel Hill, NC |
|
| 557 | Natural infection of a household pet mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus related to HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:185 (abstract no. 557) Marx PA, Lu CY, Makuwa M, Georges-Courbot MC, Telfer P, Dubreuil G, Chen Z, Smith SM, Gao F, Hahn BH |
|
| 558 | Molecular characterization of SIVcpz-gab2, a lentivirus obtained from a wild captured chimpanzee in Gabon. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:185 (abstract no. 558) Saragosti S, Peeters M, Delaporte E; INSERM, Paris, France |
|
| 559 | Genetic analysis and serologic characterization of human T cell lymphoma virus type II (HTLV-II) strains in two Venezuelan Amerindian tribes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:185 (abstract no. 559) Leon-Ponte M, Echeverria G, Bianco N, Hengst J, Dube S, Love J, Poiesz B |
|
| Session 76 — Poster Miscellaneous Pathogenesis |
||
| 560 | Role of cellular adhesion molecules in infection of HIV-1 clinical isolates and laboratory-adapted strains. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:185 (abstract no. 560) Hioe C, Hildreth J, Zolla-Pazner S |
|
| 561 | The expression of adhesion molecules and NK receptors on NK cells in HIV-infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:186 (abstract no. 561) Ahmad R, Toma E, Menezes J, Ahmad A |
|
| 563 | Effects of antigenic challenge on expression of immune activation markers and HIV replication. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:186 (abstract no. 563) Staprans S, Inkina N, Matchett J, Wieder E, Anastos K, Lindquist C, Greenblatt R |
|
| 564 | HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappaB. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:186 (abstract no. 564) Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB |
|
| 565 | HIV-1 Vpr alters potently bone marrow cell function. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:186 (abstract no. 565) Kulkosky J, Laptev A, Shetty S, Srinivasan A, Flomenberg N, Prockop D, Pomerantz RJ |
|
| 566 | Telomere length of polymorphonuclear cells and PBMCs in HIV+ and control subjects. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:186 (abstract no. 566) Felizarta F, Drew H, Solomon WB, Seligman SJ |
|
| 567 | The proteasome inhibitor MG-132 suppresses lipopolysaccharide induced tumor necrosis factor-alpha production in primary human macrophages. Implications for HIV-1 associated dementia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:186 (abstract no. 567) Fine SM, Dionne J, Elliot P, Dewhurst S |
|
| 568 | Selective repression of HIV-1 transcription by the cooperation of two host cellular factors: a mechanism for the maintenance of quiescent viral reservoirs? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:187 (abstract no. 568) Romerio F, Galvin K, Volker J, Shi Y, Hansen U, Margolis DM |
|
| 569 | Comparison of viral fitness in viruses with 3TC-selected mutation Met184val and ddI-selected mutation Leu74Val. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:187 (abstract no. 569) Sharma Pl, Crumpacker CS |
|
| 570 | A primary T cell model to study the regulation of HIV latency and replication. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:187 (abstract no. 570) Spina CA; University of California, San Diego, CA |
|
| 571 | Induction of T cell apoptosis by syncytium-inducing and non syncytium-inducing isolates of HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:187 (abstract no. 571) Estaquier J, Brunner T, Ameisen JC, Sheeter D, Moutouh L, Green DR, Richman DD, Corbeil J; INSERM, Paris, France |
|
| 572 | HIV and SIV promote chemotaxis by human and pigtail macaque peripheral blood mononuclear cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:187 (abstract no. 572) Iyengar S, Schwartz DH, Clements JE, Hildreth JE |
|
| 573 | Replicative levels of primary HIV-1 isolates in monocyte derived macrophages (MDM) provide a marker for pathogenesis of M-tropic viruses. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:187 (abstract no. 573) Anders C, Acquino MJ, Miller G, Sleasman JW, Andiman WA, Goodenow MM |
|
| 574 | Cellular HIV RNA copy number is constant in infected lymph node tissue. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:188 (abstract no. 574) Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Squires K, Sillers M, Horton D, Chiz S, Shaw GM, Bucy RP &&&University of Alabama, Birmingham, AL |
|
| 575 | Blood-derived dendritic cells from macaques support SIV replication, particularly in the presence of syngeneic memory T cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:188 (abstract no. 575) Ignatius R, Bilicic D, Cleven H, Mealy J, Steinman RM, Pope M; Laboratory of Cellular Physiology annd Immunology, Rockefeller University, New York, NY |
|
| 576 | Co-infection by HTLV is associated with a higher viral load in PBMC of HIV-infected patients in Brazil. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:188 (abstract no. 576) Brites C, Pedroso C, Pedral-Sampaio D, Netto E, Morgado M, Couto-Fernandes JC, Galvao-Castro B, Badaro R |
|
| 577 | VCAM-1 mediates HTVL-1 infection through the integrin alpha4beta7 and requires a cellular phosphatase. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:188 (abstract no. 577) Hildreth JE, Roos J, Liao Z |
|
| 578 | Plasma virus load determination in HIV-2 infections: evidence for low level of virus expression in the asymptomatic stage. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:188 (abstract no. 578) Shanmugam V, Wiktor S, Nkengasong JN, Soriano V, Heneine W |
|
| 579 | Analysis of plasma viral load in pigtail macaques (macaca nemestrina) infected with single or multiple HIV-2 isolates using a Roche PCR-based system. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:188 (abstract no. 579) Otten RA, Roberts BD, Christopherson C, Kwok S, Rayfield MA, Butera ST |
|
| Session 77 — Poster Primary HIV-1 Infection |
||
| 580 | Identification of acute HIV infection in the incarcerated setting. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:189 (abstract no. 580) Rich JD, Dickinson BP, Spaulding A, Lafazia L, Flanigan TP |
|
| 581 | Evaluation of 12-month triple nucleoside analogue therapy in 12 patients with primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:189 (abstract no. 581) Girard PM, Mariot PH, Schneider V, Damond F, Aissa N, Jacomet CH, Saimot AG, Mathez D, Rozenbaum W |
|
| 582 | Treatment of primary HIV with AZT, 3TC, and indinavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:189 (abstract no. 582) Hecht FM, Chesney MA, Busch MP, Rawal BD, Staprans SI, Kahn JO; University of California, San Francisco, CA |
|
| 583 | Use of saquinavir-containing regimens for the treatment of primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:189 (abstract no. 583) Conway B, Montessori V, Montaner J, Shillington A, Fransen S, Rouleau D |
|
| 584 | Aggressive treatment of recent HIV-1 infected subjects with prolonged undetectable HIV-1 plasma RNA is associated with low levels of HIV-1 proviral DNA. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:189 (abstract no. 584) Saget B, Goodenow M, Christopherson C, Sninsky J, Kwok S, Scheibel S; Private Practice, San Francisco, CA |
|
| 585 | Triple antiretroviral therapy in African patients with acute HIV-1 (subtype A) infection. An ongoing study in Paris. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:190 (abstract no. 585) Saimot AG, Simon F, Damond F, Mathez D, Aumaitre H, Matheron S, Bouchaud O, Coulaud JP, Bouchard C |
|
| 586 | Viral load, genotypic resistance and humoral response during triple combination therapy (TCT) initiated at primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:190 (abstract no. 586) Tamalet C, Poizot-Martin I, Koch N, Yahi N, Lafeuillade A, Lepeu G, Gallais H, Gastaut JA |
|
| 587 | Dynamics of T lymphocytes in acute HIV infection before and after treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:190 (abstract no. 587) Little S, Havlir D, Richman D, McLean A, Spina C |
|
| 588 | Lack of CD8(+) cell activation and cytotoxic T-lymphocyte (CTL) activity until after discontinuation of highly active antiretroviral therapy (HAART) for primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:190 (abstract no. 588) Daar ES, Bai J, Hausner MA, Majchrowicz M, Giorgi JV |
|
| 589 | Analysis of the primary immune response in patients with asymptomatic acute HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:190 (abstract no. 589) Demarest JF, Jones SB, Ferrari G, Greenberg M, O'Brien T, Blattner W, Edwards J, Bartholomew C, Jack N, Cleghorn F, Weinhold KJ; Duke University Medical Center, Durham, NC |
|
| 590 | Comparison of CD4+ and CD8+ responses within 3 months of acute HIV-1 infection among patients without antiretroviral therapy from Geneva, Seattle and Sydney. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:190 (abstract no. 590) Vanhems P, Collier A, Hughes J, Cooper DA, Perrin L, Vizzard J, Hirschel B, Yerly S, Corey L |
|
| 591 | Differences in immunologic and virologic markers in patients with (Syn) and without (NoSyn) acute seroconvertor (AC) syndrome. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:191 (abstract no. 591) Blattner WA, Jack N, Sill A, Edwards J, Murphy J, Mahabir B, Weinhold K, Greenberg M, O'Brien T, Bartholomew C, Cleghorn FR |
|
| 592 | Effect of combination therapy on CD8 T cell activation markers in primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:191 (abstract no. 592) Zaunders J, Kelleher A, Cunningham P, Smith D, Carr A, Cooper DA |
|
| 593 | Dynamics of CD8+ T cell receptor Vbeta gene usage before and after antiretroviral therapy in primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:191 (abstract no. 593) Larsson-Sciard EL, King D, Tarragona A, Kinloch S, Janossy G, Gotch F |
|
| 594 | Role of CD95/CD95L system in primary HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:191 (abstract no. 594) Cossarizza A, Guaraldi G, Mussini C, Borghi V, Mongiardo N, Nuzzo C, Trenti T, Guido M, Paganelli R, Rosok B, Stent G, Nagata S, Franceschi C, De Rienzo B |
|
| 595 | H4, a novel T-cell costimulatory molecule, is highly expressed in patients with acute HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:191 (abstract no. 595) Cauda R, Lucia MB, Dianzani U |
|
| Session 78 — Poster Immunology: Cytokines and Immune Regulation |
||
| 596 | Dehydroepiandrosterone and 7-keto DHEA augment interleukin 2 (IL2) production by human lymphocytes in vitro. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:192 (abstract no. 596) Nelson R, Herron M, Weeks C, Lardy H |
|
| 597 | Absolute interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) synthesis in peripheral blood of HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:192 (abstract no. 597) Tilling RS, Johnson MA, Janossy G |
|
| 598 | Dysregulation of B7.2 (CD86) expression on monocytes of HIV infected individuals is associated with altered production of T helper cytokines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:192 (abstract no. 598) Kumar A, Angel JB, Daftarian P, Cameron W, Filion L, Diaz-Mitoma F |
|
| 599 | Cytokine synthesis-defined T cell subsets in subjects with long-term nonprogressive HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:192 (abstract no. 599) Pitcher C, Quittner C, Peterson D, Maino V, Picker L |
|
| 600 | The in vitro HIV-specific CTL activity of lymphocytes isolated from HIV positive individuals with CD4 greater than 500/microliter can be increased using exogenous recombinant interleukin-12 (rIL-12). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:192 (abstract no. 600) Young J, French R, Clarkson J, Stewart G, Liang T, Widemann R, Packham D, Fulcher D, Benson EM |
|
| 601 | Restoration of antigen-presenting function and T-cell memory responses in HIV-1-infected cells in vitro by interleukin-13. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:193 (abstract no. 601) Sun J, Bailer RT, Suterwalla S, Minty A, Shull J, Holloway A, Anthony R, Kostman JR, Montaner LJ |
|
| 602 | Deficiency of IL-13 and IFN-gamma secretion in HIV infected individuals contributes to overall immune dysfunction. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:193 (abstract no. 602) Bailer RT, Holloway A, Anthony R, Lassiter S, Kostman J, Montaner LJ; Wistar Institute, Philadelphia, PA |
|
| 603 | Differential production of IL-10 by T cells and monocytes of HIV-1 infected individuals: association of IL-10 production with CD28-mediated immune responsiveness. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:193 (abstract no. 603) Kumar A, Angel J, Daftarian P, Parato K, Cameron WD, Filion L, Diaz-Mitoma F |
|
| 604 | Recombinant IL-16 inhibits HIV-replication and protects against activation-induced cell death. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:193 (abstract no. 604) Idziorek T, Khalife J, Mulot O, Hermann E, Mouton Y, Capron A, Bahr GM; Institut Pasteur de Lille, France |
|
| 605 | Altered cytokine production in HIV infection: effects of G-CSF. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:193 (abstract no. 605) Verral S, Hartung T, Pitrak D, Stevens P |
|
| 606 | Thalidomide treatment of HIV infected patients causes immune activation without increasing plasma viral burden. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:193 (abstract no. 606) Haslett PA, Klausner JD, Makonkawkeyoon S, Metatratip P, Kunachiwa W, Maneekarn N, Moreira A, Vongchan P, Boyle B, Corral L, Elbeik T, Kaplan G |
|
| 607 | Lymphocyte and monocyte subset changes during untreated and treated HIV infections in blood, lymph node and lung. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:194 (abstract no. 607) Janossy G, Beckles M, Tilling R, Johnson MA, Poulter LW |
|
| Session 79 — Poster Cytokine and Genetic Therapies |
||
| 608 | IL-2 therapy for HIV disease: a meta-analysis of three randomized, controlled trials. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:194 (abstract no. 608) Emery S, Capra W, Vig P, Smolskis M, Cooper DA, Fyfe G, Saravolatz L, Lane HC, Curtin P; NCHECR, Sydney, Australia |
|
| 609 | Effects of subcutaneous IL2 therapy on CD4 subsets and in vitro cytokine production in HIV+ patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:194 (abstract no. 609) De Paoli P, Zanussi S, Simonelli C, D'Andrea M, Bortolin MT, Tirelli U |
|
| 610 | Productive and latent HIV infection in peripheral blood and lymphoid tissue during antiretroviral therapy with or without interleukin-2. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:194 (abstract no. 610) Stellbrink HJ, Van Lunzen J, Hufert FT, Schneider C, Racz P, Tenner-Racz K |
|
| 611 | Low-dose of recombinant interleukin-2 therapy in HIV-1 patients with CD4 counts 200-500 cells/mm(3): preliminary results. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:194 (abstract no. 611) Tambussi G, Gianotti N, Guffanti M, Veglia F, Saracco A, Nozza S, Magenta L, Vicenzi E, Ghezzi S, Poli G, Lazzarin A |
|
| 612 | A randomized, open label, study of low dose of subcutaneous interleukin-2 in patients with HIV-1 infection and CD4+ cell counts less than 250/mm3. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:195 (abstract no. 612) Ruiz L, Arno A, Juan M, Zayat MK, Jou T, Balague M, Pujol R, Clotet B; "IRSICAIXA" Retrovirology Laboratory, Badalona, Spain |
|
| 613 | A phase I study of interleukin-10 (IL-10) in HIV-infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:195 (abstract no. 613) Ahrendt LD, Witek J, Dean LM, Sigler AJ, Blumberg EA, Wood CA, Molavi A, Mastoridis P, Affrime MB, Cutler DL, Gold MJ, Fuchs AC |
|
| 614 | T-cell ribozyme gene therapy of HIV-1 infection: progress report from a phase I trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:195 (abstract no. 614) Looney DJ, Poeschla E, Leavitt M, Gilles P, Marich J, Robbins J, Haidri P, Barber J, Yu M, Wong-Staal F |
|
| 615 | Safety and anti-HIV effect of GM-CSF in patients on highly active anti-retroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:195 (abstract no. 615) Skowron G, Stein D, Drusano G, Melbourne K, Mongillo A, Whitmore J, Echols R, Gilbert M |
|
| 616 | An AIDS gene therapy trial in HIV-1 discordant identical twins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:195 (abstract no. 616) Morgan RA, Walker R, Lane C, Blaese RM |
|
| 617 | Hematopoietic stem cell (HSC) mobilization in HIV infected patients and retroviral transduction with RevM10. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:195 (abstract no. 617) Deresinski SC, Camp B, Kemper CA, Yuen A, Leemhuis T, Liu J, Winger E, Moseley A, Juttner C |
|
| 618 | Transduction of CD34+ cells from the bone marrow of HIV-1 infected children: comparative marking by an RRE decoy gene and a neutral gene. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:196 (abstract no. 618) Wheeler SF, Bauer G, Church JA, Dolan C, Haden E, Salata C, Rice CR, Rothchild JC, Valdez P, Kohn D |
|
| 619 | Cell processing improvements and co-transduction of CD4 and CD8 T cells for HIV gene therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:196 (abstract no. 619) Hege KM, Walker RE, Lane HC, Roberts MR, Broad DF |
|
| Session 80 — Poster Genetic Therapies: In Vitro Studies |
||
| 620 | Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:196 (abstract no. 620) Chen JD, Bai X, Yang AG, Cong Y, Chen SY |
|
| 621 | The effect of structure in HIV-1 nef RNA on the antiviral activity of ribozymes targeted to sites in nef. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:196 (abstract no. 621) McDonald CK, Gray EA, McSwiggen JA, Campbell TB |
|
| 622 | Inhibition of HIV-1 replication by HIV-1 induced expression of a human ribonuclease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:197 (abstract no. 622) Cara A, Rybak S, Newton D, Gusella L |
|
| 624 | A novel genetic strategy to inhibit HIV-1 replication: localization of a C-terminal peptide corresponding to the dimer interface structure of protease in the virus particle. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:197 (abstract no. 624) Cartas M, Serio D, Singh SP, Rizvi TA, Kalyanaraman VS, Weber IT, Srinivasan A |
|
| 625 | Synergistic inhibition of Tat and Rev functions by one RNA molecule. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:197 (abstract no. 625) Lisziewicz J, Zeng G, Weinstein J, Lori F |
|
| 626 | Cell-type-specific gene delivery with retroviral vector particles that display the antigen-binding site of an antibody. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:197 (abstract no. 626) Jiang AN, Dornburg R |
|
| Session 81 — Poster In Vitro and Animal Model Studies of Novel Antiretroviral Agents |
||
| 627 | In vitro anti-HIV-1 activity of and viral drug resistance profiles against phosphoralaninate diesters of z- and e-methylene-cyclopropane analogues. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:197 (abstract no. 627) Yoshimura K, Uchida H, Kodama E, Maeda Y, Feldman R, Qiu YL, Zemlicka J, Mitsuya H |
|
| 628 | In vitro selectivity of BCH-10618, BCH-10619 and BCH-10652 against human immunodeficiency virus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:198 (abstract no. 628) Mansour T, Wainberg M, Salomon H, Richard N, Gourdeau H, Ouellet F, King C, Williams P, Locas C, Fortier C, Proulx L, Clement J, Bowlin T |
|
| 629 | Nucleosides with dual anti-HIV and HBV activity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:198 (abstract no. 629) Schinazi RF, Ma L, Shi J, Hurwitz SJ, Schlueter Wirtz S, Kupfer S, Juodawlkis A, McAtee J, Liotta D, McClure H, Faraj A, Sommadossi JP; Emory University, Decatur, GA |
|
| 630 | Antiretroviral activity and metabolism of bis (POC) PMPA, an oral bioavailable prodrug of PMPA. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:198 (abstract no. 630) Fridland A, Robbins BL, Srinivas RV, Bischofberger N |
|
| 631 | Induction and maintenance regimens of zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) in vitro. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:198 (abstract no. 631) Oh MD, Merrill DP, Hirsch MS |
|
| 632 | 1592U89 as a component of 2- and 3-drug regimens against zidovudine-sensitive and zidovudine resistant HIV isolates in vitro. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:198 (abstract no. 632) Tremblay C, Merrill DP, Chou TC, Hirsch MS |
|
| 633 | Synthesis, enantiomeric resolution, and virological evaluation of 3'-heteronucleosides containing selenium. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:198 (abstract no. 633) Chu CK, Ma L, Schlueter Wirtz S, Shi J, Du J, Schinazi RF |
|
| 634 | In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:199 (abstract no. 634) Ravitch JR, Bryant BJ, Reese MJ, Boehlert CC, Walsh JS, McDowell JP, Sadler BM |
|
| 635 | 1592 prevents viral spread in brain tissue of SCID mice with HIV-1 encephalitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:199 (abstract no. 635) Limoges J, Persidsky Y, Rasmussen J, Lanier R, Reinhard J, Gendelman HE |
|
| 636 | CNS penetration of the anti-retroviral 1592 in human and animal models. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:199 (abstract no. 636) Ravitch JR, Jarrett JL, Robertson White H, Polli JW, Humpreys JE, Good SS |
|
| 637 | Antiviral activity of a new class of HIV-protease inhibitor with distinct resistance and protein binding properties. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:199 (abstract no. 637) Sharmeen L, Heldsinger A, Neorr B, McQuade T, Gracheck S, Vanderroest S, Saunders J |
|
| 638 | PD178390: a novel potent non peptide HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone class. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:199 (abstract no. 638) Domagala JM, Boyer F, Ellsworth E, Gajda C, Hagen S, Hamilton H, Markoski L, Prasad V, Steinbaugh B, Tait B, Lunney E, Brodfuehrer J, Gracheck S, Hupe D, Iyer K, Pavlovsky S, Saunders J, Sharmeen L, Tummino P |
|
| 639 | Relative potency of protease inhibitors in macrophages chronically-infected by HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:199 (abstract no. 639) Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R, Yarchoan R |
|
| 640 | Efavirenz (DMP 266) cerebrospinal fluid (CSF) concentrations after chronic oral administration to cynomolgus monkeys. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:200 (abstract no. 640) Fiske WD, Brennan JM, Haines PJ, Mutlib AE, Gemzik B, Gerson R; DuPont Merck Pharmaceutical Co., Newark, DE |
|
| 641 | Quinolones as novel HIV integrase inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:200 (abstract no. 641) Gogliotti RD, Ellsworth EL, Holler TP, Hupe D, Foltin SK, Kennedy RM, Sanchez JP, Domagala JM |
|
| 642 | Triciribine inhibits HIV nuclear import and requires phosphorylation by cellular enzymes for activity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:200 (abstract no. 642) Ptak RG, Jacobson JG, Borysko KZ, Townsend LB, Drach JC |
|
| 643 | Anti-HIV agents that selectively target the retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:200 (abstract no. 643) Huang M, Turpin JA, Graham L, Janini GM, Covell DG, Maynard A, Rice WG |
|
| 644 | Inhibition of human immunodeficiency virus type 1 replication by expression of fusion protein, Vpr-single-chain variable anti-integrase. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:200 (abstract no. 644) Bouhamdan M, Duan LX, Pomerantz RJ |
|
| 645 | Targeting HIV-and SIV-infected cells with CD4/chemokine receptor pseudotypes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:200 (abstract no. 645) Endres MJ, Jaffer S, Haggarty B, Doranz BJ, Turner JD, Kolson DL, Hoxie JA |
|
| 646 | In vitro selection of NSI HIV-1 strains and reversion of the SI phenotype to NSI by treatment with AMD3100, a CXCR4 antagonist. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:201 (abstract no. 646) Este JA, Cabrera C, Schols D, Henson G, Clotet B, De Clercq E |
|
| Session 82 — Poster Novel Antiretroviral Chemotherapeutic Agents |
||
| 647 | Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:201 (abstract no. 647) Lal R, Hsu A, Granneman GR, El-Shourbagy T, Johnson M, Lam W, Manning L, Japour A, Sun E |
|
| 648 | Multiple-dose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:201 (abstract no. 648) Borin MT, Wang Y, Schneck DW, Li H, Brewer JE, Daenzer CL |
|
| 649 | Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:201 (abstract no. 649) Baldwin JR, Boron MT, Wang Y, Schneck DW, Hopkins NK |
|
| 650 | A fusion inhibitor (FP-21399) for the treatment of HIV infection: a phase I study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:201 (abstract no. 650) Dezube BJ, Wong TK, Dahl TA, Chapman B, Ono M, Gillies SD, Chen LB, Crumpacker CS |
|
| 651 | A phase I study of 2'-beta-fluoro-2',3'-dideoxyadenosine (FddA) in patients with symptomatic HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:202 (abstract no. 651) Welles L, Lietzau JA, Little R, Kelley JA, Ford H, Pluda JM, Kohler DR, Gillim LA, Mitsuya H, Yarchoan R |
|
| 652 | Preliminary clinical safety profile of (+)-calanolide A-a new novel NNRTI. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:202 (abstract no. 652) Creagh T, Xu ZQ, Ray L, Giltner J, Nayer T, Ruckle J |
|
| Session 83 — Poster Antiviral Therapy: Hydrooxyurea |
||
| 653 | Open label combination therapy with stavudine, didanosine, and hydroxyurea in nucleoside experienced HIV-1 infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:202 (abstract no. 653) Rossero R, McKinsey D, Green S, Andron L, Pollard R |
|
| 654 | Safety, sheltering, & synergy of hydroxyurea (HU) with ddI or ddI plus d4T in HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:202 (abstract no. 654) Galpin JE, Lori F, Globe DR, Casciato D |
|
| 655 | Consistent, sustained HIV suppression without rebound by hydroxyurea, ddI and a protease inhibitor prevents loss of immunologic functions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:203 (abstract no. 655) Lori F, Jessen H, Clerici M, Lieberman J, Lisziewicz J |
|
| 656 | ddI + d4T +/- hydroxyurea for HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:203 (abstract no. 656) Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza P, Bucher H, Bernasconi E, Yerly S, Perrin L, Hirschel B |
|
| 657 | Improvement in CD4 cell diversity during 7-month trial of hydroxyurea in combination with ddI or ddI and d4T. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:203 (abstract no. 657) Galpin JE, Lori F, Globe DR, Casciato D |
|
| Session 84 — Poster Antiretroviral Therapy: Nucleoside Reverse Transcriptase Inhibitors |
||
| 658 | Preliminary long-term open-label data from patients using abacavir (1592) containing antiretroviral treatment regimens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:203 (abstract no. 658) Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Steel HM, Lanier ER, Pearce G |
|
| 659 | Antiviral effects of abacavir (1592) following 36 weeks of therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:203 (abstract no. 659) Torres R, Saag M, Lancaster D, Sonnerborg A, Feinberg J, Thompson M, Lang W, Schooley R, Mulder J, D'Aquila R, Santin M, Lafon S; St Vincent's Hospital, New York, NY |
|
| 660 | A randomized study comparing treatment with AZT plus 3TC, ddI or ddC in 254 nucleoside experienced HIV infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:204 (abstract no. 660) Yeni P, Aboulker JP, Halley A, Nunn A, Brun-Vezinet F, Gazzard B, Darbyshire JH; Hopital Bichat, Paris, France |
|
| 661 | A randomized double-blind study of d4T+ddI vs ZDV+ddI as initial treatment in subjects with CD4 count less than or equal to 500 cells/mm(3). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:204 (abstract no. 661) Fisher M, Stoehr A, Podzamczer D, Angarano G, Silleni M, Ledeine JM, Dunkle LM |
|
| 662 | Virologlc effect of therapy with reverse transcriptase inhibitors (RTIs) in patients with AIDS and less than 50 CD4+ T cells per mm(3): a substudy of ACTG 193a. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:204 (abstract no. 662) Erice A, Tierney C, Balfour HH Jr, Liou S, Kahn JO, Henry WK; University of Minnesota, Minneapolis, MN |
|
| 664 | Therapy with d4T plus 3TC produces sustained undetectable levels of plasma HIV RNA (pHIV) in patients treated with reverse transcriptase (RT) inhibitors for 10 years. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:204 (abstract no. 664) Balfour HH Jr, Erice A, Reed NV, Allman AR, Li W |
|
| 665 | Study HIV-NAT 001: a randomized, double-blind, comparative trial to evaluate the efficacy of combination antiviral therapy with ZDV 200 mg TID plus ddC 0.75 mg TID versus ZDV 100 mg TID plus ddC 0.375 mg TID for the treatment of HIV-1 infection in a Thai study population. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:204 (abstract no. 665) Kroon E, Ungsedhaphan C, Ruxrungtham K, Cheuenyam M, Ubolyam S, Van Leeuwen R, Kunanusont C, Poolcharoen W, Forster G, Buranapradikul S, Sirivichayakul S, Lange J, Cooper D, Phanuphak P |
|
| 666 | Study HIV-NAT 002: the safety and efficacy of didanosine (ddI) plus or minus stavudine (d4T): high/low dose combinations in a high prevalence HIV-1 clade E, antiretroviral naïve Thai adults with CD4 counts 150 350/mm(3). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:204 (abstract no. 666) Ruxrungtham K, Kroon E, Ungsedhaphan C, Teeratakulpisarn S, Ubolyam S, Weverling GJ, Kunanusont C, Poolcharoen W, Kattinanon U, Buranapraditkul S, Sirivichayakul S, Lange JA, Cooper D, Phanuphak P |
|
| 667 | Clinical implications of HIV-1 RNA and CD4 cell count in the DELTA trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:205 (abstract no. 667) Weverling GJ |
|
| 668 | Do dual nucleoside regimens have a role in an era of plasma viral load driven antiretroviral therapy? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:205 (abstract no. 668) O'Shaughnessy MV, Hogg RS, Rhone SA, Yip B, Sherlock C, Conway B, Schechter MT, Montaner JS |
|
| 669 | Phase 3 study of the antiviral activity of AZT+3TC given as separate regimens versus a new fixed dose combination (Combivir). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:205 (abstract no. 669) Rozenbaum W, Chauveau E |
|
| 670 | Bioequivalence of Combivir tablet and Epivir plus Retrovir tablets. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:205 (abstract no. 671) Moore KH, Lloyd PP, Duncan B, O'Mara M, Culverhouse E, Kearney M, Morris D, Kunka RL, Shaw S |
|
| 671 | Resistance to nucleoside-analog antiretroviral drugs among blood donors recently infected with HIV-1 and naïve to antiretroviral treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:205 (abstract no. 672) deOliveira CF, Machado DM, Rawal BD, Sullivan M, Jacobs T, Gwinn M, Kessler D, Janssen RS, Busch MP |
|
| Session 85 — Poster Resistance to Antiretroviral Nucleoside Reverse Transcriptase Inhibitors |
||
| 672 | Resistance to Nucleoside Analog Antiretroviral Drugs among Blood Donors Recently Infected with HIV-1 and Naive to Antiretroviral Treatment Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:205 (abstract no. 672) Deoliveira CF1 |
|
| 673 | Prevalence of resistance to nucleoside analogues in Spain (1993 vs 1997) among naïve and pre-treated patients (the ERASE study). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:206 (abstract no. 673) Rubio A, Gomez-Cano M, Puig T, Perez-Olmeda M, Olivera M, Ruiz L, Xaus N, Zamora L, Clotet B, Leal M, Soriano V |
|
| 674 | Correlates of resistance to individual nucleoside drugs in patients who have never taken them. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:206 (abstract no. 674) Miller V, Phillips AN, Hertogs K, De Bethune MP, Pauwels R, Staszewski S; Goethe Universitat, Frankfurt, Germany |
|
| 675 | Genotypic prevalence of ZDV-resistant HIV-1 strains and preexistent mutations in protease coding region of recently infected subjects. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:206 (abstract no. 675) Berlusconi A, Violin M, Colombo MC, Corvasce S, Gori A, Gervasoni C, Rusconi S, Papagno L, Zhou D, Mazzucchelli R, Galli M, Moroni M, Balotta C |
|
| 676 | Genotypic analysis of experienced patients treated by d4T/3TC combination (ALTIS 2). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:206 (abstract no. 676) Calvez V, Descamps D, Valantin MA, Cecille A, Damond F, Coutellier A, Mouroux M, Longuet C, De Sa M, Bonmarchand M, Matheron S, Lancar R, Costagliola D, Katlama C, Brun-Veznet F; Pitie Salpetriere Hospital, Paris, France |
|
| 677 | Antiviral susceptibilities of HIV-1 RT recombinant viruses derived from AIDS patients after prolonged adefovir dipivoxil therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:206 (abstract no. 677) Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM |
|
| 678 | Emergence of HIV-1 resistance in seminal plasma of men on antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:206 (abstract no. 678) Eron JJ, Johnston D, Fiscus SA, Cohen MS, Alcorn T, Vernazza P; University of North Carolina, Chapel Hill, NC |
|
| 679 | An in frame insertion into the HIV RT gene is associated with a decreased patient viral load. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:207 (abstract no. 679) Ross L, Johnson M, Graham N, Shaefer M, Griswold M, St. Clair M |
|
| 680 | The M184V substitution in reverse transcriptase increases sensitivity of both HIV-1 and SIV to PMPA. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:207 (abstract no. 680) Wainberg MA, Quan Y, Salomon H, Cherrington J |
|
| 681 | The 184V mutation in SIV reverse transcriptase arises directly from a M184I precursor and not from wild-type virus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:207 (abstract no. 681) Cherry E, Slater M, Salomon H, Rud E, Wainberg MA |
|
| 682 | In-vivo comparison of RT inhibitor resistance patterns in paired cerebrospinal fluid and blood of HIV-1 infected patients with a novel line probe assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:207 (abstract no. 682) Cunningham P, Smith D, Satchell C, Cooper DA, Brew B |
|
| 683 | Presence of mutation conferring resistance to 3TC in plasma and cerebrospinal fluid in HIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:207 (abstract no. 683) Valdez H, Aouad G, Chien, McClernon D, St. Clair M, Lederman M; Case Western Reserve University, Cleveland, OH |
|
| 684 | Codon 215-region zidovudine resistance mutations display a novel symmetry in sequence and structure. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:207 (abstract no. 684) Colgrove R, Japour A |
|
| 685 | Persistance of zidovudine resistance pol 215 mutation in patients treated with protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:208 (abstract no. 685) Karmochkine M, Si Mohamed A, Batisse D, Piketty C, Kazatchkine MD, Belec L; Broussais Hosp, Paris, France |
|
| 686 | Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral load response. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:208 (abstract no. 686) Lanier ER, Stone C, Griffin P, Thomas D, Lafon S |
|
| 687 | Susceptibility of clinical HIV-1 isolates to 1592U89. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:208 (abstract no. 687) Mellors JW, Hertogs K, Peeters F, Lanier R, Miller V, Graham N, Larder B, Stoffels P, Pauwels R |
|
| 688 | Lack of phenotypic cross-resistance of HIV-1 isolates obtained from HIV-1 infected children receiving combinations of lamivudine (3TC), zidovudine (ZDV), and didanosine (ddI). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:208 (abstract no. 688) Martin-Carpenter L, Keller A, Lewis L, Church J, Wheeler S, Jacobson F, Pizzo P |
|
| Session 86 — Poster Combination Chemotherapy: Role of Non-nucleoside Reverse Transcriptase Inhibitors |
||
| 692 | Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) suppression to "less than 1 copy/ml" (OD=background) by Amplicor as a predictor of virologic treatment response [DMP 266-003, cohort IV]. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:208 (abstract no. 692) Kahn J, Mayers D, Riddler S, Stein D, Bach M, Havlir D, Ruiz N, Manion D, Friedman P, Labriola DF, Gorelick K, Faulkner E, Saxton T, Goldberg A, Chao G |
|
| 694 | Use of HIV-1 RNA PCR in patients on rescriptor (DLV) + retrovir (ZDV) + epivir (3TC), ZDV+3TC, or DLV+ZDV allowed early differentiation between treatment arms. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:209 (abstract no. 694) Wathen L, Freimuth W, Getchel L, Greenwald C, Crampton D |
|
| 695 | Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:209 (abstract no. 695) Montaner J, Reiss P, Cooper D, Vella S, Dohnanyi C, Harris M, Conway B, Wainberg M, Smith D, Robinson P, Myers M, Hall D, Lange JM |
|
| 696 | Early results of combined stavudine, lamivudine, and nevirapine: a twice daily, well-tolerated, protease inhibitor-sparing regimen for the treatment of HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:209 (abstract no. 696) Kaspar R, Werntz G, DuBois DB |
|
| 697 | Nevirapine+ddI+3TC - first experience with a once-daily dosing combination regimen. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:209 (abstract no. 697) Rieger A, Hein U, Schon H, Forstenlehner M, Kleibl-Popov C, Tschachler E, Stingl G |
|
| 698 | A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of DMP 266 (efavirenz, SUSTIVA) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) [DMP 266-005]. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:209 (abstract no. 698) Hicks C, Hass D, Seekins D, Cooper R, Gallant J, Carpenter C, Ruiz NM, Manion DJ, Ploughman LM, Labriola DF |
|
| 699 | Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with rescriptor (DLV) + retrovir (ZDV) + epivir (3TC). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:209 (abstract no. 699) Sargent S, Green S, Para M, Freimuth W, Wathen L, Getchel L, Greenwald C; University of Tennessee, Memphis, TN |
|
| 700 | Analysis of nevirapine (NVP) effect on clinical endpoints (CEs) of HIV progression or death in ACTG trial 193A. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:210 (abstract no. 700) Robinson P, Cotton D, Curry R, Henry K, Hall D, Myers M |
|
| 701 | A randomised trial comparing regimens of four RT inhibitors given together or cyclically with a standard two drug regimen: the Quattro trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:210 (abstract no. 701) Kitchen V |
|
| Session 87 — Poster Resistance to Antiretroviral Non-nucleoside Reverse Transcriptase Inhibitors |
||
| 702 | A resistance and cross resistance profile for SUSTIVA (efavirenz, DMP 266). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:210 (abstract no. 702) Jeffrey S, Baker D, Tritch R, Rizzo C, Logue K, Bacheler L |
|
| 703 | Resistance to efavirenz (SUSTIVA) in vivo. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:210 (abstract no. 703) Bacheler L, George H, Hollis G, Abremski K |
|
| 704 | Baseline sequence clusters predict response to combination therapy in ACTG 241. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:211 (abstract no. 704) Leigh Brown AJ, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD; University of Edinburgh, Scotland |
|
| 706 | HIV-1 drug susceptibilities during therapy with delavirdine (DLV)+ZDV, DLV+ddI, or DLV+ZDV+ddI. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:211 (abstract no. 706) Demeter L, Griffith B, Bosch R, Scott W, Nokta M, Fisher E, Pollard R, Freimuth W, Fischl M, Friedland G |
|
| Session 88 — Poster HIV-1 Replication in the Female Genital Tract |
||
| 707 | Characteristics of a factor in the female genital tract that stimulates HIV-1 expression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:211 (abstract no. 707) Spear GT, Hashemi F, Al-Harthi L, Sha B, Roebuck KA, Landay AL; Rush Medical College, Chicago, IL |
|
| 708 | Genotypic evidence of local HIV expression in the female genital tract. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:211 (abstract no. 708) Subbarao S, Wright T, Ellerbrock T, Lennox JL, Hart C |
|
| 709 | In vivo immune responses increase CCR5 mRNA expression in the female genital tract. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:212 (abstract no. 709) Patterson BK, Landay A, Andersson J, Brown C, Jiyamapa D, Burki Z, Stanislawski D, De Frias D, Garcia P |
|
| 710 | Genotype and phenotype characterization of HIV-1 in the blood and genital secretion of HIV-1 seropositive women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:212 (abstract no. 710) Shaheen F, Sison A, Bagasra O, Geist A, Pomerantz RJ |
|
| 711 | HIV is readily detectable in the female genital tract of HIV+ women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:212 (abstract no. 711) Kovacs A, Reichelderfer P |
|
| 712 | Quantification of cervicovaginal lavage and plasma HIV-1 RNA in HIV-1 seropositive women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:212 (abstract no. 712) Hoesley C, Sfakianos G, Bragg S, Alvarez R, Squires K |
|
| 713 | HIV-1 RNA levels in the genital tract of women on antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:212 (abstract no. 713) Cu Uvin S, Caliendo A, Russo R, Reinert S, Flanigan TP, Mayer KH, Carpenter CC; Brown University, Providence, RI |
|
| 714 | HIV shedding occurs through the vaginal mucosa. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:212 (abstract no. 714) Hart C, Lennox JL, Evans-Strickfaden T, Bush T, Schnell C, Clancy K, Pratt-Palmore M, Conley L, Ellerbrock TV |
|
| Session 89 — Poster HIV Infection in Women: Manifestations, Disease Progression, and Therapy |
||
| 715 | Human papilloma virus (HPV)-associated cervical cytologic abnormalities among women with or at risk for HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:213 (abstract no. 715) Duerr A, Warren D, Shah K, Burk R, Piepert J, Christenson C, Kieke B, Klein RS |
|
| 716 | HIV RNA level is a risk factor for abnormal cervical cytology. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:213 (abstract no. 716) Massad LS, Riester K, Fruchter RG, Palefsky J, Burk RD, Burns D, Miotti P, Jordan C, Muderspach LI, Anastos K, Greenblatt R; Cook County Hospital, Chicago, IL |
|
| 717 | Prevalence of invasive cervical cancer among HIV-infected and uninfected hospital patients, 1994-1995. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:213 (abstract no. 717) Weber T, Chin K, Sidhu JS, Janssen RS |
|
| 718 | Factors associated with oral (OC) and vaginal candidiasis (VC) among Candida colonized HIV+ and at-risk HIV- women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:213 (abstract no. 718) Schuman P, Sobel JD, Ohmit SE, Mayer KH, Rompalo A, Duerr A, Smith DK, Warren D, Klein RS |
|
| 719 | The changing pattern of neoplastic disease complicating HIV infection. A new epidemic of lymphoma and unusual neoplasms in women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:213 (abstract no. 719) Kaplan MH; North Shore University Hospital, Manhasset, NY |
|
| 720 | Causes of death in women with AIDS in Chicago. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:214 (abstract no. 720) Cohen M, French A, Murphy J, Burke J |
|
| 721 | Predictors of undetectable plasma viral loads in 250 HIV+ women in care. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:214 (abstract no. 721) Flanigan TP, Dickinson BP, Merriman N, Holmes L, Tashima K, Thomas MS, Rich JD, Carpenter C |
|
| 722 | Women first: a study in HIV positive women of quadruple therapy: nelfinavir (NFV), saquinavir (SQV), stavudine (d4T) and lamivudine (3TC). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:214 (abstract no. 722) Zorrilla C, Clark R, Currier J, Squires K, Till M, Gersten M, Farnsworth A, Schmitt J, Daniels R, Clendeninn N |
|
| Session 90 — Poster Opportunistic Infections: Mycobacterium avium and Other Atypical Mycobacteria |
||
| 723 | Increase in CD3+ CD4- CD8- T-lymphocytes with 7 disseminated Mycobacterium avium complex infection (D.MAC) in patients with AIDS: a prospective study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:214 (abstract no. 723) Bonnet F, Dequae L, Sire S, Dupon M, Ragnaud JM, Lacoste D, Dabis JF, Pellegrin JL, Moreau JF |
|
| 724 | Neutrophils from AIDS patients treated with G-CSF demonstrate enhanced killing of M. avium. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:214 (abstract no. 724) George S, Coffey M, Cinti S, Kaul D, Armstrong W, Collins J, Kazanjian P |
|
| 725 | Effect of clarithromycin prophylasis on circulating TNF-alpha and IL-6 levels in advanced HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:215 (abstract no. 725) Haas DW, Lederman M, Clough LA, Wallis RS, Feiler JR |
|
| 726 | Mycobacteria avium intracellulare (MAIS) reversal syndrome set off by highly active anti retroviral therapy (HAART). Improved immunity is not always good but it is better than no immunity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:215 (abstract no. 726) Kaplan MH; North Shore University Hospital, Manhasset, NY |
|
| 727 | Trends in disseminated Mycobacterium avium infection (DMAC) in AIDS patients since the availability of primary prophylaxis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:215 (abstract no. 727) Rimland D, St. John A; VA Medical Center, Atlanta, GA |
|
| 728 | Secondary prophylaxis for mycobacterial infections with once weekly azithromycin. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:215 (abstract no. 728) Moyle GJ, Gill J, Nelson M |
|
| 729 | Eradication of disseminated Mycobacterium avium complex (DMAC) in four patients after twelve months anti-mycobacterial therapy and response to highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:215 (abstract no. 729) Aberg JA, Yajko DM, Jacobson MA |
|
| 730 | Significance of single respiratory isolates of Mycobacterium kansasii (MK) in patients with HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:215 (abstract no. 730) Rivera FA, Campo CE, Campo RE |
|
| Session 91 — Poster Opportunistic Infections: Mycobacterium tuberculosis Pathogenesis, Prevention, and Treatment |
||
| 731 | The impact of tuberculosis on survival of AIDS patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:216 (abstract no. 731) Tacconelli E, Tumbarello M, Ardito F, Cauda R |
|
| 732 | The effect of HIV co-infection on weight (WT) loss and repletion in patients with tuberculosis (TB). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:216 (abstract no. 732) Guimaraes K, Raghavan S, Medard F, El-Sadr W |
|
| 733 | Preventive therapy (PT) for tuberculosis (TB) in HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:216 (abstract no. 733) Rey R, Lopez L, Rivero A, Castillo R, Verdejo J, Garcia M, Lozano F, Diez F, Escribano J, Pasquau J, Canueto J, Hernandez J, Gomez A, Kindelan J |
|
| 734 | The concordance of AFB smear and Mycobacterium tuberculosis (MTB) culture results in HIV+ and HIV- patients (P) in respiratory isolation at a large inner city medical center. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:216 (abstract no. 734) Ajudia K, Wester W, Pulvirenti J, Denbesten K, deGuzman D, Braswell K, Welbel S |
|
| 735 | Acquired rifamycin mono-resistant tuberculosis among HIV-infected patients treated with once-weekly isoniazid and rifapentine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:216 (abstract no. 735) Benator D, Burman W, Chaisson R |
|
| 736 | Phase I trial of Mycobacterium vaccae immunization in HIV infected and healthy adults in Lusaka, Zambia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:217 (abstract no. 736) Lein AD, Waddell RD, Chintu C, Baboo KS, Zumla A, Morin PM, Karagas MR, von Reyn CF |
|
| 737 | Childhood BCG immunization and the subsequent risk of adult disseminated mycobacterial disease among AIDS patients in Lusaka, Zambia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:217 (abstract no. 737) Waddell RD, von Reyn CF, Baboo KS, Chintu C, Kreiswirth B, Frothingham R, Wieland-Alter W, Zumla A |
|
| Session 92 — Poster Opportunistic Infections: Pneumocystis carinii Pneumonia/Respiratory and Other Bacterial Infections |
||
| 738 | Changes in HIV RNA load associated with bacterial or Pneumocystis carinii pneumonia (PCP). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:217 (abstract no. 738) Stansell JD, Osmond DH, Chernoff D, Wallace JM, Huang L, Turner JR, Hopewell PC |
|
| 739 | Factors associated with Pneumocystis carinii pneumonia (PCP) in the setting of frequent use of PCP prophylaxis and highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:217 (abstract no. 739) Grodesky M, Johnson S, Hageman A, Williams W |
|
| 740 | Pattern and timing of adverse events after initiation of different doses of trimethoprim-sulfamethoxazole (TMS) prophylaxis for P. carinii pneumonia. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:218 (abstract no. 740) El-Sadr W, Yurik T, Luskin-Hawk R, Hafner R |
|
| 741 | Increased risk of P. carinii pneumonia but not death or other AIDS events among trimethoprim-sulfamethoxazole intolerant patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:218 (abstract no. 741) El-Sadr W, Yurik T, Luskin-Hawk R, Murphy R, Hafner R, Neaton J; Harlem Hospital Center, New York, NY |
|
| 742 | Efficacy of CD40 ligand and other modulators on Pneumocystis carinii infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:218 (abstract no. 742) Oz HS, Hughes WT, Rehg JE, Thomas EK |
|
| 743 | Diagnosis of Pneumocystis carinii pneumonia (PCP) in HIV-infected persons using PCR testing on BAL fluid: a blinded comparison to standard methods. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:218 (abstract no. 743) Torres J, Goldman M, Lee CH, Bartlett MS, Tang X, Smith JW, Allen SD, Connolly PA, Wheat J |
|
| 744 | Penicillin-resistant Streptococcus pneumoniae (broncho-pulmonary infections in HIV-infected patients:risk factors for penicillin resistance. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:218 (abstract no. 744) Landi B, Eliaszewicz M, Mainardi JL, Goldstein FW, Dupont B |
|
| 745 | Streptococcus pneumoniae (SP): prevalence of penicillin resistance among HIV positive and negative patients. Clinical implications. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:218 (abstract no. 745) Montesano L, Verdejo J, Polo R, Gomez C, Toro C, Alvarez P, Buhigas I, Martinez ML, Adrados M, Martin-Fontelos P, Gonzalez-Lahoz J |
|
| 746 | G-CSF/GM-CSF do not improve outcome in neutropenic HIV patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:219 (abstract no. 746) Ambati BK, Perlman DC, Salomon N |
|
| Session 93 — Poster Cytomegalovirus Infections: Immunopathogenesis, Diagnostic Markers, and Disease |
||
| 747 | Proliferative responses against CMV in AIDS patients on HAART and with healed CMV retinitis who stopped maintenance therapy (MT). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:219 (abstract no. 747) Torriani FJ, Havlir DV, Freeman WR, Durand D, Schrier R |
|
| 748 | Changes in T cell repertoire after antiretroviral therapy in HIV associated CMV disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:219 (abstract no. 748) Worrell S, Tarragona A, Emmery V, Gazzard B, Gotch F, Larsson-Sciard EL |
|
| 749 | The K513N mutation in human cytomegalovirus DNA polymerase selected in vitro by cidofovir is associated with decreased susceptibility to cidofovir and ganciclovir and a slow-growth phenotype in vitro. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:219 (abstract no. 749) Cihlar T, Fuller MD, Mulato AS, Cherrington JM |
|
| 750 | Resistance to ganciclovir (GCV) and UL97 gene mutations in cytomegalovirus (CMV) blood strains from AIDS patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:219 (abstract no. 750) Abraham B, Lastere S, Reynes J, Bibollet-Ruche F, Vidal N, Segondy M; University Hospital, Montpellier, France |
|
| 751 | Diagnosis of cytomegalovirus CNS infection using a commercial PCR assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:220 (abstract no. 751) Weinberg A, Spiers D |
|
| 752 | Evolution of CMV blood markers in HIV infected patients receiving protease inhibitor (ANRS PREDIVIR cohort). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:220 (abstract no. 752) Salmon-Ceron D, Mazeron MC, Chaput S, Matheron S, Molina JM, Chavanet J, Raffi F, Bazin C, Leclerc P, Bentata M, Jarrousse B, Leport C, Katlama C; AP-HP, Paris, France |
|
| 753 | Predictive value of pp65 cytomegalovirus (CMV) antigenemia for the occurrence of CMV disease in patients with HIV-infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:220 (abstract no. 753) Chevret S, Scieux C, Garrait V, Dahel L, Modai J, Morinet F, Decazes JM, Molina JM |
|
| 754 | Local and systemic relapses in patients with CMV retinitis value of pp65 antigen. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:220 (abstract no. 754) Arrizabalaga J, Blanco A, Iribarren JA, Camino X, Rodriguez F, von Wichmann MA |
|
| 755 | Entoptic perimetry: a rapid, inexpensive screening technique for CMV retinitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:220 (abstract no. 755) Plummer DJ, Sample PA, Freeman WR |
|
| 756 | Prevalence of asymptomatic CMV retinitis in AIDS patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:220 (abstract no. 756) Brosgart C, Pulling C, Chaloner K, Fisher E, Coakley D, Verheggen R, Diggins M, Ioannidis J |
|
| 757 | Ophthalmologic manifestations of immune recovery in AIDS patients on HAART therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:221 (abstract no. 757) Freeman WR, MacDonald JC, Torriani FJ, Karavellas M |
|
| 758 | Impact of protease inhibitors (PI) on the incidence of recurrent CMV retinitis (CMVR). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:221 (abstract no. 758) Gerard M, Postelmans L, De Wit S, Sommereijns B, Caspers L, Libert J, Clumeck N |
|
| 759 | The effect of protease inhibitors concomitant therapy on the efficacy of oral ganciclovir (OGCV) for the maintenance treatment of CMV retinitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:221 (abstract no. 759) Losso M, Luppo S, Cassetti I, Lasala M, Benetucci J, Corral J, Cahn P, Massera L |
|
| 760 | Evolution and presentation of CMV retinitis in AIDS-patients treated by combinations including antiprotease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:221 (abstract no. 760) Bendenoun M, Eliaszewicz M, Jobin D, Miclea-Boy M, Dupont B |
|
| 761 | A prospective study of CMV infection of the CNS in AIDS patients with CMV retinitis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:221 (abstract no. 761) Madridano O, Gonzalez-Garcia J, Tenorio A, Pena P, Pozo F, Echevarria J, Pena JM, Vazquez JJ, Arribas JR |
|
| 762 | In vivo anti-CMV activity, safety and pharmacokinetics (PK) of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:221 (abstract no. 762) Lalezari JP, Aberg JA, Wang LH, Miner RC, Wire MB, Jacobson MA, Drew WL |
|
| Session 94 — Poster Diagnostics: CMV |
||
| 763 | Assessment of CMV cellular load in AIDS patients using viremia, pp65 antigenemia and bDNA CMV 1.0. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:222 (abstract no. 763) Devianne-Garrigue I, Pellegrin I, Pellegrin JL, Dupon M, Ragnaud JM, Fleury HJ; University of Bordeaux, France |
|
| 764 | Cytomegalovirus viral load determination by quantitative DNA PCR in relation other virological parameters for the diagnosis of CMV infection, in HIV infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:222 (abstract no. 764) Schuurman R, Blank B, Pouw W, Manjiry R, Van Dijk W, Boucher C, Meenhorst P |
|
| 765 | Flow cytometry based assay for foscarnet susceptibility of human cytomegalovirus (HCMV) clinical isolates. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:222 (abstract no. 765) McSharry J, Lurain N, Czerniewski M, Olson B, Landay A, Crumpacker C; Albany Medical Center, Albany, NY |
|
| 766 | Usefulness of quantitative pp65 cytomegalovirus antigenemia assay for diagnosis of cytomegalovirus retinitis in AIDS patients and follow-up. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:222 (abstract no. 766) Padilla B, Catalan P, Berenguer J, Miralles P, Cosin J, Garcia Lechuz J, Rodriguez P, Bouza E |
|
| Session 95 — Special Symposium Host Factors in HIV Infection: Implications for Therapy |
||
| S43 | Host factors in the pathogenesis of HIV disease: role of cellular activation and cell signalling. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:238 (abstract no. S43) Fauci AS |
|
| S44 | The role of the thymus in reconstituting the immune system in AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:238 (abstract no. S44) Haynes BF |
|
| S45a | Genetic variants in chemokine receptor and chemokine genes that regulate progression to AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:239 (abstract no. S45a) O'Brien SJ, Dean M, Carrington M, Smith M, Winkler C, Stephens JC, Modi WS; ALIVE |
|
| Session 96 — Special Symposium Antiretroviral Therapeutics: Current Issues |
||
| S46 | Managing HIV drug resistance: can new technologies help? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:239 (abstract no. S46) Mellors JW |
|
| S47 | Pharmacologic causes of treatment failure. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:239 (abstract no. S47) Flexner C |
|
| S48 | New agents on the horizon. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:240 (abstract no. S48) Hammer SM |
|
| Session 97 — Slide Late-breakers |
||
| LB1 | Dual effect of IL-4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. LB1) Pavlakis GN, Valentin A, Lu W, Rosati M, Schneider R |
|
| LB2 | Interruption of the IL-2 activated Jak-STAT signaling pathway by CD4-ligand HIV gp120 binding. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. LB2) Goebel J, Lempicki R, Franks A, Robey F, Lowry RP |
|
| LB3 | Functional characterization of transcriptional regulatory elements of the CCR5 promoter. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. LB3) Liu R, Zhao X, Yang J, Gurney T, Landau NR |
|
| LB4 | The transcription program of the Kaposi's sarcoma-associated herpes virus HHV8. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. LB4) Xiang C, Bittner M, Chen Y, Gillim L, Gooden GC, Leighton S, Meltzer P, Newcomb F, Pohida T, Smith P, Trent J, Yarchoan R, Zeichner SL |
|
| LB5 | A randomized trial of 2 months of rifampin (RIF) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive (+), PPD+ patients (pts). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:223 (abstract no. LB5) Gordin F, Chaisson R, Matts J, Miller C, Garcia L, Hafner R, O'Brien R |
|
| LB6 | Fomivirsen safety and efficacy in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:224 (abstract no. LB6) Muccioli C, Goldstein DA, Johnson DW, Perez JE, Mora-Duarte JF, Sheppard JD, Mansour SE, Chan CK, Palestine AG, Grillone LR, Chandler JW |
|
| LB7 | Protease inhibitors and declining AIDS deaths in New York City (NYC). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:224 (abstract no. LB7) Reggy A, Wong T, Chiasson M, Simonds R, Loo V, Heffess J |
|
| LB8 | The safety and efficacy of PMPA prodrug monotherapy: preliminary results of a phase I/II dose-escalation study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:224 (abstract no. LB8) Deeks SG, Barditch-Crovo P, Lietman PS, Collier A, Safrin S, Coleman R, Cundy KC, Kahn JO |
|
| LB9 | Potent antiretroviral efficacy of low dose FTC, initial results from a phase I/II clinical trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:224 (abstract no. LB9) Pottage J, Thompson M, Kahn J, Delehanty J, McCreedy B, Rousseau F; CCCR, Chicago, IL |
|
| LB10 | Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naïve and antiretroviral experienced HIV+ patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:224 (abstract no. LB10) Back DJ, Hoggard PG, Gibbons SE, Lloyd J, Khoo SH, Wilkins EG, Merry C, Barry MG |
|
| LB11 | Drugs suppressing HIV replication and cell proliferation decrease proviral DNA to undetectable levels. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:224 (abstract no. LB11) Lori F, Jessen H, Clerici M, Lieberman J, Siliciano RF, Lisziewicz J; RIGHT, S. Matteo, Pavia, Italy |
|
| LB12 | Early combination antiretroviral therapy of vertical HIV-1 infection: viral kinetics and control of viral replication. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:225 (abstract no. LB12) Luzuriaga K, Mcmanus M, Britto P, Wu H, Lindsey J, Smith B, Mofenson L, Sullivan JL |
|
| LB13 | Responses of follicular dentritic cells to antiretroviral combination therapy of HIV-1 infection in lymphoid tissues. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:225 (abstract no. LB13) Zhang ZQ, Schuler T, Cavert W, Notermans DW, Havlir D, Wong JK, Little S, Henry K, Danner SA, Richman DD, Haase AT |
|
| LB14 | Immunologic effects of 48 weeks of AZT/3TC/ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:225 (abstract no. LB14) Connick E, Lederman M, Kotzin B, Wade M, Spritzler J, Kuritzkes D, St. Clair M, Kessler H, Roe J, Fox L, Martinez A, Heath-Chiozzi M, Rousseau F, Landay A |
|
| LB15 | Results of TRILEGE trial, a comparison of three maintenance regimens for HIV infected adults receiving induction therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:225 (abstract no. LB15) Raffi F, Pialoux G, Brun-Vezinet F, Gastaut JA, Dellamonica P, Delfraissy JF, Meiffredy V, Flandre P, Aboulker JP; University Hospital, Nantes, France |
|
| LB16 | Randomized trial of indinavir (IDV) vs. zidovudine (ZDV)/lamivudine (3TC) vs IDV/ZDV/3TC maintenance therapy after induction IDV/ZDV/3TC therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:225 (abstract no. LB16) Havlir DV, Hirsch M, Collier A, Marschner I, Bassett R, Tebas P, Ioannidis J, Richman DD |
|
This information is designed to support, not replace, the relationship that exists between you and your doctor.